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Abstract
The calcium channel alpha-2-delta ( ( X 2 8 )  subunit is an auxiliary subunit associated with 
voltage-dependent calcium channels. It is implicated in the trafficking and functional 
expression o f  the calcium channel complex. This study expands the functional role o f 
the VWA domain and the RRR m otif o f the 0128 subunit, and the interaction between this 
subunit and the anti-epileptic drug, gabapentin
The VWA domain is normally found in integrins, where it mediates binding to 
extracellular proteins. A mutation in the (X28-2  subunit VWA domain (pM IDAS) did not 
produce the increase in current amplitude elicited by the wildtype (WT) 0128-2 control. 
Co-immunoprecipitation studies using tsA-201 cells (stably expressing (X28-2  containing 
a mid-HA tag) co-cultured with cerebellar granule cells identified potential proteins 
from the cerebellar cultures that co-immunoprecipitate with the 0128-2 protein. This 
suggests that protein from cerebellar cultures may bind the 0128-2 subunit.
Secondly, an RRR m otif found in 0 1 2 8 -1 subunit has been implicated as important for 
binding o f the anticonvulsant drug gabapentin (Wang et al., 1999). The 
electrophysiological properties o f the RRA mutant 0128 proteins were examined, and 
found not to enhance current amplitude to the full extent seen by WT C C 2 8 - I  and OC2 8 - 2  
coexpression. Binding studies using both membrane and lipid raft o f tsA-201 cells 
expressing 0 1 2 8 - I  confirmed a lack o f 3H-gabapentin in the R217A mutant condition.
Chronic exposure o f tsA-201 cells expressing Cav2.1, (34, (X 2 8 - 2  or Cav2.2, [31b, 0 1 2 8 -1 to 
gabapentin resulted in a reduction in size o f the resultant currents. The inhibitory action 
o f gabapentin was prevented by pre-incubation o f cells with the system-L amino-acid 
transport inhibitor, suggesting gabapentin acts intracellularly after uptake via this 
transport mechanism. The inhibitory effects o f gabapentin exposure were not replicated 
using co-expression o f ot28-3 , or the non gabapentin-binding mutant a 28 -l R217A or
CL2&-2 R282A proteins. This indicated the inhibitory effect was mediated through 
gabapentin-binding calcium channel OC26 subunits.
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Chapter 1: Introduction
1.1 T he physiological relevance o f C a2+
1.1.1 T he action potential
The nervous system fulfils the need within a physiological system for a mechanism o f 
fast information transfer, with the capacity for complex encoding o f  signals. The action 
potential is the fundamental mechanism for this information transfer along neurons. It 
was originally characterised in squid axon, and led to the ionic hypothesis (Hodgkin and 
Huxley, 1952). The action potential relies on ion flux across a membrane, and therefore 
requires an electrostatic potential to be present across the membrane in order for ions to 
flow. Initiation o f the action potential is caused by membrane depolarisation, usually by 
influx o f Na+ ions.
phases o f  the action potential in a typical nerve cell. Membrane
N a+ ion influx passes the activation threshold, and results in the steep
rising phase. This ceases at the peak (with channel inactivation), followed by
repolarisation and hyperpolarisation phases. Figure reproduced from
http://librarv.thinkquest.org/C003758/Function/UnderstandingActionPotential.htm.
F igure 1.1. The
depolarisation by
-2 3  -
The phases o f the action potential are shown in Figure 1.1. The resting membrane 
potential is determined by the number and type o f ion channels present in the membrane. 
The sodium / potassium pump is important in maintaining resting potential. Using ATP, 
it exchanges three intracellular sodium ions for two extracellular potassium ions. 
Membrane depolarisation causes opening o f sodium channels, followed by Na+ ion 
influx down the electrochemical gradient (towards the reversal potential for Na+ ions, 
roughly +50 mV depending on the cell). Depolarisation must be sufficient for the 
membrane potential to reach a threshold (the activation threshold), in order for action 
potential generation. Above the activation threshold, opening o f voltage-gated sodium 
channels begins a positive feedback loop, culminating in a sharp influx o f Na+ ions 
(rising phase). With the peak o f the action potential, Na+ influx diminishes and K+ efflux 
through potassium channels (opened by depolarisation) causes a repolarisation o f the 
membrane. This proceeds past the original membrane potential, leading to a brief 
hyperpolarisation. A refractory period (lasting milliseconds) follows, during which time 
further action potentials cannot be initiated due to Na channel inactivation.
The depolarisation o f surrounding membrane causes the action potential to propagate 
along the nerve. This occurs in only the forward direction however, as the refractory 
period ensures action potentials do not propagate backwards. The propagating action 
potential maintains a constant speed and amplitude (Hille, 2001).
The initial characterisation in squid axon found the action potential to be composed of 
Na+ and K+ conductances. This contrasts with action potentials in mammalian neurons, 
which are typically formed o f  multiple components o f sodium, potassium and calcium 
current (reviewed in Bean, 2007). This extra layer o f complexity present in mammalian 
neurons is necessary for encoding information into action potentials, subtle differences 
in the trains o f action potentials can alter the pattern o f Ca2+ entry at presynaptic 
terminals, and by extension the release pattern o f neurotransmitter quanta.
- 2 4 -
1.1.2 The physiological roles of Ca2+
With the accepted structural function o f calcium in the human body (a constituent o f 
bones and teeth), the discovery that it had a role as a biological signal was perhaps a 
surprise, and accordingly came as result o f  using tap water in the laboratory (Ringer, 
1883). Sydney Ringer had been using the London supply o f piped water in his 
experiments as opposed to using distilled water. When he came to repeat previous work 
demonstrating rat heart contraction using distilled water, the contractions became 
weaker, before stopping altogether. Using a mixture o f different salts (as a result o f 
calculating the constituent salts o f water “supplied by the New River Water Company”), 
he deduced that it was the calcium salts that led to the continued contraction o f the heart 
tissue.
Ca2+ ions are now acknowledged as one o f the major signalling ions, indeed Ca2+ ions 
act as “the most widespread, versatile and promiscuous signaling molecule within 
intracellular compartments” (Nilius et al., 2006). Entry o f Ca2+ ions into cells involves
9-1-its translocation across membranes. Ca ions release from intracellular stores (such as 
endoplasmic reticulum (ER) or sarcoplasmic reticulum) is mediated by store-operated 
calcium channels. Movement across the plasma membrane is mediated by voltage-gated
I
calcium channels (VGCCs), as well as other Ca -permeable channels, and leads to a 
number o f  essential cellular functions (reviewed in Hille, 2001), such as: initiation o f 
gene expression; muscle contraction; secretion (of neurotransmitters, hormones and 
enzymes among others), as well as initiation o f other secondary cellular processes, some 
o f which are shown in Figure 1.2.
The typical intracellular concentration o f  Ca2+ ions is kept very low (-30  nM to -200  
nM depending on the cell type), by a combination o f ATP-dependent Ca2+ pumps and 
Na+-Ca2+ exchangers (Hille, 2001). Entry o f Ca2+ ions through VGCCs allows the local 
Ca2+ concentration to rise up to -100  pM (for review see Bregestovski and Spitzer,
2005). These large changes in [Ca2+] as a result o f Ca2+ entry are possible due the steep 
electrochemical gradient favouring Ca influx- for example the N em st potential is given
-25  -
as +129 mV (when [Ca2+]0 = 1.5 mM and [C a 2+]j = 100 nM; Hille (2001)). Ca2+ influx 
results only in a very localized [Ca2+] change however, producing regions o f  high [Ca2+] 
known as calcium microdomains (Augustine and Neher, 1992; reviewed in Berridge,
2006).
Figure 1.2. Intracellular processes arising from Ca2+ influx. Calcium mobilizing signals 
are shown in blue (such as the generation o f iositol- 1,4,5- triphosphate), and refer to 
those mechanisms producing Ca2+ in cells (for example as a result o f receptor 
activation). Activating signals are shown in green, and activate those processes shown 
by pink arrows. Cessation o f  calcium signaling is carried out by processes shown in red 
(such as transport mechanisms to remove calcium from the cell). Figure taken from 
Berridge et al., (2000).
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1.2 The identification and characterisation o f VGCCs
1.2.1 Electrophysiology and pharmacology
The first evidence for Ca2+ acting as a permeant ion was shown in the muscle fibres o f 
crab legs (Fatt and Katz, 1953). Substitution of Na+ ions (thought to be essential for 
excitability) with choline or TEA ions resulted in increased excitability, and an increased 
action potential duration. Choline and TEA act to block potassium channels, preventing 
their repolarisation o f the membrane (Hille, 2001). Coupled with the more positive 
Nemst potential for Ca2+ ions with respect to Na+ ions, the cells became substantially 
more excitable than before, with a corresponding increase in muscle contraction force 
and duration. The permeant ion responsible was subsequently found to be Ca2+ (Fatt and 
Ginsborg, 1958), in agreement with the observation that radiolabelled Ca2+ ions move 
into the cell during the action potential o f the squid axon (Hodgkin and Keynes, 1957).
After the discovery o f VGCCs in crustacean muscle, they were then found to be present 
in other invertebrate muscle preparations. A number o f criteria had to be met before the 
inward current could be denoted a calcium spike (reviewed in Hagiwara & Byerly, 
1981). These included: an overshoot that correlates with external [Ca2+]; a sufficiently 
large measurable movement o f radioactive calcium to be tied to the observation o f a 
spike; block o f spikes with ions such as Mn or verapamil, but an absence o f block with 
the sodium channel blocker tetrodotoxin (TTX); and a continuation o f spikes by 
replacing extracellular Ca2+ ions with Ba2+or Sr2+ ions.
The same omnipresence o f  calcium channels in invertebrate twitch muscle fibres was 
not observed in vertebrate twitch muscle fibres, where the action potential is almost 
entirely Na+ ion-mediated (Hagiwara and Byerly, 1981). There were exceptions, such as 
in the twitch muscle fibres o f embryonic chick and rat, however these findings were 
absent in adult subjects. It was a different story in vertebrate smooth muscle and cardiac 
muscle however, where influx o f Ca2+ appeared to be essential for muscle contraction 
(Reuter, 1973). Work carried out in Purkinje fibres o f sheep and calf heart led to the
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discovery that it was Ca2+ ions rather than Na+ ions that made up the current flow upon 
depolarisation o f the fibre (Reuter, 1967). This demonstrated the heart as the first 
vertebrate tissue in which Ca2+ ions initiated the action potential (and therefore muscle 
contraction).
The first evidence for multiple subtypes o f calcium current came with experiments in 
starfish (Hagiwara et al., 1975), where two distinct Ca2+ conductances were found. One 
required the expected voltage step to about -7 mV, whilst the other required a lesser 
voltage-step (to about -55 mV). This identified another calcium channel activated at 
low-voltage, later termed “low-voltage activated” (LVA) current or T-type (T for 
“transient”) due to its fast rate o f inactivation. “High-voltage activated” (HVA) current 
on the other hand had a slowly inactivating current in comparison, and was named “L- 
type” (for “long-lasting”) accordingly. The LVA current was speculated to be a pace- 
making mechanism due to its inactivation at normal resting potential (Carbone and Lux, 
1984).
In addition to electrophysiological classification, pharmacological classification was 
possible to distinguish L- and T-type channels. L-type channels are activated by the 
agonist Bay K 8644 and blocked by dihydropyridines (DHPs; such as nitrendipine), 
phenylalkylamines (PAAs) and benzothiazepines (BZPs). These modulatory effects are 
brought about by changes in the gating behaviour o f the L-type channels (Hess et al., 
1984).
With the advent o f  the patch-clamp technique (Hamill et al., 1981) came the ability to 
record from smaller cells, in particular vertebrate neurons. One such experiment 
identified a new type o f current in chick dorsal root ganglion (DRG) neurons (Nowycky 
et al., 1985). Application o f DHP antagonists (or agonists such as Bay K 8644) had no 
effect. The current was named N-type, as it was “neither” L- nor T-type current. This 
channel still required a stronger depolarisation to activate, but the rate o f inactivation 
was significantly faster (between 40 and 110 ms) than L-type currents which did not 
seem to inactivate in response to a 200 ms step (Fox et al., 1987). Whilst N-type current
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is unaffected by DHPs, it been found to be specifically and irreversibly blocked by the 
sea snail {Conus geographus) toxin co-conotoxin GVIA (Sher and Clementi, 1991).
The use o f toxins also helped identify another neuronal calcium current, this time in 
cerebellar Purkinje cells (Llinas et al., 1989). The use o f the funnel-web spider venom 
blocked Ca2+-dependent spikes in Purkinje cells. These channels were unaffected by co- 
conotoxin GVIA. The current was named P-type after the Purkinje cells in which they 
were found. Later, co-agatoxin IVA was purified (from Agelenopsis aperta) as a more 
specific blocker o f P-type current (Mintz et al., 1992). A similar current type (named Q- 
type due to it similarity) was found in cerebellar granule cells (GCs; Randall and Tsien,
1995), this current inactivated more rapidly than P-type current, and was less sensitive to 
block by co-agatoxin IVA.
Finally, an HVA current “resistant” to DHPs, co-conotoxin GVIA (except in the 
millimolar range) and co-agatoxin IVA was found, and consequently named R-type 
current (Ellinor et al., 1993; Soong et al., 1993). R-type current inactivated more quickly 
than the other HVA currents, though not to the same extent as T-type current (Randall 
and Tsien, 1997). In addition R-type current was blocked by application o f N i2+ ions.
1.2.2 Purification and molecular structure
Purification o f calcium channels involved the extensive use o f DHPs to bind “DHP 
receptors” in skeletal muscle, due to the much higher (50 -  100 times) abundance o f 
DHP receptor here than in any other tissue (Hess, 1990b). DHP receptors were 
speculated to be linked to calcium channels (Borsotto et al., 1985) due to the observed 
block o f calcium currents by DHPs, as well as the lack o f labelling o f DHP-receptors in 
the muscle sarcolemma compared to the t-tubule membranes (which correlated with the 
occurrence o f calcium currents).
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Using the radiolabelled DHP 3H-nitrendipine in guinea pig ileum smooth muscle 
membrane preparations, a molecular weight o f 270,000 was deduced for the calcium 
channel (Venter et al., 1983), and provided an initial estimate for the size o f the DHP- 
receptor complex. The first purification o f calcium channel subunits followed (Curtis 
and Catterall, 1984). Three polypeptides were purified, and were named a  (160 kDa), p 
(50 kDa) and y (33 kDa) subunits. The a  subunit was reduced to form a 130 kDa subunit 
by the reducing agent dithiothreitol (DTT). Reconstitution o f these subunits into an 
artificial membrane produced functional (L-type) calcium channel currents, suggesting 
that the DHP-receptor was not only linked to a calcium channel, but was the channel 
itself (Flockerzi et al., 1986).
Another a  subunit was subsequently found as a subunit o f equivalent size and equimolar 
stoichiometry which was not reduced in mass under reducing conditions, suggesting it 
did not contain disulphide bonds (Vaghy et al., 1987; Leung et al., 1987). The non­
reducing subunit was termed a i (termed Cava i here), and the reducing subunit termed 012 
(Vaghy et al., 1987).
Identification o f the amino-acid sequence o f the Cavoti (Cavl . l  from rabbit skeletal 
muscle) subunit (Tanabe et al., 1987) showed it to be a 4 transmembrane (TM) structure 
which contained the binding site for DHPs and also formed the channel pore. This 
structure was analogous to that o f the voltage-gated sodium channel (Noda et al., 1984). 
Similar functional residues were identified as compared to those located in sodium 
channels. These included charged residues at every third position in the S4 segment, 
responsible for voltage sensing.
The purification o f L-type channels from skeletal muscle was followed by purification 
o f other channel types as they were identified by their electrophysiology in other tissues.
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1.3 The V G C C  C avcxi subun it
1.3.1 Topology o f the C av(Xi subun it
The structure o f the VGCC Cava i subunit is similar to that o f  the pore-forming subunits 
o f voltage-gated potassium and sodium channels (reviewed in Catterall, 2000), and 
therefore the studies o f one type o f channel may generalise for the others. VGCC a i 
subunits are composed o f 4 TM domains, each containing 6 segments (SI to S6). A 
representation o f VGCC channel structure (with associated auxiliary subunits) is shown 
in Figure 1.3.
C ava
'-s= s-
III IV
Figure 1.3. Schematic representation o f VGCC topology. The Cavoti subunit is 
represented as a 24 TM protein structure, arranged into four domains (I-IV) with each 
domain containing six TM segments (1-6). The voltage-sensing S4 segments are shown, 
as well as the S5 and S6 segments (between which lie the membrane re-entrant loops 
which make up the channel pore). The intracellular p, membrane-bound y and 
extracellular a 2 (associated with the membrane-bound 8) auxiliary subunits are shown.
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“C” and “N” refer to carboxyl and amino terminal sequences respectively. S=S 
represents one or more disulphide bonds between the 0L2 and 5 polypeptide sequences.
1.3.2 The channel pore and selectivity filter
The Cava i subunit forms the channel pore (which can function as a calcium channel in 
the absence o f auxiliary subunits), and therefore must be able to selectively distinguish 
between ions. The channel pore itself is formed by the membrane re-entrant pore-loop 
(“P-loop”) between segments S5 and S6  (Yellen et al., 1991). The P-loop is about 20 
amino-acids long and forms the narrow extracellular end o f the channel pore (Yellen, 
1998). The solution o f  the structure o f the KcsA potassium channel from Streptomyces 
lividans (Doyle et al., 1998) provided much insight into the structure o f the ion channel 
pore. For this channel the length o f the channel pore was 45A, with a variable diameter. 
Within the pore lies the selectivity filter. The selectivity filter accommodates the 
permeant ions at a number o f sites determined by signature charged amino-acids 
(depending on the channel type). This part o f the pore is constricted so that the ion is 
stripped o f its hydration. VGCCs select for Ca2+ ions over other cations by virtue of 
conserved glutamate residues in the P-loops o f Domains III and IV (Yang et al., 1993) 
and aspartate residues in Domains I and II. These residues are aspartate residues in the 
II-III and III-IV loops o f Cav3.x channels (Lacinova, 2005). However, additional 
residues in the Domain III S5-S6 region (a domain homologous to an EF hand, which 
binds calcium) also contribute to the ionic selectivity o f VGCCs (Feng et al., 2001). The 
EF hand is shown in Figure 1.7.
1.3.3 The voltage-sensor
Voltage-gated channels need to open and close in response to changes in potential across 
the cell membrane. This is achieved by the movement o f charged residues within the 
channel structure which couple to gating machinery. These residues are located in the
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C av(Xi subunit o f VGCCs (Tanabe et al., 1987). Repeats o f arginine and lysine residues 
within the S4 segments suggested the cloned skeletal muscle calcium channel was 
indeed a voltage-gated channel, as the same motifs had been found previously for 
voltage-gated sodium channels (Noda et al., 1982; Noda et al., 1984). The movement o f 
these charged residues can be observed by removing permeant ions from the external 
solution, whereby a small “gating” current remains in the absence o f ion flow 
(Armstrong and Bezanilla, 1974). The contribution o f each S4 charged residue to the 
gating current can be calculated by its removal (Aggarwal and MacKinnon, 1996). A 
number o f models exist for how the S4 segment moves in response to a depolarisation to 
enable channel opening (Catterall, 1988; Cuello et al., 2004; Jiang et al., 2003).
The gating o f  voltage-gated channels allows another means by which channels can be 
modulated. Inhibition o f  channels is possible either by a physical block o f the channel 
pore, or by preventing the movement o f the gating machinery (for review see Catterall et 
al., 2007). As with pore-blocking drugs, it is possible to influence channel function by 
interfering with the voltage sensor, as is the case with DHPs (Doering and Zamponi,
2003).
1.4 Current classification o f VGCC Cav(Xi subunits
Originally divided into HVA and LVA families, and then according to their 
electrophysiological characteristics (L, P/Q, N, R, T-type), VGCCs are now classified 
according to gene homology (Ertel et al., 2000). A total o f 10 genes for different oti 
subunits have been identified and the resulting channels are arranged into three families: 
Cavl.x; Cav2.x; and Cav3.x. The sequence similarity between members o f  the different 
VGCC families is shown in Figure 1.4.
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Figure 1.4. Phylogeny o f VGCCs. The 10 human VGCC genes (and the channels they 
produce) are shown, as is their similarity in amino acid sequence to one another. 
Adapted from Ertel et al., (2000).
1.4.1 The Cavl.x  subfamily (L-type)
Members o f the Cavl.x  gene family give rise to channels with L-type current (see 
Section 1.2.1). They are also characterized pharmacologically by their sensitivity to 
DHPs. These can have an antagonistic action on the channels (such as isradipine) or 
agonistic effect (such as Bay K 8644; reviewed in Catterall., 2005). DHPs bind at the 
S5-S6 regions in Domains III and IV, and influence the gating machinery so that 
channels enter a more or less “willing” state (Doering and Zamponi, 2003). PAAs bind a 
different site (albeit one with overlapping residues), but cause channel block rather than 
altering gating properties. BZPs also bind Cavl.x  channels at another distinct site 
involving many o f the same residues.
A number of studies have attempted to produce images o f VGCCs by electron 
microscopy in an attempt to further elucidate their structure (reviewed in Wang et al.,
2004), as shown in Figure 1.5. These studies used VGCCs purified from skeletal or 
cardiac muscle tissue due to VGCC abundance there, and as a result examine Cavl.x  
channel structure.
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Figure 1.5. Representations o f VGCC structure using purified Cavl.x  channels from 
skeletal muscle. The studies are relatively consistent in showing a membrane-bound 
Cavoti subunit, intracellular (3 subunit (although shown to be located in the membrane in 
(D)), and an extracellular 0 ,2  subunit that extends into the extracellular space. Figure 
adapted from Wang et al., (2004).
1.4.1.1 C avl . l  (a is)
Due to it high occurrence in skeletal muscle, Cavl. l  was the first VGCC subunit to be 
purified. Its main location is in the t-tubules o f skeletal muscle fibres, where it is 
involved in excitation-contraction coupling and Ca2+ homeostasis (Catterall et al., 2005). 
Cavl.l  associates with the auxiliary subunits a 25, (3 and y (Takahashi et al., 1987), 
Blockers include DHP antagonists such as verapamil and isradipine), whilst activators 
include BayK8644 and DHP agonists (Catterall et al., 2005). Cavl. l  channels open with 
characteristically slow kinetics, and therefore allow negligible Ca2+ entry with a single 
muscle action potential.
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Cav 1 -1 in skeletal muscle is implicated in excitation-contraction coupling (ECC), but this 
is dependent on the gating charge movement o f the L-type channel in response to 
depolarisation, rather than by entry o f calcium ions (Rios and Brum, 1987). This charge 
movement makes an interaction with ryanodine receptors in the sarcoplasmic reticulum, 
triggering Ca2+ release (Catterall, 2000). Accordingly, mutations o f the Cavl . l  subunit 
result in a number o f skeletal muscle-related pathologies. The absence o f Cavl.l  causes 
muscular dysgenesis, a lethal condition arising from a failure o f ECC (Adams and Beam,
1990).
Regulation o f skeletal Cavl . l  channels occurs via phosphorylation o f both the a i and 
associated p subunits, as reviewed in Catterall (2000). The a i subunit is regulated by 
cAMP-dependent protein phosphoylation, with cAMP-dependent protein kinase causing 
an increase in the mean open-time o f single channels (Flockerzi et al., 1986). 
Phosphorylation sites have been identified in both the a i and p subunits, as reviewed in 
Catterall (2000).
1.4.1.2 Cav1.2 (otic)
Cav1.2 (otic) was originally purified from chick cardiac muscle (Chang and Hosey, 
1988; Cooper et al., 1987), however it is also found in smooth muscle and central 
nervous system (CNS; Snutch et al., 1991). The a l  subunit is larger (185 kDa) than the 
Cavl . l  a i  subunit (-170 kDa), and was poorly recognised by antibodies against Cavl . l  
(Chang and Hosey, 1988). Cav1.2 undergoes significant phosphorylation by cAMP- 
dependent protein kinase (reviewed in Kamp and Hell, 2000). It is involved in 
excitation-contraction coupling in cardiac muscle, as well as propagating the action 
potential in the sino-atrial and atrio-ventricular nodes o f the heart (reviewed in Catterall 
et al., 2005). In cardiac muscle tissue, the Cav1.2 channel makes a functional interaction 
to ryanodine receptors which does involve the influx o f calcium, rather than a 
mechanical interaction resulting in the release o f Ca2+ from the sarcoplasmic reticulum,
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as in skeletal muscle (Avila and Dirksen, 2000). In neurons, Cav1.2 channels form 
clusters, and have been shown to localize in the extrasynaptic space in hippocampal 
neurons (Obermair et al., 2004). As with Cavl . l ,  Cav1.2 is subject to alternative splicing 
(Snutch et al., 1991).
1.4.1.3 Cav1.3 (oiid) and Cav1.4 (a iF)
The existence o f Cav1.3 and Cav1.4 subunits occurred at the same time as alternative 
splice variants o f Cavl . l  and Cav1.2 were being discovered (Snutch et al., 1991; Perez- 
Reyes et al., 1990; Seino et al., 1992; Tomlinson et al., 1993). Cav1.3 was considered a 
“neuroendocrine” channel due to its location in endocrine cells (such as pancreatic p 
cells) as well as neurons, sensory receptor cells, vascular smooth muscle and nodes of 
the heart (reviewed in Catterall et al., 2005). Cav1.3 knockout mice displayed deafness, 
due to a lack o f sound-evoked depolarization in cochlear inner hair cells. These mice 
also displayed bradycardia and arrhythmia, as a result o f sinoatrial node dysfunction 
(Platzer et al., 2000).
Cav1.4 is located in retinal photoreceptors, where mutations can lead to congenital 
stationary night-blindness (Strom et al., 1998), as well as localizing in spinal cord and 
lymphoid tissue (Catterall et al., 2005).
1.4.2 The Cav2.x subfamily
The Cav2.x family makes up the predominantly neuronal family o f VGCCs. These 
channels typically give rise to currents intermediate in their rate o f  inactivation between 
Cavl.x  and Cav3.x families. Cav2.x VGCCs are classically blocked by various peptide 
neurotoxins, which enabled their pharmacological dissection from one another.
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Cav2.1 (aiA, P/Q type)
The initial identification (Llinas et al., 1989) and characterization (Mintz et al., 1992; 
Usowicz et al., 1992) o f P-type channels found them to possess HVA currents with little 
inactivation over a 1 second depolarization. Currents were inhibited rather than activated 
by Bay K 8644, although the inhibition was slight (Usowicz et al., 1992). Cav2.1 
channels are implicated in neurotransmitter release at central synapses (Turner et al., 
1992; Takahashi and Momiyama, 1993).
Purification o f the (Cav2.1) protein (Mori et al., 1991; Starr et al., 1991) identified a 
calcium channel subtype expressed throughout the nervous system (Hillman et al.,
1991). As well as being located on the dendrites and cell bodies o f Purkinje cells, a high 
incidence o f Cav2.1 protein was found at presynaptic terminals, o f  many neurons 
(Westenbroek et al., 1995). P-type channels encoded by the Cav2.1 subunit are highly 
sensitive to block by co-agatoxin IVA with an IC50 in the region o f 1-3 nM (Mintz et al.,
1992) and co-conotoxin MVIIC with an IC50 o f 18 nM (Hillyard et al., 1992; 
McDonough et al., 1996), whilst being insensitive to co-conotoxin GVIA block. 
Application o f funnel-web spider venom showed a block o f muscle contraction and 
evoked neurotransmitter release (Uchitel et al., 1992), implicating Cav2.1 in these 
functions, co-agatoxin IVA is thought to bind the S3-S4 linker in Domain IV and shift 
activation kinetics, whilst w-conotoxin MVIIC is thought to occlude the channel pore 
(reviewed in McDonough et al., 2002).
Q-type current was subsequently identified in cerebellar granule cells. When the Cav2.1 
gene (expected to produce P-type channels) was expressed in Xenopus oocytes, it was 
found to be less sensitive to co-agatoxin IVA and possess faster activation and 
inactivation kinetics (Sather et al., 1993). The sensitivity to co-agatoxin IVA block was 
lower than that o f P-type channels with an IC50 o f 100-200 nM (Catterall, 2000). 
Alternative splicing o f Cav2.1 appears to be responsible for the production o f both P and 
Q channel types (Bourinet et al., 1999). A valine insertion (V42i) in the I-II linker region 
(near to the f3 binding site), as well as the insertion o f Asp and Pro (N 1605-P16O6) residues
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in domain IV caused the production o f an oiia subunit with properties such as a reduced 
inactivation rate. A mutation in the S5-SS1 linker region (E1740R) produced a threefold 
increase in peak current (Hans et al., 1999). Therefore, alterations in the Domain IV 
structure can induce significant changes on the biophysical properties o f the resultant 
channels.
Mouse Cacnala mutants give rise to a number o f phenotypes displaying ataxia and 
dyskinesias. Tottering, leaner and rolling phenotypes all result in a decrease in Pukinje 
cell current density (reviewed in Zwingman et al., 2001). Other phenotypes include 
tottering-3J and rocker. These phenotypes all result in ataxia, with tottering also causing 
dyskinesia (Zwingman et al., 2001) and tottering, leaner, rocker and tottering-3J 
resulting in absence seizures.
Mutations in human Cav2.1 have also been found to result in a number o f pathological 
phenotypes such as familial hemiplegic migraine (FHM), episodic ataxia type 2 (EA2), 
and spinocerebellar ataxia type 6  (SCA6 ; Pietrobon, 2002). SCA6  is caused by a 
polyglutamine expansion in the carboxy terminal region o f the CACNA1A gene, whilst 
FHM is caused by various mutations throughout the coding region, and EA2 is most 
usually caused by mutations that result in truncations o f Cav2.1 (Ducros et al., 1999).
The knock-out o f Cav2.1 in mice results in ataxia and dystonia, and proves fatal within 
two to three weeks (Fletcher et al., 2001; Jun et al., 1999). P/Q type currents were found 
to be absent from dissociated Purkinje cells and GCs. However, there was evidence for a 
compensatory contribution from N and R type current, although this was not sufficient 
to recover the quantal release o f neurotransmitter (Urbano et al., 2003).
The contribution o f individual domains to channel properties has been investigated, 
following the identification o f what may be a two-domain form o f Cav2.1 (or a 
breakdown product) which interacts with the channel complex (Scott et al., 1998). This 
95 kDa glycoprotein is comprised o f Domains I and II o f Cav2.1 (as well as part o f the 
II-III linker region), and interacts with both the Cav2 .1 and |3 subunits. It is found to be
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enriched in the cerebellum (Arikkath et al., 2002). When a Domain I-II construct o f 
Cav2.1 was expressed with a Domain III-IV construct o f Cavl . l ,  the hybrid subunit 
showed an ability to recover voltage sensing (Ahem et al., 2001), suggesting this protein 
may provide a functional voltage sensing contribution to its associated Cav2.1 subunit in 
neurons. Co-expression with the Cav2.1 subunit was also found to inhibit currents via 
competition for p subunit binding (Arikkath et al., 2002).
1.4.2.2 Cav2.2 (a iB, N-type)
N-type channels were the first additional calcium channel to be identified by 
electrophysiology after L-type channels (Nowycky et al., 1985), and d ie  protein shown 
to be present in neurons (Dubel et al., 1992). Following the cloning o f Cav2.2 by 
homology with other calcium channels, it was identified as the molecular counterpart o f 
N-type channels. Cav2.2 plays a role in neurotransmitter release from motor nerve 
terminals. This is mainly at early times during development however, with Cav2.1 
channels replacing them in the adult (Urbano et al., 2003), except at some synapses 
(such as sensory neurons in the peripheral nervous system). The role in neurotransmitter 
release comes from the association o f Cav2.2 with soluble V-ethylmaleimide-sensitive 
factor attachment protein receptor (SNARE) proteins (see Section 1.9). These include 
syntaxin 1A, synaptotagmin and synaptosomal-associated protein 25 (SNAP-25), which 
can inhibit Cav2.2 function (Bezprozvanny et al., 2000; Wiser et al., 1996a; Sheng et al., 
1997). Cav2.2 is also important in synaptogenesis and regulation o f gene expression 
(Gray et al., 2007). As is the case for other Cav2.x VGCCs, Cav2.2 channels are 
modulated by G proteins (Dolphin, 2003b). They are also selectively blocked by co- 
conotoxin GVIA. Unlike co-agatoxin IVA, co-conotoxin GVIA appears to act as a pore- 
blocker, binding residues in the S5-S6 linker region o f Domain III (Ellinor et al., 1994).
Cav2.2 associates with auxiliary subunits oc2d and [3 (McEnery et al., 1991; Scott et al.,
1996). Its localization and organization in the developing synapse is regulated by 
laminin (33 (Nishimune et al., 2004).
- 4 0 -
Cav2.2 (for example in dorsal root ganglion cells) is important for mediating nociceptive 
information from the periphery to the central nervous system (Altier et al., 2007). Cav2.2 
is subject to alternative splicing (Stea et al., 1999), and different isoforms o f the channel 
can alter the excitability o f nociceptive neurons (Raingo et al., 2007). A peptide blocker 
o f Cav2.2 channels based on co-conotoxin MVIIC (Ziconotide), has shown efficacy in 
treating hyperalgesia, allodynia and inflammatory pain (reviewed in Catterall et al., 
2005).
1.4.2.3 Cav2.3 (c x ie , R-type)
The R-type current was originally classified according to its “resistant” or “residual” 
nature, when applying toxins to block L, N and P/Q type currents. R-type current 
inactivated more rapidly than either N or P/Q type, as well as activating at lower 
potentials. It was initially considered both an HVA and an LVA channel (Ellinor et al., 
1993; Soong et al., 1993). Following the cloning o f Cav2.3, it was found to have 
properties in common with channels giving rise to R-type current. A number o f Cav2.3 
isoforms are produced, each with differing sensitivity to the tarantula toxin SNX-482, 
selectivity for Ca2+ ions and Ba2+ ions, as well as having differences in voltage- 
dependence o f current activation (Tottene et al., 2 0 0 0 ).
The VGCCs which gave rise to R-type current are now recognized as HVA channels. 
These currents are not affected by DHPs, co-agatoxin IVA or co-conotoxin GVIA, 
although studies have shown a sensitivity to co-agatoxin IVA (Stephens et al., 1997). 
They are blocked by Ni2+ ions, unlike other VGCC subtypes (Soong et al., 1993) and 
also SNX-482, with an IC5o o f 15-30 nM (Newcomb et al., 1998). SNX-482 inhibits 
Cav2.3 channels irreversibly, by preventing normal activation gating o f the channels 
rather than by blocking them. This depolarises the voltage-dependence o f channel 
opening, an effect reliant on Domains III and IV (Bourinet et al., 2001). Additional
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modulation comes from activated G proteins, which bind to the I-II linker o f  Cav2.3 
channels (Dolphin, 2003b).
Cav2.3 knockout mice have increased the confusion surrounding Cav2.3 and R-type 
current (Wilson et al., 2000). A small component o f the “residual” current in cerebellar 
GCs and dorsal root ganglion was ablated in Cav2.3 -/- mice, which corresponded to that 
blocked by application o f SNX-482. In both cases however, a significant proportion o f 
the current remained, suggesting Cav2.3 channels make up only part o f this residual 
current.
1.4.3 The Cav3.x subfamily ( a ic /  otiH / an , T-type)
Channels o f the Cav3.x family pass T-type current, characterized by a transient influx o f 
calcium with a fast rate o f inactivation. These currents were first observed in starfish 
(Hagiwara et al., 1975) and chick sensory neurons (Carbone and Lux, 1984). These 
currents activate at lower potentials than members o f the Cavl.x  and Cav2.x families 
(HVA channels), and are known as low-voltage activated (LVA) channels. LVA VGCCs 
are roughly equally selective for Ba2+ ions and Ca2+ ions, unlike the HVA channels.
Three Cav3.x channels have been described (Catterall, 2000). Cav3.1 is found 
predominantly in the brain, as well as heart, placenta and ovary (Catterall et al., 2005). 
Cav3.2 is found in kidney, smooth muscle and heart. Cav3.3 is found exclusively in brain 
tissue (Catterall et al., 2005). Due to their characteristic current-voltage relationship, 
Cav3.x channels are important for producing low-voltage spikes in neurons, as well as 
being involved in hormone secretion from the adrenal gland (Lacinova, 2005). 
Expression o f Cav3.1 and Cav3.2 subunits produces calcium currents similar to those 
seen in native cells, and Cav3.x amino acid sequences do not contain an AID sequence, 
suggesting they do not associate with auxiliary subunits (Lacinova, 2005).
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No specific T-type current blockers were identified initially, ruling out pharmacological 
classification o f the currents. However newer agents such as the gating modifier 
kurtoxin (from scorpion) have since been identified (Chuang et al., 1998), although their 
absolute specificity for Cav3.x channels is not assured, with block o f Cav2.x channels 
(and also voltage-gated sodium channels) observed. Ni2+ ions also block Cav3.x 
channels, with greatest affinity block for Cav3.2 (reviewed in Catterall et al., 2005) 
However, Ni ions also block Cav2.x channels with a lower affinity (reviewed in 
Doering and Zamponi, 2003).
1.5 Function and modulation o f VGCCs
1.5.1 Channel inactivation
One o f the important characteristics o f channel function is the kinetics o f activation and 
inactivation. This imposes a degree o f control over the amount o f Ca2+ that will enter the 
cell for a given duration o f depolarization. Three mechanisms o f inactivation exist: 
calcium-dependent and voltage-dependent: o f which there are fast and slow forms 
(reviewed in Hering et al., 2000).
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Figure 1.6. Inactivation states o f VGCCs. Open, closed and the three inactivated states 
o f VGCCs, represented as single protein structures (black) embedded in the membrane 
(blue). Channels may move between states as indicated by the arrows. Figure adapted 
from Hering et al., (2000).
1.5.1.1 C alcium -dependent inactivation
Another inactivation mechanism for VGCCs (specifically Cav1.2 and Cav2.1) involves
I ^  | O-L. 0-1—
the entry o f  Ca“ itself. Replacing Ca~ ions with Sr or Ba~ ions resulted in a change 
in the time-course o f inactivation, suggesting Ca2+ ions were involved in switching off 
the current (Lee et al., 1985). The underlying cause o f this inactivation was indeed the 
entry o f Ca2+ ions, and their association with calmodulin. Calmodulin binds to an IQ 
domain on the C-terminal o f VGCCs (Zuhlke and Reuter, 1998). Residues within this 
domain are responsible for binding calmodulin/Ca2+ and mediating this inactivation 
(Zuhlke et al., 2000b). It is thought that calmodulin binds to the IQ domain
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constitutively, but only has an effect upon inactivation kinetics when Ca binds to it 
(Catterall, 2000).
The IQ domain is responsible for mediating calcium-dependent facilitation in addition 
(Zuhlke et al., 2000a), and is thought to be mediated by binding o f calmodulin/Ca2+ to 
the IQ domain. Facilitation can be observed by applying double or multiple pulses. 
Demonstrating the facilitation effect with a pre-pulse, a larger peak current was obtained 
in the presence o f Ca2+ ions, but not Ba2+ ions (Xiao et al., 1994). The facilitation could 
also be blocked by application o f the Ca2+ chelator BAPTA, as well as the CaMKII 
blocker ICK. The same inhibitory and facilitatory effects have been observed in Cav2.1 
currents (Lee et al., 1999), and involve Ca2+-calmodulin binding to the C-terminal end o f 
the Cav2.1 a i subunit at a novel site (Catterall, 2000).
1.5.1.2 Voltage-dependent inactivation
Voltage-dependent inactivation confers a level o f control over VGCC activity in relation 
to excitability. VGCCs inactivate in response to a long depolarisiation, from members of 
the Cavl.x  family which show little or no inactivation, to members o f the Cav3.x family 
which inactivate in the order o f tens o f milliseconds (reviewed in Catterall et al., 2005). 
Cav2.3 inactivates only marginally more slowly than Cav3.x channels, and Cav2.2 and 
Cav2.1 inactivate more slowly. It was found that Ba2+ flux through VGCCs decayed in a 
bi-exponential manner in a number o f cases, suggesting the presence o f two (fast and 
slow) voltage-dependent phases o f inactivation (reviewed in Hering et al., 2000).
A number o f mutation studies (involved in disease phenotypes) have been demonstrated 
to have an effect on voltage-dependent channel inactivation, such as Cav2.1 mutations in 
S6  segments and their involvement in familial hemiplegic migraine (FHM; Kraus et al., 
1998; Kraus et al., 2000). Cav2.1 mutations associated with FHM patients were 
introduced into rabbit Cav2.1. A total o f six mutations were found to alter the rate o f 
inactivation (and recovery from inactivation). Additionally, chimeric studies using the
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S6  segment o f Domain I (in Cav2.1) as a replacement for that o f  the faster-inactivating 
Cav2.3 caused a slowing o f inactivation (Zhang et al., 1994). Mutation o f residues in the 
I-II linker (Herlitze et al., 1997), as well as regions in the S3-S4 and S5-S6 linker 
regions in Domain IV o f Cav2.1 (Hans et al., 1999) also alter inactivation.
The slow-phase o f voltage-dependent inactivation is not well dissected from the fast- 
phase and have a time constant o f several seconds in Cavl.x  channels, as reviewed in 
Lacinova, (2005). In many instances decay curves can be fitted adequately using a single 
exponential (see Materials and Methods).
Membrane potential is therefore an important factor in VGCC inactivation. A given 
potential will result in a certain proportion o f the channel population that is in the 
inactivated state, the rest being in open, closed or calcium-inactivated states (see Figure 
1.6). The proportion o f channels that are voltage-inactivated will vary with membrane 
potential, and can be described by a Boltzmann function (see Materials and Methods). 
This is referred to as steady-state inactivation.
1.5.2 G protein modulation
For Cav2.x channels (especially Cav2.1 and Cav2.2 type channels), modulation by G 
proteins represents a significant mechanism for modulation (Scott and Dolphin, 1986; 
Dolphin, 2003b), with calcium currents in many neurons such as dorsal root ganglion 
and superior cervical ganglion being inhibited by G proteins. Studies trying to identify 
the type o f G protein involved found that a number o f G a subunits caused G protein- 
mediated inhibition. It was subsequently found that the GPy subunit rather than the G a 
subunit was responsible for inhibition (Herlitze et al., 1996). The required GPy subunits 
are provided by activation o f a number o f receptor types- such as a 2-adrenoceptors, 8  
and p opioid receptors, GABAb receptors and adenosine A l receptors (Dolphin, 2003b).
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G proteins bind to the I-II linker o f the Cav(Xi subunit in Cav2.x channels (Dolphin, 
2003b), to a site which overlaps with the binding site o f the Cavp subunit. Binding o f the 
p subunit facilitates voltage-dependent G protein modulation, rather than preventing it 
(Canti et al., 2000; Meir et al., 2000). The same site in Cavl.x  channels will bind the 
Cavp subunit, but not GPy (Bell et al., 2001; Herlitze et al., 1997).
G protein-mediated inhibition o f calcium channels is characterized by a shift in voltage- 
dependence to more depolarized potentials (Bean, 1989), rather than a reduction in 
single-channel conductance or a reduction in the number o f channels present. The shift 
in voltage-dependence is due to a shift o f the channel population to the “reluctant” mode 
(with Gpy bound) rather than the “willing” mode (with no Gpy bound). A prolonged 
depolarisation o f the channels by pre-pulse (Bean, 1989; Ikeda, 1991) offers a means o f 
relief from G protein modulation, and suggests the importance o f action-potential 
frequency in the modulation o f presynaptic inhibition.
1.5.3 Channel phosphorylation
The Cav(Xi (and p ) subunits are subject to phosphorylation, which results in an increased 
expression o f both subunits in skeletal muscle (reviewed in Catterall, 2000). This occurs 
via the cAMP-dependent protein kinases (A and C). Phosphorylation also enhances 
current amplitude and shifts channels towards the “willing” mode, and can reverse G 
protein modulated inhibition in Cav2.2 channels (Swartz, 1993).
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Figure 1.7. Sites o f modulation and functional importance in the Cava i subunit. Sites 
shown are: the AID sequence and N- / C- termini, which bind (3 subunits (depending on 
the Cava i subunit and p isoform); the synprint site, involved in binding SNARE 
proteins; the IQ domain (in Cavl.x channels), which binds the Ca2^  / calmodulin 
complex; the main Gpy binding site, overlapping with the AID sequence; and the EF 
hand involved in Ca" selectivity, located within the S5-S6 linker of Domain III. Binding 
regions for co-agatoxin IVA (in Cav2.1) in the S3-S4 region o f Domain IV, and for co- 
conotoxin GVIA (in Cav2.2) in the S5-S6 region of Domain III are shown. Multiple sites 
o f importance (such as individual residues implicated in inactivation, or the binding of 
DHPs in Cavl .x channels) are omitted for simplicity, and referred to in the text.
1.6 The beta (p) subunit
The p subunit was originally purified as one peptide o f the DHP receptor complex 
(Curtis and Catterall, 1984). It was found to contain a-helices, but no TM domains, 
suggesting it was an intracellular protein (Ruth et al., 1989) associated to the Cavcxi 
subunit via a protein-protein interaction. Four p subunit genes (cacnb 1-4, each with 
additional splice variants) have been identified (Ruth et al., 1989; Castellano et al., 
1993a; Castellano et al., 1993b; Hullin et al., 1992; Perez-Reyes et al., 1992; 
Birnbaumer et al., 1998). A schematic o f the p subunit structure is shown in Figure 1.3.
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One o f the primary effects o f the (3 subunit is to increase the observed current amplitude 
through the Cavoti subunit, as seen when p i was co-expressed with Cav1.2 (Perez-Reyes 
et al., 1992). Additional biophysical effects include a hyperpolarizing shift in current- 
voltage relationship with co-expression o f p i or P3 subunits, but a depolarization with 
co-expression o f p2 (Bimbaumer et al., 1998), as well as acceleration o f inactivation 
kinetics (Singer et al., 1991) and hyperpolarisation o f the steady-state inactivation 
(Leroy et al., 2005). The co-expression of different p subunits affects the rate o f 
inactivation differently, with p i accelerating inactivation rate, and p2 a slowing it 
(Bimbaumer et al., 1998).
The increase in peak-current amplitude with co-expression o f p subunits is attributed to 
an enhancement o f trafficking o f the Cava i subunit (Brice et al., 1997). The ability o f p 
subunits to enhance expression is controversial however, with some studies finding a 
lack o f increase in the gating charge movement (for review see Richards et al., 2004). 
The interaction site between the a i and p subunits has been shown to be in the I-II linker 
region o f the Cava i subunit (Pragnell et al., 1994). The I-II linker was subsequently 
found to contain an ER retention signal, which prevents full expression o f produced 
Cav<xi protein (Bichet et al., 2000). Binding o f p subunits to the I-II linker prevents the 
function o f this retention signal, and allows enhanced membrane expression o f Cavoti 
subunits. The site at which the p subunit binds is the “alpha interaction domain” (AID), 
an 18 amino acid sequence (QQxExxLxGYxxWIxxxE in HVA channels, where x can be 
any amino acid) within the I-II linker sequence (Dolphin, 2003a). A tryptophan residue 
within this is essential for the p subunit binding. However this is not the case in the 
palmitoylated p2 a subunit, suggesting the presence o f another binding site, and / or the 
additional role o f palmitoylation in increasing juxta-membrane concentration (Berrou et 
al., 2002; Leroy et al., 2005). The AID is not the sole binding site within Cava j subunits 
for p subunit binding, as there are also thought to be sites in the C and N termini 
(reviewed in Dolphin, 2003a).
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As with the calcium channels they modulate, (3 subunits are located throughout the body. 
The p i a subunit is found in skeletal muscle where it is vital for excitation-contraction 
coupling (Schredelseker et al., 2005), whilst the p lb  subunit is distributed throughout 
the brain and heart tissue (reviewed in Dolphin, 2003a). p2 is present in some neurons 
(such as Purkinje cells), as well as smooth muscle. p3 and p4 subunits are preferentially 
expressed in brain tissue, such as the cerebellum in the case o f P4 (Ludwig et al., 1997).
Structural analysis o f the p lb  subunit has shown it to be a five-domained structure 
(Hanlon et al., 1999), similar to membrane associated guanylate kinases (MAGUKs), 
important for correct arrangement o f ion channels and adhesion molecules at the synapse 
(Helton and Home, 2002). The domain structure o f p subunits includes a PDZ-like 
domain, .srohomology 3 (SH3) domain and a guanylate kinase-like (GK) domain 
(Hanlon et al., 1999). The SH3 and GK domains are linked by a HOOK region 
important for causing p-mediated effects on voltage-dependent inactivation o f channels 
(Richards et al., 2007).
Alternative splicing o f p subunits affects their interaction with and influence over the 
Cav(Xi subunit. An example of this is the alternately spliced p4 subunit (Helton and 
Home, 2002), found with both a short and a long-form o f the N-terminal domain. Co­
expression o f the short form results in more pronounced effects on voltage-dependent 
inactivation.
- 5 0 -
1.7 The gamma (y) subunit
The y subunit (now y l) was initially purified as a 32 kDa constituent protein o f the 
skeletal muscle DHP-R complex (Curtis and Catterall, 1984). The y subunit is shown in 
Figure 1.3. Sequencing o f the subunit (Jay et al., 1990) revealed it to be a 25 kDa 4 TM 
structure with two glycosylation sites. Stargazin, a second gamma subunit (y2) was 
found solely in the brain, as opposed to yl being found in muscle (Letts et al., 1998). 
The y2 knockout mouse (stargazer) displays unusual gait as well as frequent head 
elevations, implicating y proteins in the regulation o f neuronal excitability. A further 6  y 
proteins have been found (Chu et al., 2001; Klugbauer et al., 2000): y3 and y4 are 
localized exclusively in brain (Klugbauer et al., 2000; Moss et al., 2003); y5 is also 
found in various tissues outside the brain (Klugbauer et al., 2000); y6  is found in skeletal 
and cardiac muscle; y7 in most tissues (although concentrated in the brain), and y8 in 
brain and testis (Chu et al., 2001). All y subunits contain a 4 TM structure, although the 
number o f exons present varies between subunits.
Co-expression o f y subunits causes different effects on the resultant VGCC complex, 
depending on the y subunit expressed, yl has been found to cause a decrease in current 
amplitude, although studies also suggest an acceleration o f inactivation kinetics (Black, 
III, 2003). The status of most other putative y subunits as VGCC “subunits” is 
questionable, it is not clear whether these y homologues are actually associated with, or 
influence VGCC activity. The y2 subunit hyperpolarizes steady-state inactivation of 
Cav2.1 channels (Letts et al., 1998), although y2 (and y4) were found to have no effect 
on peak current density, steady state inactivation or voltage dependence o f activation o f 
Cav2.2-mediated currents (Moss et al., 2003). y4 and y5 co-expressed with Cav2.1 
channels caused a hyperpolarisation in steady-state inactivation (Klugbauer et al., 2000). 
Co-expression o f y7 with Cav2.2 channels resulted in a significant reduction in Cav2.2 
expression (Moss et al., 2002).
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A significant overlap exists between the calcium channel y subunits and the alpha- 
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPA-R) 
transmembrane AMPA-R regulatory proteins (TARPs). y l  is known to modulate AMPA 
receptor activity- enhancing trafficking and regulating channel gating (Tomita et al., 
2007; Bats et al., 2007). Therefore the role o f y subunits in regulating synaptic efficacy 
is not limited to action at VGCCs.
1.8 The alpha-2-delta (a 25) subunit
1.8.1 Topology of the a ib  subunit
The initial purification o f the DHP-receptor complex from rabbit skeletal muscle (Curtis 
and Catterall, 1984) isolated the 0128 subunit as a large 160 kDa polypeptide subunit o f 
the channel, non-covalently associated with smaller (3 and y subunits. The 160 kDa 
subunit was reduced to 130 kDa by di-sulfide bond reduction, another study showing 
this reduction (from 170 to 142 kDa) also produced a 32 kDa subunit (Schmid et al., 
1986). The reduction o f this subunit allowed it to be recognized as separate from the 175 
kDa subunit (Cooper et al., 1987; Leung et al., 1987), and was termed the 012 subunit 
(Vaghy et al., 1987). The other subunit product o f the ot2 reduction reaction was named 
the 8  subunit (Takahashi et al., 1987).
The initial model o f the a 28  subunit was a 3 TM structure, with three hydrophobic 
regions proposed at amino acids 422-444, 882-906 and 1043-1062 (Ellis et al., 1988). 
However, the structure has since been revised, as shown in Figure 1.3. 012 can be 
removed from membranes by reduction, whereas the 8  subunit remains membrane- 
associated (Jay et al., 1991), suggesting a 2 is extracellular. Antibody targeting o f TM 
regions in permeabilised and non-permeabilised cells (Brickley et al., 1995), as well as 
improper processing o f a TM III truncation (Wiser et al., 1996b) provide extra evidence 
that a 28  is a single TM protein. The N-terminus o f the 8  subunit, as well as the N-
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terminus o f 0C2 and the sequence between previously proposed TM segments were all 
found to be extracellular, suggesting the 012 subunit was located extracellularly and 
anchored to the cell membrane via the 5 subunit (Brickley et al., 1995). A number o f 
studies have provided structural representations o f L-type calcium channel complexes 
(Wang et al., 2004). These reported structures share a common feature in that the ot2 
subunit is proposed to be a large extracellular protrusion (see Figure 1.5).
The 0,25 protein is extensively glycosylated (Ellis et al., 1988). Deglycosylation (using 
peptide-N-glycosydase F) causes a reduction in mass from 150 kDa to 106 kDa in ( X 2 8 - I ,  
and co-expression o f this deglycosylated form o f O C 2 8 - I  with Cav2.1 / p4 subunits caused 
a 67% reduction in current amplitude (compared to co-expression o f fully-glycosylated 
( X 2 8 - I )  when expressed in oocytes (Gumett et al., 1996). Deglycosylated ( X 2 8 - I  still 
associates with the Cavcxi subunit, but significantly reduces the amount of Cava i 
expression (Gumett et al., 1997). Deglycosylated (X28 also fails to enhance currents to 
the same extent as fully glycosylated 0028 (Sandoval et al., 2004).
The 012S subunit is the protein product o f a single gene (De Jongh et al., 1990). It is post- 
translationally cleaved to produce ot2 and 8 , which remain joined by one or more 
disulphide bonds (Jay et al., 1991). The disulphide bond is formed between cysteine 
residues within the (X28 sequence, however the exact residues involved are not yet 
identified.
Recent work has further probed the processing and cleavage o f 0128. Non-cleaved forms 
of (X28 exist are present when ot2S is heterologously expressed in cell-lines, however it 
appears to retain its functionality (Douglas et al., 2006), suggesting either that cleavage 
is not essential, or that the small proportion o f cleaved a 28  is sufficient for function on a 
cellular level.
The processing o f (X28 is reviewed in Douglas et al. (2006), and shown in Figure 1.8. 
This involves production o f a pro-form of the a 28  protein. The N-terminal signal
- 5 3 -
sequence is removed, and glycosylation and disulphide bind formation occur, followed 
by cleavage and expression. The site o f cleavage has not been mapped to a specific site, 
but multiple mutations between Arg-941 and Val-946 in rat 0126-1 steadily reduce its 
effect on current amplitude without affecting its biophysical modulation o f the resultant 
currents (Andrade et al., 2007).
Figure 1.8. Processing o f the o^d subunit, including cleavage and disulphide formation 
steps to produce the “mature” form o f the protein. Taken from Douglas et al. (2006).
A total o f four o^d genes have now been described (CACNA2D1-4), which encode the 
ot2d - l -4  subunits (Klugbauer et al., 1999; Qin et al., 2002). All 012b subunits show 
several structural similarities including: hydrophobicity profiles; conserved
glycosylation sites and cysteine residues involved in disulphide bond formation 
(Arikkath and Campbell, 2003). The ot2b-2 , a 2d-3 and ot2b-4  subunits show 56%, 30% 
and 30% homology to ot2b-l respectively. Differences in structure arise in structures 
such as the VWA domain (see Section 1.8.6). a 2d-l is located primarily in skeletal 
muscle, but also expresses in the brain and heart (Arikkath and Campbell, 2003). 
Expression in the brain is most pronounced in the cerebral cortex, hippocampus, 
cerebellum and olfactory bulb (Klugbauer et al., 1999). The a 2d-2 subunit shows a more 
diverse localization- including the brain, heart, pancreas and liver (Hobom et al., 2000). 
Within the brain, ot2b-2  is localized strongly in the cerebellum, in particular Purkinje 
cells (Barclay et al., 2001). ot2b-3  is present in the heart and skeletal muscle, as well as 
showing strong expression in the hippocampus, cortex and caudate putamen (Klugbauer
- 5 4 -
et al., 1999). (X28-4  is not found in the brain, but found in heart, skeletal muscle and 
endocrine tissues such as the adrenal glands and pituitary (Qin et al., 2002).
1.8.2 Effect of (X28 co-expression on VGCC electrophysiology
The most apparent feature o f 0126 co-expression is a significant enhancement o f 
macroscopic current size when expressed with numerous Cava i subunits (Mori et al., 
1991; Singer et al., 1991; Gumett et al., 1996; Walker and De Waard, 1998; Catterall, 
2000; Bangalore et al., 1996). Radioligand binding studies suggested this increase in 
current amplitude to be linked to an increase in Cava i subunit cell-surface expression 
(Shistik et al., 1995), as have studies examining the extra gating charge when 0128 is co­
expressed (Bangalore et al., 1996; Jones et al., 1998). Enhancement o f current amplitude 
was not found when the 8  subunit was expressed alone (Felix et al., 1997; Gumett et al.,
1997), suggesting the importance o f the 012 subunit in this function. It has since been 
found that 0128 makes an intracellular interaction with the Cava i subunit by means of a 
von Willebrand Factor-A (VWA) domain (see Section 1.8.6.1) which leads to an 
enhancement o f Cavcti trafficking and subsequent cell-surface expression (Canti et al.,
2005), although this has only been demonstrated for ( X 2 8 - I  and CC28-2  so far.
It is clear that the (3 subunit is also important (perhaps more so than 012S) in mediating an 
increase in Cavoti cell-surface expression, and the presence o f the (3 subunit is often 
required for the effects o f <*28 to be manifested (De Waard and Campbell, 1995; 
Arikkath and Campbell, 2003). In addition to enhancing trafficking o f the VGCC 
channel complex, (X28 appears to play a role in maintaining the expressed channels at the 
cell-surface for longer, by delaying their internalization and subsequent degradation 
(Bernstein and Jones, 2007).
The 0128 subunit elicits changes in the biophysical properties o f channels with which 
they associate. These properties include channel activation and inactivation rates, as well
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as the voltage-dependence o f current activation and maximal whole-cell conductance 
(Welling et al., 1993; Singer et al., 1991; Bangalore et al., 1996; Shirokov et al., 1998; 
Felix et al., 1997; Qin et al., 1998). These biophysical effects appear to be mediated by 
the 8  subunit. Co-expression o f the 8  subunit (of 0128-1) alone caused an equivalent 
acceleration o f inactivation as intact a ^8 (Felix et al., 1997). The same study found co­
expression o f the 8 subunit alone also caused a hyperpolarisation o f steady-state 
inactivation. Therefore, the association o f the 8  subunit with the Cava i subunit is 
sufficient to influence voltage-dependent inactivation.
Unlike the gamma subunit, where interactions with the VGCC complex are often not to 
be found, 0128 associates and makes a functional interaction with all members o f the 
Cavl.x  and Cav2.x families. However, their association with Cav3.x channels is not clear 
(see Section 1.4.3).
1.8.3 The 0,28 subunit and disease
1.8.3.1 Epilepsy
A number o f mutations in the a 28-2 subunit give rise to epileptic phenotypes (Barclay et 
al., 2001; Brill et al., 2004; Ivanov et al., 2004). Mutation o f the mouse 0 ,28-2  gene 
(Cacna2d2), by a duplication and inversion within exon 3, results in a loss o f full-length 
0 2 8  protein and production o f a truncated form of the protein (Barclay et al., 2001). The 
mutant mouse strain was termed “ducky” (<du) due to their wide-based gait, duldu mice 
also displayed ataxia and absence epilepsy, as well as an inability to survive beyond 35 
days. Another mutation (du2J), caused by a deletion in exon 9, also results in loss o f full- 
length 0 ,28-2  (Barclay et al., 2001). Both duldu and d ^ ld i? 1 mice display reductions in 
the size o f the dendritic arbor o f their Purkinje cells, and the amplitude o f calcium 
currents recorded from them.
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Another mutation in the Cacna2d2 gene produces the entla phenotype (Brill et al.,
2004). The Cacna2d2snth allele contains a duplication (in exon 3), which results in the 
production o f a membrane-expressed 0126-2 protein which is cleaved, but not 
subsequently disulphide linked. This produced a phenotype o f absence epilepsy and 
dyskinesia, as well as reduced calcium current amplitude from Purkinje cells.
1.8.3.2 Neuropathic pain
The role o f ct25 in enhancing Ca2+ influx has been implicated as a factor in the 
establishment o f neuropathic pain. Neuropathic pain refers to a collection of conditions 
including allodynia (in which non-noxious stimuli cause pain) and hyperalgesia 
(exaggerated pain response to mild noxious stimulus). Traditional analgesics (opiates 
and non-steroidal anti-inflammatory drugs) are less effective in these conditions, and 
other drugs such as anti-epileptic drugs (carbamazepine (a sodium channel blocker) and 
gabapentin (GBP)) have proven more useful (reviewed in Backonja, 2000). Although 
carbamazepine and GBP act upon different channels, their clinical efficacy may be due 
to control o f neuronal over-excitability. GBP binds 0026-1 and (X28-2  subunits, and is 
discussed in more detail below.
Recent studies have implicated a 28 -l upregulation in central sensitisation, a mechanism 
involving alterations in neuronal excitability as a result o f changes in channel 
expression, which is a cause o f neuropathic pain. 0128-1 is upregulated in dorsal horn 
(Xiao et al., 2007) and DRGs o f nerve-injured rats (Luo et al., 2001), which corresponds 
to onset o f allodynia. This up-regulation o f 0128-1 diminishes in rats recovering from 
allodynia, and corresponds to sensitivity to the anti-allodynic effects o f GBP (Luo et al., 
2002).
1.8.3.3 Tumour suppression
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The human a 28-2 gene (CACNA2D2) is located in a tumour suppressor gene region in 
chromosome 3p21.3 (Gao et al., 2000). This allele is frequently deleted or mutated in 
many lung and breast cancers (among others), suggesting a possible additional function 
o f a 28 -2 .
1.8.3.4 Role in photoreceptors
The a 28-4 subunit has a physiological role in photoreceptors, as determined by 
spontaneously arising a 28-4 mutant mice (Wycisk et al., 2006a). The mutation causes 
the expression o f a truncated a 28-4 protein, and results in rod-cone photoreceptor 
dysfunction. This mutation correlates with one found in exon 25 of the human 
CACNA2D4 gene, which underlies autosomal recessive cone dystrophy, leading to night 
blindness (Wycisk et al., 2006b).
1.8.4 Localisation of a 28 to cholesterol-rich microdomains
Cholesterol-rich microdomains (or lipid rafts) are cholesterol-containing regions of 
plasma membrane, thought to represent regions o f order within the comparatively 
disordered plasma membrane (Brown, 2006). They were isolated as detergent-resistant 
membranes (DRMs) across a sucrose gradient (Brown and Rose, 1992), although these 
may not correspond directly to the lipid rafts that are thought to exist in native cells, due 
to the cold temperatures required for their purification (Brown, 2006). Along with 
purification o f DRMs, disruption o f lipid rafts (using agents such as methyl-p- 
cyclodextrin (MBCD), filipin or nystatin) has been used to demonstrate the importance 
o f lipid rafts in a number o f cellular functions.
Lipid rafts consist of certain lipids (such as sterols and sphingolipids) that spontaneously 
form crystalline structures within the otherwise disordered membrane structure. A 
number o f trans-membrane proteins are thought to associate with lipid rafts, and their 
association may represent either a form o f membrane specialization or a targeting
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mechanism. The CX28 subunit, along with the Cav2.1 and Cav2.2 subunits have been 
shown to be such proteins (Toselli et al., 2005). These associations are discussed further 
in Chapter 4.
1.8.5 Gabapentin binding to the ct25 subunit
GBP has been demonstrated to be clinically useful in a number o f conditions. It shows 
efficacy in a number o f epilespy models, such as maximal electroshock; DBA/2 
audiogenic seizure and genetic absence (reviewed in Taylor et al., 2007). Its original role 
as an anti-epileptic agent has been expanded to include a number of other conditions 
(Bialer et al., 2007). There is evidence for anti-nociceptive effects in neuropathic pain, 
and efficacy in generalized anxiety disorder, as well as other conditions such as SCA6 , 
migraine headaches and bipolar disorder (Maneuf et al., 2003).
The effective doses o f GBP used to treat epileptic conditions have been high compared 
to other drugs. Doses range from 300 mg to 900 mg, with an approved maximum of 
3600 mg per day (reviewed in Wang and Ketter, 2002). The average daily dose o f GBP 
is 1500 mg / day, 1424 mg / day resulted in a plasma concentration o f 8.54 pg / ml 
(reviewed in Bialer et al., 2007). GBP is not metabolized by humans, and its maximal 
bioavailability before saturation is in the region o f 65-70% (Stewart et al., 1993). 
However, subsequent studies have questioned the saturation o f GBP absorption 
(attributed to saturation o f System-L amino acid transport) in dose escalation studies 
(reviewed in Bialer et al., 2007). In recent years, the focus o f GBP treatment has shifted 
from epilepsy to neuropathic pain, (Bialer et al., 2007).
GBP was initially synthesized in 1977 in an attempt to produce an analogue o f gamma- 
aminobutyric acid (GABA) with better CNS penetrating properties. However, whilst 
GBP acted to reduce evoked neurotransmitter release (Reimann, 1983; Schlicker et al., 
1985), this was not altered by the presence of baclofen (a GABAb receptor antagonist)
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or high concentrations o f GABA, suggesting GBP did not act through GABA receptors 
(Martin et al., 2002).
The identification o f calcium channel 0126 subunit as the binding site for GBP (Gee et 
al., 1996) led to the proposal that modulation o f calcium currents through voltage-gated 
calcium channels was the mechanism o f effect o f the drug. However, a direct inhibitory 
effect o f GBP upon calcium channels has proven hard to demonstrate. Several studies 
have concluded a direct inhibitory effect o f acute application o f GBP on calcium channel 
currents. An inhibition o f up to 34% was observed when 10 mM GBP was applied to 
pyramidal neocortical cells (Stefani et al., 1998), along with smaller inhibitions seen in 
other cells types. Incubation o f DRG neurons with 10 pM GBP for 60 min caused a 
reduction in HVA VGCC current amplitude, after application o f a pre-pulse (Alden and 
Garcia, 2001). Similar results were observed in skeletal myotubes. A small inhibition of 
VGCC current amplitude in cultured DRG neurons and F-l 1 cell cultures was observed 
with 2.5 pM GBP application by Martin et al (2002), which correlated with the amount 
of (*,26 protein present in cells.
Other studies have provided evidence against such an inhibitory effect: Brown and 
Randall (2005) found only a small reduction (-10% ) in amplitude o f EPSCs in 
hippocampal slices in the presence o f 10 pM GBP; Rock et al (1993) failed to find any 
inhibitory effect o f GBP (up to 100 pM) upon VGCC current amplitude in a variety of 
cultured neurons; as was the case with 10 pM application to cultured Purkinje cells 
(Davies et al., 2006).
Rather than a direct inhibition o f VGCC currents, some studies have observed reductions 
in either the amplitude o f frequency o f excitatory postsynaptic potentials (EPSCs) in the 
presence o f GBP, and concluded that a reduction of neurotransmitter release comes as a 
result o f GBP-mediated VGCC inhibition. K+-evoked release o f noradrenaline from rat 
neocortical slices was reduced by both GBP and pregabalin (PGB) in the low 
micromolar range (Dooley et al., 2000a). Glutamate release from rat neocortical or 
hippocampal slice preparations was reduced (by 10 - 25%) in the presence o f 100 mM
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GBP (Dooley et al., 2000b). Cunningham et al (2004) looked at evoked and spontaneous 
release o f glutamate from layer V neurons o f rat entorhinal cortex, and found a reduction 
in evoked EPSC amplitude, as well as a reduction in spontaneous EPSC frequency in the 
presence o f 20 pM GBP. In addition, release o f capsaicin-evoked release o f sensory 
neuropeptides in spinal cord sensory neurons is reduced by 10 pM GBP (Fehrenbacher 
et al., 2003).
A number o f factors have been suggested to be important in GBP-mediated action at 
VGCCs, and that may explain the discrepancies in results. The culture conditions for 
DRG neurons (in particular the type o f nerve growth factor used) proved important in 
the GBP-mediated inhibition o f VGCC currents (Cunningham et al., 2004), this may be 
explained by a difference in the VGCC abundance in these cells. Also, long-term 
incubation o f GBP has been found to be vital for the reported GBP-mediated inhibition 
in several studies (Alden and Garcia, 2001; Fox et al., 2003).
Gabapentin represents the first o f an emergent class o f compounds to bind to the (X28 
subunit (Belliotti et al., 2005). Both the 0,2 and the 8  parts of the protein are required for 
GBP binding (Brown and Gee, 1998). The concept o f (X28 ligands has come to light with 
the finding that many amino acids and related compounds will bind 0 ,28 , and some o f 
these have proven to be efficacious in neuropathic pain treatment, such as (L)- 
phenylglycine (Lynch, III et al., 2006). However, other a 28  binding compounds fail to 
have such an effect (Lynch, III et al., 2006), suggesting a 28  binding is not a simple route 
to therapeutic effect.
The importance of interruption o f ct28  function was at first not apparent. However, 
recent studies have implicated ( X 2 8 - I  upregulation in central sensitization, a condition 
where nociceptive neurons are more susceptible to firing following peripheral tissue 
damage. a 28 -l protein production is upregulated in dorsal horn (Xiao et al., 2007) and 
mRNA production in DRGs is also increased in nerve-injured rats (Luo et al., 2001), 
which corresponds to the onset of allodynia. This up-regulation o f a 28 -l diminishes in
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rats recovering from allodynia, and corresponds to sensitivity to the anti-allodynic 
effects o f GBP (Luo et al., 2002).
The importance o f (X28 up-regulation is another compounding factor that may explain the 
lack o f GBP-mediated inhibition o f calcium currents in some cases. Evidence has shown 
that 0128 ligands such as GBP act to block activity o f <228 in the sensitized state, but not 
the normal state (Li et al., 2006). Different culture conditions (such as time spent in 
culture for cells that have had axons / dendrites cut) may influence the regulation o f (X28 
in cultured cells, and the ability o f GBP to inhibit its function.
1.8.6 Adhesion domains in the (X26 subunit
1.8.6.1 The VWA domain
The von-Willabrand Factor A (VWA) domain is found in a variety of proteins (such as 
integrins and extracellular matrix proteins) and is involved in making adhesion 
interactions (Whittaker and Hynes, 2002). The discovery of a VWA domain within the 
a 2 portion o f the a 28  subunit (Bork and Rohde, 1991) suggested that ot28  might make 
functional adhesion interactions via this domain in a divalent cation-dependent process, 
much in the same way integrins and other VWA domain-containing proteins. The 0128-2 
VWA is located in the 0,2 portion o f the subunit, and is therefore situated extracellularly 
when the subunit is expressed at the cell surface.
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Figure 1.9. Structure o f the a,2§-2 VWA domain. The approximate location of the VWA 
domain within the 0 .2  structure is shown. In the enlarged view is the p sheet, as well as a  
helices containing the residues required for co-ordinating binding of a divalent cation 
with the MIDAS motif. A divalent cation is included (shown in purple). Model o f VWA 
structure adapted from Canti et al. (2005).
The VWA domain does not consist o f a completely conserved amino acid sequence 
across the range o f proteins in which it is found (Bork and Rohde, 1991). It consists o f a 
single p sheet, with amphipathic a  helices at each face o f the p sheet (reviewed in 
Springer, 2006). An important sequence within the VWA domain is the metal ion 
dependent adhesion site (MIDAS). This is a five amino acid sequence (DVSGS) which 
binds a divalent cation. The divalent cation (e.g. Mg2^ ) coordinates to aspartate and 
threonine residues in “MIDAS loops”, and with the MIDAS itself. The binding o f  a 
divalent cation to these sites triggers a conformational change in the VWA domain, 
which allows binding o f a protein ligand. The protein ligand contributes a final co­
ordinating amino acid (glutamate or aspartate) to bind the divalent cation with high 
affinity. A VWA domain model is shown in Figure 1.9.
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1.8.6.2 Cache domains
The 0 2 8  subunit contains two cache domains (Anantharaman and Aravind, 2000). These 
domains (derived from their occurrence in Ca2+ channels and chemotaxis receptors) are 
located adjacent to the VWA domain. The first cache domain is situated from amino 
acid 446 to 540 in human 0 ,26-1 and the second from 764 to 869. Cache domains are 
involved in the binding and recognition o f small-molecule ligands (Anantharaman and 
Aravind, 2000), although the exact ligand (if any) for the 0128 subunit has not yet been 
described. Multiple point mutations in the first cache domain (of porcine 0 ,28-1) resulted 
in an abolition o f GBP binding (Wang et al., 1999). However, mutation o f a non-cache 
domain amino acid (residue 217 in porcine 0 2 8 - 1) in the same study also abolished GBP 
binding, suggesting the cache domain is not the sole binding site involved.
1.8.7 Splice variants of (X28
OC28 subunit RNA is subject to alternative splicing. Three areas o f alternative splicing 
have been identified in 0 ,28- 1 : two consecutive upstream regions spanning 19 and five 
amino acids, and a downstream region spanning eight amino acids (Angelotti and 
Hofmann, 1996). These variants have been observed in murine and human 0 2 8 - 1. The 
different splice variants are distributed across different tissues, suggesting physiological 
significance for localization of different splice variants. For example, skeletal muscle 
and brain tissue each express only one splice variant o f 0 2 8 - 1, whereas cardiovascular 
tissue expresses all five (Angelotti and Hofmann, 1996).
0 2 8 -2  possesses two regions across the 39 exon subunit which show alternative splicing 
in the human and murine a 28-2 subunits described (Hobom et al., 2000; Barclay and 
Rees, 2000). The first o f these is exon 13, which is only present in 13% of the total 
expressed 0 2 8 -2  protein (Barclay and Rees, 2000). In addition, a variation in the 3’ 
acceptor region within intron 38 leads to the insertion o f CP residues. This is the case for
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25% of expressed a 28-2 protein (Barclay and Rees, 2000). These splice variants have 
been observed in human a 25-2 (Hobom et al., 2000) and do not correspond to changes in 
electrophysiology.
The a 28-4 subunit has also been found to display alternative splicing (Qin et al., 2002), 
leading to four potential variants. The protein is composed from 39 exons, and both the 
N- and C-termini display two variants.
1.9 VGCCs at the synapse
Ca2+ ions have long been implicated in mediating neurotransmitter (NT) release. NT 
release at the neuromuscular junction was calculated to be proportional to the fourth 
power o f Ca2+ concentration (Dodge, Jr. and Rahamimoff, 1967). The influx o f Ca2+ 
required for this enters the cell via presynaptic VGCCs, i.e. Cav2.1 and Cav2.2 channels 
(Dunlap et al., 1995). This transduction o f presynaptic membrane depolarisation into 
Ca2+ influx drives the synaptic machinery, which couple Ca2+ to docking of vesicles to 
the presynaptic membrane, and release o f the neurotransmitter they contain.
SNARE proteins make up the machinery required for neurotransmitter release. Several 
SNARE proteins make functional interactions with VGCCs, specifically Cav2.1 and 
Cav2.2 (Sheng et al., 1994; Catterall, 1999), although interactions with Cav1.2 have been 
observed (Wiser et al., 1999). These interactions are made via a site in the II-III linker 
on the VGCC (the “synprint” site, see Figure 1.7), to which syntaxin 1A, SNAP-25 and 
synaptotagmin bind (Rettig et al., 1996; Sheng et al., 1997) and have an inhibitory effect 
on VGCCs. This may represent a means of negative feedback to avoid excessive 
neurotransmitter release during periods o f increased activity (Pozzi et al., 2007). 
Synprint peptides prevent the binding of these proteins (Sheng et al., 1994).
Syntaxin 1A is important for bringing the synaptic vesicle into contact with the plasma 
membrane (Jarvis and Zamponi, 2005). It also regulates the activity o f the VGCCs to
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which it binds. These interactions lead to a reduction in the level o f VGCC expression, 
as well as hyperpolarizing the steady-state inactivation o f the expressed channels 
(Catterall, 2000; Sutton et al., 1999). Syntaxin 1A also enhances the G protein-mediated 
inhibition o f Cav2.2 (Jarvis et al., 2000).
SNAP-25 inhibits Cav2.2 (although not through an enhancement o f G protein-mediated 
inhibition). In addition, it also inhibits the syntaxin lA-mediated inhibition o f Cav2.2 
(Wiser et al., 1996a). This has led to the notion that incomplete SNARE complexes will 
inhibit Ca2+ influx, but complete (and functional) SNARE complexes will not (Jarvis 
and Zamponi, 2005).
A number o f interactions with proteins at the synapse are also mediated by VGCCs, such 
as the association with synaptic adaptor proteins such as CASK and Mintl (Maximov et 
al., 1999). Laminin p3 binds to VGCCs, preferentially Cav2.1 and Cav2.2 (Nishimune et 
al., 2004). Here, the association promotes clustering o f VGCCs, which is proposed to be 
required for correct synaptic development. Another adhesion molecule family, the a -  
neurexins, couple VGCC-mediated Ca" influx at the synapse to neurotransmitter release 
(Missler et al., 2003). In addition, the RIM1 protein is required for making interactions 
with other components o f the presynaptic active zone (Kiyonaka et al., 2007). One of 
these components is the VGCC p subunit (p4 and p2a were tested in the study), which 
binds RIM1 via the SH3 and GK domains. This association decelerates inactivation 
kinetics (and depolarises the voltage-dependence o f inactivation) and leads to an overall 
increase in neurotransmitter release.
1.10 Aims o f the study
At the beginning o f the study, several key pieces of information regarding the a 2b 
subunit were unknown. The a 28  subunit had been found in most studies to enhance 
current amplitude in many expressed VGCC complexes (see Section 1.8.2). This had 
been proposed to be due to an increase in the number of available channels at the cell-
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surface, whether by an increase in forward trafficking (Shistik et al., 1995) or a 
reduction in channel turnover when at the membrane. The presence o f a number o f 
potential binding domains within the 0,28 subunits (see Section 1.8.6) alluded to the 
possibility that (X28 functionality involved binding ligands. The presence o f a VWA 
domain within the 012 portion o f the subunit suggested that ot2 may play an additional 
role in the function o f the subunit, given that the 8  portion is responsible for many o f the 
biophysical effects o f 0128 co-expression (Felix et al., 1997).
Therefore, two sites implicated in potential ligand interactions (the VWA domain, found 
on integrins) and the RRR m otif essential for GBP binding were investigated in this 
study. Interruption o f these sites by mutating amino acids within them would allow their 
physiological function to be assessed, and allow the importance o f any ligand binding to 
be established. In the case o f the VWA domain, the identification and location o f 
binding o f a potential ligand could be established. In the case o f the RRR motif, where 
the exogenous ligand is known to be GBP / PGB, the possibility o f an endogonous 
ligand could be investigated.
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Chapter 2: Materials and Methods
2.1.1 Suppliers
All chemicals were supplied by Sigma Aldrich Chemicals Ltd. (UK) unless stated 
otherwise. All water used was obtained from a water purification system (Millipore), 
unless stated otherwise.
2.1.2 cDNAs and expression vectors.
Most o f the complementary deoxyribonucleic acids (cDNAs) used in this investigation 
were subcloned into the pMT-2 mammalian expression vector. pMT-2 is a plasmid 
expression vector displaying a relatively high level o f expression o f heterologous 
proteins, which have proven to be both functional and stable over the course o f a 
transient transfection (Swick et al., 1992). pMT-2 contains the simian virus 40 (SV40) 
promoter.
Mouse (X25-2  (Genbank accession number AF247139) was used (Barclay and Rees, 
2000), from which a number o f constructs were produced. Mouse brain (X28-2  RNA 
displays alternative splicing in exons 23 and 38 (Barclay and Rees, 2000). The mouse 
0126-2 was the common splice variant form, which lacked exon 23 and 6  base pairs o f 
exon 38 (see Section 1.8.7). This cc25-2  was used to produce both the stable ct26-2  mid- 
HA and a 28-2 R282A constructs (Davies et al., 2006). An internal hemagglutinin (HA) 
tag was inserted between amino acids 652 and 653 to produce the mid-HA construct, 
and the R282A construct was produced by site-directed mutagenesis. A similar mutation 
(R217A) was introduced into rat brain a 28 -l (M86621) in the lab. All (X26-2  constructs 
were subcloned into pMT-2.
Additional cDNAs used that were subcloned into pMT-2 included: rabbit Cav2.2 
(D14157, lacking the 3’-untranslated region); rat (31b (Tomlinson et al., 1993); rat (34 
(L02315) and rat Cav2.1 E1686R (M64373). The E1686R mutation in rat Cav2.1 is the 
equivalent mutation as that used in human Cav2.1 E1740R (Hans et al., 1999), an
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engineered gain-of-function mutation in the S5-SS1 extracellular loop (in Domain IV). 
This mutation results in an elevation in expressed Cav2.1 protein and a corresponding 
three-fold increase in current amplitude, as well as a hyperpolarised V50, inact (see 
Introduction). No significant changes in activation or inactivation kinetics were observed 
compared to WT Cav2.1.
Mut-3 green fluorescent protein (GFP; M2653) was used as a reporter gene for 
successful heterologous protein expression, due to the green fluorescence observed when 
exposed to ultraviolet light. Mut-3 GFP contains mutated amino acids in the 
chromophore sequence, resulting in a greatly enhanced fluorescence intensity compared 
to GFP (Cormack et al., 1996).
Two cDNAs used in the study (porcine brain 012S-I (WT) and 0126-1 R217A, both gifts 
from Pfizer) were subcloned into the mammalian expression vector pcDNA3 
(Invitrogen). 0,2 and 8  were subcloned into pcDNA separately from full-length porcine 
brain 0,28 cDNA (Wang et al., 1999). The porcine and rat brain splice variants used are 
96% homologous to one-another, and are identical in the three regions o f alternative 
splicing for 0128-1 (Angelotti and Hofmann, 1996; Wang et al., 1999).
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2.1.3 Antibodies
A list o f the primary and secondary antibodies used is provided in Table 2.1.
Name Antigen Species Supplier Dilution
Anti-HA HA peptide sequence 
(YPYDVPDYA)
Rat Roche 1 :1 0 0 0
Anti-a,2- l Residues 27 -  41 o f rat 012 Rabbit Alomone 1:500
Anti-a25-1 
(chicken)
Unknown (generated in- 
house @ Pfizer)
Chicken Pfizer 1:500
Anti-Cav2.2 Peptides in the II -  III loop Rabbit Generated 
in lab
1:500
Anti-Flotillin Whole molecule Mouse BD
Biosciences
1 :1 0 0 0
Anti-Rabbit
IgG
Whole molecule Goat Sigma 1 :1 0 0 0
Anti-Rat IgG Whole molecule Mouse Abeam 1 :1 0 0 0
Anti-Chicken
IgG
Whole molecule Rabbit Sigma 1:500
Table 2.1 Antibodies used in the study.
2.2 Cell Culture
All cell-cultures were maintained at 37°C in an atmosphere containing 5% CO2. All 
culture solutions were filter-sterilised before used.
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2 . 2.1 tsA-201 cells
The temperature-sensitive A (tsA-201) cell-line (European Collection o f Cell-Cultures 
number 96121229) is a modified form o f the HEK293 (human embryonic kidney) cell- 
line, stably expressing a simian virus 40 (SV40) temperature-sensitive T antigen. This 
allows a higher expression of recombinant proteins from plasmids containing the SV40 
promoter.
tsA-201 cells were maintained as adherent monolayers, cultured in Dulbeco’s modified 
Eagle’s medium (D-MEM; GIBCO) plus: 10% (v/v) Foetal bovine serum (FBS; 
GIBCO), 1% (v/v) Penicillin-Streptomycin (5 Kunits/ml penicillin and 5 mg/ml 
streptomycin stock), and 2 mM glutamine. Cells were maintained in either flasks (175 
cm2 or 75 cm2) or dishes (35 mm diameter). The cells were passaged twice weekly when 
they reached a confluency o f approx. 80-90%, and split to a confluency of 
approximately 2 0 %.
Passaging o f cells proceeded as follows. The density o f the cell monolayer was 
estimated using a light microscope. The D-MEM culture medium was then removed 
from the adherent cells by means o f 2  gentle washes with warm phosphate-buffered 
saline (PBS). Having removed the PBS, cells were then washed in either 1 ml (for a 75 
cm2 flask) or 3 ml (for a 175 cm2 flask) trypsin (500 units/ml). The flask was moved and 
swirled gently, to allow trypsin to cover all cells in the flask and to gently encourage the 
lifting-off o f  cells. After one minute o f  trypsin application, a volume o f the D-MEM was 
added (~10 ml, depending on the estimated density o f the monolayer). Gentle trituration 
o f the cell-trypsin-medium mixture then followed, and 1 ml volumes o f this mixture then 
used to seed cells in a fresh flask.
Seeding o f 35 mm (-10  cm2) dishes with tsA-201 cells for transfection was often carried 
out concurrently with passaging, and achieved by further diluting the mixture as was 
deemed necessary to allow them to grow up to a confluency o f 100% after 2 days. At 
this point, they were re-plated for use in electrophysiological recording (see Section 2.7).
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Cell cultures were maintained for approximately eight weeks before being discarded. 
They were replaced with a newly grown up culture (from frozen stocks). The majority 
of tsA-201 cell-culture work was carried out routinely by a tissue-culture technician.
2.2.2 DRG cell-culture
All DRG cell culture was carried out by a colleague in the lab (Fay Heblich). Adult 
Sprague-Dawley rats (21 days) were used, within a weight range o f 300-400 grams.
2.2.3 GC cell-culture
Initial steps in this protocol were carried out using dissection medium (DM). DM 
consisted of: Hanks balanced salt-solution (HBSS; GIBCO) and gentamycin (100 pg/ml; 
Sigma-Aldrich). Seeding o f GCs onto poly-lysine-coated coverslips was carried out in 
seeding medium (SM). This consisted of: Basal medium Eagle (BME; GIBCO) and 
foetal calf serum (10% v/v; GIBCO). GC medium was used for maintainng GC cultures. 
A 50 ml stock solution o f GC medium consisted of: BME (42 ml); glucose (2.4 ml o f a 
10% (w/v) solution); peneci 11 in-streptomycin (100 pi o f a 5 Kunits/ml penicillin and 5 
mg/ml streptomycin stock); glutamine (1 mM); NaCl (20 pM); growth cocktail (500 pi; 
Sigma-Aldrich); KC1 (20 pM); horse serum (5 ml; GIBCO).
Four rats (aged postnatal day 1 (PI)) were killed by decapitation. Cerebella were 
removed with forceps and placed in a dish on ice, containing DM. Meninges and blood 
vessels were removed using forceps and a dissection microscope. Cerebella were 
transferred to warm DM and inverted gently to remove small pieces o f tissue, then 
centrifuged (1000 RPM) for 2 min. The DM was replaced with fresh warm DM (10 ml) 
and inverted again. This was removed, and replaced with 2 ml 0.1% (w/v) Trypsin 
(GIBCO). Cells were left to trypsinize in a shaking waterbath for 10 min. Following this,
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two DM wash / two minute 1000 RPM centrifugation cycles were carried out, and then 
cells were removed to a 1 ml volume o f D-MEM containing 2000 units / ml 
deoxyribonuclease I (DNAse). DNAse cuts DNA released by cells lysed in the 
dissection procedure, and thus helps prevent clumping. Cells were triturated in this 
volume, first using a large-bore pipette, followed by a small-bore pipette and finally with 
a 200 pi Gilson pipette. This ensured that the cells were reduced to a single-cell 
suspension. Following this, 9 ml DM was added, and cells were inverted. Cells were 
centrifuged for five min (1500 RPM), and all medium / DNAse was removed. Cells 
were then re-suspended in 1 ml SM. A 100 pi sample o f this suspension was taken, and 
an estimate o f the cell density made using a haemocytometer. Having done this, the 
volume o f SM added to the cells was increased to attain a cell density o f roughly 106 
cells / ml.
90 pi o f cells in SM were pipetted onto each poly-lysine-coated coverslip. These 
coverslips were kept in 35 mm dishes in an incubator (37°C) for 3 h, to allow the cells to 
adhere to the coverslips. After 3 h, 2 ml GC medium was added to each dish, and cells 
left until required. Cells were fed by replacing the GC medium every two days. Figure
2.1 shows CG cultures after two (Figure 2.1 A) and seven (Figure 2.1 B) days.
2.2.4 GC / tsA-201 cell co-cultures
Co-cultures made use o f already-established GC and tsA-201 cell-cultures. tsA-201 cells 
were transfected (see Section 2.3) and left for 3 h. The following evening, cells were 
replated. tsA-201 cells were washed in warm PBS and then resuspended in cell 
dissociation solution (CDS). The cell / CDS mixture was added straight to 35 mm dishes 
containing coverslips o f GCs. tsA-201 cells were plated at a lower density than would be 
the case for tsA-201 cells alone, as they were left in culture with GCs overnight before 
being used in the morning. An example GC / tsA-201 cell co-culture is shown in Figure
2.1 C.
- 7 4 -
A: B:
L  .
\  V
Figure 2.1. GC and GC / tsA-201 cell co-cultures. (A), GCs, two days in culture. (B), 
GCs, seven days in culture. The neurite network is significantly more established than 
that of the two day old culture. (C), GC / tsA-201 cell co-culture. Photo is taken o f a 
seven day GC culture, 14 h after the addition of tsA-201 cells, (t = tsA-201 cell; g = 
GC). GCs were identified by size and morphology, and were phase-bright compared to 
tsA-201 cells. Scale = 50 pm.
2.3 Transfection of cells
For transfection o f tsA-201 cells in 25 mm dishes, a cDNA mix (containing all cDNAs 
necessary for a particular experiment) was prepared in advance. This allowed a more 
reproducible and uniform method of heterologous transfection than transfecting 
individual subunit cDNAs. The mix contained VGCC subunit cDNAs for Cav(Xi, |3, a 2 8 
and mut-3 GFP in a 3:2:2:0.2 ratio.
tsA-201 cells were transfected using the Fugene 6 reagent (Roche). The transfection 
procedure involved mixing 3% Fugene 6 (in serum-free medium) with cDNA (1 pg/pl) 
in a 3:2 ratio (Fugene 6 : cDNA). The quantities used depended on the flask being 
transfected (ratios shown are Fugene 6 : cDNA in pi): 45:30 (in 5 ml serum-free 
medium) for a 175 cirT flask; 30:20 (in 2 ml serum-free medium) for a 75 cm2 flask, and 
3:2 (in 100 pi serum-free medium) for a 35 mm dish. Transfection involved diluting the 
Fugene 6 reagent in serum-free medium, before mixing with cDNA. After being left for
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15 min, the mixture was added to cells. A confluency o f  20 -  30% was selected for cells 
at the point o f transfection in order to allow 2  days for protein expression.
2.4 T reatments
2.4.1 Cholesterol depletion
A stock o f methyl-P-cyclodextrin (MBCD) was produced on a daily basis. MBCD does 
not have an exact molecular mass, due to variable methylation, and hence it was 
assumed to be 1300. 50 mM MBCD (in serum-free medium) was sterile-filtered to 
remove small clumps o f un-dissolved material, and kept for no longer than 10 h. The 
treatment o f cells on 35 mm dishes with MBCD caused them to lift o f the bottom of the 
dishes. For this reason, cells to be treated with MBCD (and as well as the control 
condition) were re-plated onto collagen-coated dishes. Re-plated cells were exposed to 5 
mM MBCD for 1 h at 37 C, immediately before electropysiological experiments (as in 
Christian et al., 1997). Control cells were treated with serum-free medium for the same 
length o f time.
2.4.2 Cholesterol addition
Cells were cultured in the same way for experiments involving cholesterol addition as 
for those involving cholesterol depletion. 10 mM cholesterol was dissolved in serum- 
free medium and left overnight at 4°C on a rotator in order to facilitate its entry into 
solution. 50 mM MBCD was then added to complete the stock solution, as above. 
Exposure to a final concentration o f 5 mM MBCD / 1 mM cholesterol was then carried 
out at 37°C for 1 h before recording.
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2.4.3 Application of GBP / PGB
GBP (Sigma-Aldrich or VWR) and PGB (a gift from Pfizer) were applied to cells 
chronically, from shortly after the point o f transfection, up to the point o f re-plating (a 
total o f 40 h).
GBP / PGB were obtained as powder. This powder was dissolved in water to make a 100 
mM stock solution. The stock solution was kept at 4°C. GBP / PGB were applied to cells 
1 h after adding the (Fugene 6  / cDNA) transfection mixture, to prevent any interruption 
o f transfection. GBP was added to the culture medium to obtain a final concentration o f 
either 100 pM or 1 mM in the 2 ml culture medium. PGB was applied to make a final 
concentration of either 200 pM  or 1 mM in the culture medium. In all cases the 
equivalent volume o f water was added to the control condition. This application would 
last roughly 40 h, until the point at which cells were re-plated for electrophysiology 
(Section 2.7). GBP / PGB application was effectively stopped at this point, as GBP / 
PGB were omitted from the media used for re-plating.
2.5 Biochemistry
o
All steps were carried out at 4 C unless stated otherwise. PBS solutions were made up 
from tablets left to dissolve in water. Protease inhibitor (Roche) was added to PBS 
solution in tablet form. This produced a PBS / protease inhibitor (PI) solution used in 
most experiments.
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2.5.1 Sample preparation
2.5.1.1 Cell harvesting and preparation of whole-cell lysate
tsA-201 cells were harvested from either 75 cm2 or 175 cm2 flasks, both using the same 
method. First, cells were washed twice in ice-cold PBS, before being left in an ice-cold 
PBS solution containing 5 mM ethylenediamine tetraacetic acid (EDTA) for five min. 
After this, cells could be gently washed off the bottom o f the flask. Cells were then 
pelleted at 3000 x g for 5 min, the supernatant removed, and stored at -20 C until 
required.
Whole-cell lysate was prepared for Western blotting experiments (Section 2.5.3). 
Harvested cell-pellets were left to thaw on ice, and made up to 200 pi volumes with PBS 
/ PI. Samples then underwent three rounds of low-intensity sonication, each round 
lasting 5 seconds. 50 pi Igepal (5% v/v) was added before the last round o f sonication. 
Samples were left to solubilise for 30 min on ice, and then spun at 1300 RPM in a 
bench-top centrifuge for 15 min to pellet non-lysed cells. After this, a sample o f the 
supernatant was removed for a protein assay (see Section 2.5.2).
2.5.1.2 Preparation of membrane samples
In order to harvest sufficient material for 3H-GBP binding to membranes, six 175 cm2 
flasks containing transfected tsA-201 cells were grown up. The resultant pellet (after 
cell-harvesting) was re-suspended in a final volume o f 25 ml PBS / PI containing 10 mM 
HEPES.
Cells were sonicated for three rounds of 15 seconds each (and left on ice for a minute 
between each round), before being left to solubilise on ice for a further 30 min. Cell 
debris and non-lysed cells were pelleted using a Beckman desktop centrifuge for 15 min 
at 1000 x g. The resulting supernatant was removed to a 30 ml thick-walled
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ultracentrifuge tube (Beckman-Coulter). Membranes were pelleted in an ultracentrifuge 
(Beckman-Coulter) for 1 h at 100,000 x g.
After ultracentrifugation, the supernatant was removed by aspiration. Samples were re­
suspended in a 4 ml o f the PBS / PI / HEPES buffer, and two 20 pi samples taken for 
protein assay. Having completed the protein assay, a volume o f buffer equating to 50 mg 
sample was aliquoted into storage tubes for subsequent use in binding assays (50 mg 
being the required amount of sample for a single binding assay).
2.5.1.3 Preparation of lipid raft samples
As with membrane samples, six 175 cm2 o f tsA-201 cells were required for binding
o
assays involving lipid rafts. After harvesting (and storage at -20 C in some cases) pellets 
were kept on ice (and thawed if  they had not been harvested immediately beforehand).
A number o f sucrose solutions and buffer solutions were prepared. See Appendix I for 
the composition o f Buffers 1 and 2. Sucrose solutions (5%, 35% and 90% w/v) were 
prepared in 50 ml volumes. Whilst the 5% and 35% sucrose solutions dissolved easily in 
PBS, it was necessary to heat the 90% sucrose solution in a waterbath (~90 C) until it 
dissolved fully.
Cell pellets o f each 175 cm flask were re-suspended in 1 ml Buffer 1. 1 ml Buffer 2 was 
added, before incubating on ice for 40 min (to lyse and solubilise the sample). The 
volume was doubled again to 4 ml using the 90% sucrose solution. This 4 ml sucrose / 
cell mixture was then added to a 13 ml ultracentrifuge tube (Beckman), followed by the 
addition o f 4 ml 35% sucrose and 5 ml 5% sucrose solutions. All additions were made 
using a 1 ml Gilson pipette, taking care not to allow sucrose solutions to touch the sides 
o f the tube. For the 5% sucrose additions the narrow tip o f the plastic pipette was cut o ff 
to reduce the speed at which solution was added to the tube and reduce the risk o f  5% 
sucrose solution mixing with 35% sucrose solution. For one experiment (the western
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blot o f which is shown in Figure 4.1C), 5 ml 90 % sucrose, 4 ml 35% sucrose and 5 ml 
5% sucrose were added to each ultracentrifuge tube, due to an excess o f sample. The 
resultant six ultracentrifuge tubes were then paired, and the mass o f each pair equaled by 
the addition o f 5% sucrose solution. Samples were then centrifuged at 70,000 x g for 18 
h.
After centrifugation, fractions were removed from each o f the six tubes 1 ml at a time. 
Detergent-resistant membranes were observed at the boundary between the 5% and 35% 
sucrose solutions, these “peak-fractions” were usually fractions 4 & 5 or fractions 5 & 6 . 
100  pi o f each 1 ml fraction were removed from one o f the ultracentrifuge tubes in order 
to determine the presence o f (X28 protein by western blot analysis. Sodium dodecyl 
sulphate polyacrylamide gel-electrophoresis (SDS-PAGE) and western blot analysis 
were performed as described in Section 2.5.3. However, a 15-well Tris-acetate gel 
(Invitrogen) was used instead o f the 10-well gel described.
The peak-fractions o f the six ultracentrifuge tubes were then pooled and a 20 pi sample 
taken for protein assay. From the result o f the protein assay it was possible to make 
aliquots from the pooled lipid raft samples, each one containing 120  pg lipid rafts for 
use in a binding assay.
2.5.2 Assay o f protein concentration
A modified Bradford assay (Bio-Rad protein assay; Bio-Rad) was used to assess protein 
concentration in biochemical experiments. These steps were performed at room 
temperature. The Bradford protein assay involves binding o f Coomassie blue dye to 
(primarily basic and aromatic) amino-acids in order to provide quantification o f protein. 
Bio-Rad reagent concentrate (Bio-Rad) was used for the protein assay, and consisted o f 
dye, phosphoric acid and methanol. It was diluted with water to obtain the correct 
concentration. Protein concentrations of a known standard (bovine serum albumin) were 
measured initially in order to provide a conversion factor between the absorbance and
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the protein concentration o f the sample. Absorbance was measured using a DU800 
spectrophotometer and associated software (Beckman-Coulter).
Assessment o f protein concentration was carried out using small volumes o f Bio-Rad 
reagent, mixed with a range o f concentrations o f the protein sample. At least three 
concentrations were selected, within the linear range o f the assay (0.2 to 0.9 mg/ml). 
Duplicates o f each protein concentration were prepared. Absorbance was measured at 
595 nm, and the conversion factor applied in order to obtain a value o f protein 
concentration. Assuming no significant outliers from the straight line, the mean value o f 
protein concentration was taken from the various concentrations and duplicates.
2.5.3 Gel-running and western-blotting
2.5.3.1 SDS-PAGE
Before being subjected to electrophoresis, 4x loading sample buffer (Invitrogen) was 
added to solubilised cell samples (this produced a lx  final concentration o f buffer). The 
composition o f 4x loading sample buffer is given in Appendix II. Loading sample buffer 
also contained 200 pM DTT which was included in order to reduce disulphide-bonded 
protein structures. Solubilised cell samples then were denatured in a heating block 
(90°C) for 10 min. After the denaturing step, sample tubes were centrifuged using a 
bench-top centrifuge to reclaim any evaporated content stuck to the lid o f the tubes.
SDS is an anionic detergent which denatures protein (although not disulphide bonds) 
and confers effectively a uniform negative charge to protein according to its mass. 
Therefore, the subsequent charge separation by PAGE equates to separation by size o f 
the proteins. Separation by SDS-PAGE was carried out using NuPAGE 3-8% Tris- 
acetate gel kits (Invitrogen) in a NuPAGE electrophoresis chamber (Invitrogen). The 
outer chamber was filled with gel running buffer (see Table 2.2 for composition), and 
the central chamber was also filled with gel running buffer, plus thioglycolic acid
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(0.01% v/v). The purpose o f  this was to prevent disulphide bond formation during the 
running o f the gel. The inner chamber was filled to above the level o f the wells, and the 
wells were then washed in the running buffer / thioglycolic acid solution using a P I0 0 0  
Gilson pipette.
Gels were routinely loaded with 25 pi sample, which contained between 10 and 30 pg 
protein, depending on the antibody being used for detection. Full-range Rainbow 
molecular weight marker (Amersham) was used to provide a measure o f protein size. 
Gels were run for approximately 1 h at 150 mV, 50 mA.
After electrophoresis, the gel was removed from its plastic case and immersed in gel 
equilibration buffer solution for 10 min (see Table 2.2). The SDS in the buffer solution 
inhibited protein binding to the gel, thus facilitating movement o f protein during the 
electro-transfer step.
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Buffer solution Component reagent Quantity
Gel running buffer 
(800 ml w/ water)
(20X) NuPAGE Tris-acetate running 
buffer or (20X) NuPAGE MOPS 
running buffer (see Appendix II)
40 ml
Gel equilibration buffer 
(50 ml w/ water)
(2OX) NuPAGE transfer buffer 5 ml
20% SDS (v/v) 80 pi
Gel transfer buffer 
(50 ml w/ water)
(20X) NuPAGE Transfer Buffer 10  ml
Methanol 10  ml
2% (v/v) Thioglycolic acid 100  pi
Blocking buffer 
( 50 ml w/ water)
(10X) TBS 10 ml
10 % (v/v) Tween 20 10 0  pi
Bovine serum albumin 1.5 g
Antibody diluent 
(1 1 w/ water)
TBS 100  ml
Tween 20 500 pi
Bovine serum albumin 30 g
Goat serum 1 0 0  ml
Ovalbumin chicken egg 5 g
Table 2.2. Composition o f  solutions used for SDS-PAGE and subsequent electro­
transfer.
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2.5.3.2 Electro-transfer
Protein transfer was carried out from the gel to a polyvinylidene difluoride (PVDF) 
membrane (Bio-Rad). The PVDF membrane binds protein as it is moved from the gel by 
the voltage difference. The PVDF membrane (with an area o f 7.5 cm x 8.5 cm to 
approximate the dimensions o f the gel) was soaked in methanol for 5 min, followed by 
water, followed by gel transfer buffer (see Table 2.2 for composition). Similarly, two 
sets o f three blotting paper squares (each 7 cm x 5 cm; Whatman) were soaked in gel 
transfer buffer. The presence o f methanol in the gel transfer buffer prevents SDS binding 
to the protein, thus removing SDS from the PVDF membrane.
Electro-transfer took place in a semi-dry electophoretic transfer cell (Bio-Rad). Transfer 
is possible by direct contact o f the electrodes with the gel / membrane stack. The 
arrangement o f  the PVDF membrane, blotting paper and gel within the cell is shown in 
Figure 2.2. Layers o f the stack were placed in succession, with a small volume o f 
transfer buffer applied in between each layer. A tube was rolled across the top o f the 
stack to remove any bubbles o f air left between layers. The lid / cathode was secured and 
the protein transferred over a 30 - 35 min period at 10 V, 400 mA.
C athode
Gel (soaked  in equilibration buffer) 
PVDF m em brane (soaked  in transfer buffer)
Anode
W hatm an blotting paper (x3)
Figure 2.2. Arrangement o f the electro-transfer apparatus. Transfer buffer was applied 
to all layers, and air bubbles removed to allow optimal electrical contact between the 
electrodes and through the stack.
- 8 4 -
2.5.3.3 Antibody step
After electro-transfer, PVDF membranes were subjected to a blocking step in blocking 
buffer (see Appendix III for composition) for 1 h. This step took place at room 
temperature on a rotator. After this, blocking solution was removed, and replaced with a 
small volume (3 ml) o f antibody diluent (see Table 2.2 for composition) containing the 
appropriate dilution o f antibody (see Section 2.1.3 for a complete list o f antibodies 
used). The PVDF membrane was left submerged in antibody / antibody diluent 
overnight at 4°C.
Following overnight exposure to primary antibody, three washes in a 1 M Tris-buffered 
saline (TBS) solution were carried out, each wash lasting 10 min. The purpose o f this 
was to remove any primary antibody not bound to the target protein on the PVDF 
membrane and therefore reduce non-specific binding. The three TBS washes were 
followed by exposure to secondary antibody (see Section 2.1.3 for a complete list), an 
antibody specific to the species o f the primary antibody (IgG). This secondary antibody 
was conjugated to the horseradish-peroxidase (HRP) enzyme in order to allow 
visualisation in the following imaging step.
2.5.3.4 Imaging
Imaging o f the labelled protein on the PVDF membrane was carried out using the ECL- 
plus Western Blotting detection system (Amersham). Enhanced chemiluminescence 
(ECL) arises in the ECL-plus system due to oxidation o f  a Lumigen PS-3 Acridan 
substrate, by the combined presence o f  HRP and peroxide.
Three washes (in TBS) o f the PVDF membrane were carried out, to remove any non­
bound secondary antibody. The PVDF membrane was then immersed in ~2 ml detection 
mixture for at least five min. Detection solutions A and B (from the ECL-plus kit) were
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mixed at a ratio o f  40:1 to produce the detection mixture. Imaging was the carried out 
using a Typhoon 9410 variable mode imager (Molecular Dynamics).
The majority o f western blot analysis was carried out in order to demonstrate simply the 
presence o f a particular protein. When quantitative comparison was required, the 
ImageQuant program (Amersham) was used. Areas o f  interest (i.e. boxes surrounding an 
imaged protein band) were selected. Corresponding areas containing no protein were 
subtracted in order to provide a correction for the background immunoreactivity. 
Immunoreactivity was then calculated as a function o f intensity o f the band, and 
normalised to the peak value o f the WT condition. Values are presented as mean ± 
standard error o f  the mean (SEM).
2.5.4 Immunoprecipitation assay
Freshly harvested cell pellets were made up to 250 pi with lysis buffer. Lysis buffer 
contained (in PBS / PI): 50 mM tris-HCl; 100 mM NaCl; 1% Igepal. Samples were left 
on ice to solubilise for 60 min. Following this the lysate was sonicated for five seconds. 
Samples were then left to bind primary antibody (anti-HA) on an end-to-end mixer for 2 
h.
Sepharose beads conjugated to IgG (Invitrogen) were used for precipitation o f the HA 
immunoreactive protein. Following antibody binding, 30 pi Protein G-sepharose beads 
(50% slurry in lysis buffer) were added to the lysate /  antibody samples and left to 
incubate for a further 60 min. The protein G-sepharose beads were then pelleted using a 
bench-top centrifuge ( 1 0 0 0  x g for two min), before three further cycles o f washing with 
1 ml lysis buffer and centrifugation.
Bound protein was eluted with the addition o f 40 pi loading sample buffer, followed by 
incubation for 20 min and subsequent centrifugation o f the protein G-sepharose beads. 
Samples o f the supernatant were taken for SDS-PAGE, and run on a 4 -  12% Bis-Tris
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gel kit (Invitrogen). This step was essentially the same as the gel-running step described 
previously (Section 2.5.3.1), except that NuPage MOPS running buffer (Invitrogen; see 
Appendix II for composition) was used instead o f Tris-acetate running buffer.
Solution Component
reagent
Quantity
Fixing solution (250 ml w/ water) Ethanol 100 ml
Acetic acid (glacial) 25 ml
Sensitizing solution (250 ml w/ water) Ethanol 75 ml
Glutardialdehyde 
(25% w/v)
1.25 ml
Sodium thiosulphate 
(5% w/v)
10 ml
Sodium acetate 17 g
Silver reaction solution (250 ml w/ water) Silver nitrate 
(2% w/v)
25 ml
Formaldehyde 
(37% w/v)
0.1 ml
Developing solution (250 ml w/ water) Sodium carbonate 6.25 g
Formaldehyde 
(37% w/v)
0.05 ml
Stopping solution (250 ml w/ water) EDTA-Na2-2H20 3.65 g
Preserving solution (250 ml w/ water) Glycerol 
(87% w/v)
25 ml
Table 2.3. Component reagents o f the solutions used in silver-staining o f  gels.
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Silver staining was carried out to detect protein. Solutions used are described in Table 
2.3. An initial fixation step was carried out by immersion in fixing solution for 30 min. 
This was followed by immersion in sensitizing solution for 30 min, to prime the gel for 
the following silver reaction. Three washes o f the sensitized gel were carried out in 
water (each one lasting 5 min), before immersion in the silver reaction solution for 20 
min. Two washes with water (each 1 min) were then carried out, followed by 
development o f the silver-stained gel. Developing the gel involved immersion in 
developing solution, and over the course o f a few minutes, bands (corresponding to the 
occurrence o f protein in the gel) appeared. At a suitable point, this process was halted by 
exposure to stopping solution ceased. Silver-stained gels were then immersed in 
preserving solution (for 20 min), coated in plastic film, and imaged using a scanner.
2.6 Radioligand binding
2.6.1 Binding assay
3H-GBP was stored at -80 C until use. All solutions and reagents were prepared and 
maintained on ice unless stated otherwise. Tubes were prepared containing: cell sample 
(3 jug cholesterol-rich microdomains or 50 pg membranes) in 10 mM HEPES buffer; 
various concentrations o f  3H-GBP (in 10 mM HEPES/KOH, pH 7.4); GBP (in water). 
Volumes were made up to 250 pi with 10 mM HEPES buffer (containing PI). Binding 
was carried out in a final volume o f 250 pi at room temperature over the course o f 2 h. 
Each replicate experiment was carried out in triplicate, and the mean value used for 
subsequent analysis. Total counts per minute were determined (also in triplicate) to give 
an estimate o f the activity o f the 3H-GBP. Non-specific binding was determined using 
10 pM unlabelled PGB.
Transferring the membrane samples or Triton X-insoluble membrane fractions to 
scintillant vials was carried out using a Brandel Harvester (Brandel). The GF/B filter
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paper used to recover material was soaked in 0.3% polyetheleneimine briefly before 
harvesting in order to reduce non-specific binding to the filter paper. Samples were 
transferred by Tris-HCl (10 mM, pH 7.4) washes o f the tubes, and then GF/B cut-outs 
were removed to vials containing 5 ml scintillant.
Detection for chemiluminescence arising from 3H decay was carried out on a 
scintillantion counter (Beckman Coulter) for a period o f 10 min per scintillant vial. A 
14C count was performed in conjunction in order to detect luminescence arising from 
auto-fluorescing entities, such as detergent / scintillant vials etc.
2.6.2 Data analysis
Data were fitted with a hyperbola function (see Equation 1) using the Origin 7.0 
program (Microcal), in order to obtain estimate values for the dissociation constant ( K d) 
and maximum number o f binding sites (Bmax)- All data are presented as mean ± SEM. 
An example curve is shown in Figure 2.3.
y = Bmax.x/(KD + x)
(Eq. 1)
Where:
x = [GBP] (nM)
y = GBP bound (pmol / mg protein)
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Figure 2.3. Sample radioligand binding assay curve. The mean data are fitted with the 
hyperbola function.
2.7 W hole-cell electrophysiology
2.7.1 Preparation o f cells
For experiments using solely tsA-201 cells (as opposed to tsA-201 / GC co-cultures) it 
was necessary to re-plate the transfected cells before they were utilised for 
electrophysiological recordings. This ensured cells were isolated, rather than being in 
clumps. 35 mm dishes were seeded so that they were confluent on the morning o f 
recording, either 2 or 3 days after seeding / transfection. Re-plating o f co-cultures was 
not possible because this would disrupt the presence o f GC projections.
tsA-201 cells were re-plated as follows. 35 mm dishes with a confluent monolayer o f 
cells were taken and immersed in CDS for two min. This prevented adherence o f the 
cells to the dish and caused them to lift off. Cells were then removed into 10 ml warm 
culture medium and gently triturated using a graduated pipette, before being split across
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a further five 35 mm dishes. These dishes were left at 37 C for at least 30 min before 
experimental use, to ensure adherence to the bottom o f the dish.
For the experiments using GC / tsA-201 co-cultures, cells did not need replating, having 
been seeded the evening before recording took place. They were therefore used 
immediately.
As with tsA-201 cells, re-plating DRGs before use was necessary prior to 
electrophysiology, in order to reduce the cell density achieved in cell culture. Cells were 
re-suspended by a mixture o f washing in culture medium (using a Pasteur pipette) or 
scraping (with a cell-scraper). They were then triturated gently before being added drop- 
wise to coverslips. Coverslips were then left for at least 1 h before further use.
2.7.2. Equipment
2.7.2.1 Microscope and recording chamber
The recording set-up consisted o f a Nikon Diaphot 200 inverted microscope (Nikon) and 
the recording chamber arranged around it, as illustrated in Figure 2.4. Phase contrast was 
employed to improve visibility. Cells (in a 35 mm dish) were held in a Perspex 
recording chamber. The recording chamber was separated from KC1 solution (3 M) by 
an agar bridge. This KC1 solution made contact with a AgrAgCl pellet, which was then 
connected by wire to the headstage.
The entire recording set-up was maintained on an airtable (Technical Manufacturing 
Corporation) in order to minimise the impact o f vibrations. The microscope, Faraday 
cage and airtable were connected to the signal grounding point o f  the amplifier.
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Microscope
V isible /  UV 
illumination
C ondenser
Eyepiece
H e a d s t a g e
a m p l i f i e r
Microelectrode Agar bridge
3M KCI
l/V 
amplifier
Ag/AgCI pellet
Objective
I n t e r f a c e
P e r s o n a l
c o m p u t e r
Figure 2.4. Microscope and microelectrode set-up. The cell-containing dish and KCI 
solution are connected by an agar bridge, and secured within a platform on the 
microscope. The recording apparatus and microscope were enclosed within a Faraday 
cage.
2.7.2.2 A m plifier and  acquisition a p p a ra tu s
Two set-ups were used for making electrophysiological recordings, both o f which made 
use o f  an Axopatch 1-D amplifier (Molecular Devices). The associated head-stage had a 
gain o f 1 (see Figure 2.5). Initially, recordings were made using an Intel 80486 personal 
computer running Clampex program o f the pClamp 6  suite o f programs (Molecular 
Devices), using a Digidata 1200 (M olecular Devices) These recordings make up the data 
presented in Chapter 3. The data presented in Chapters 4 & 5 were produced from 
recordings obtained using a Digidata 1322A interface and a Pentium III personal 
computer running Clampex in the pClamp9 suite (M olecular Devices). In both cases, 
Clampex was used both to produce voltage pulses and record current. Currents were 
sampled at 10 kHz and filtered at 2 kHz.
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2.7.3.3 Microelectrodes
Electrodes were composed o f borosilicate glass capillary. Capillary glass was pulled by 
the double-pull procedure, using a Flaming-Brown Model P-90 horizontal puller (Sutter 
Instruments). Microelectrodes were fire-polished using a microforge (Narishige). The 
typical resistance o f these microelectrodes was 2-3 MQ, as calculated by the current 
passed from a known potential difference. Those that were significantly outside this 
range were discarded.
2.7.4 Solutions
A 10 mM Ba -containing external solution was used for experiments on tsA-201 cells, 
as has been described previously (Campbell et al., 1995). The external solution 
contained (in mM): BaCl2 (10); tetraethylammonium Br (150); D-glucose (4); MgCl2 
(1); NaHCC>3 (1); HEPES (10); KCI (3). The pH o f the solution was adjusted to pH 7.4 
with NaOH and the osmolarity was adjusted to 320 mOsm with sucrose. The internal 
solution contained (in mM): Cs-aspartate (140); EGTA (5); MgCl2 (2); CaCl2 (0.1); 
K2ATP (2); HEPES (10).
In the case o f  recordings made from DRGs, an internal solution o f the same composition 
was used, with the exception that the external solution contained 1 mM BaCl2 (instead o f 
10 mM BaCl2) due to the larger size o f DRGs compared to tsA-201 cells. The external 
solution contained 500 nM TTX to block sodium currents.
External solutions were adjusted to pH 7.4 and internal solutions adjusted to pH 7.2. The 
osmolarity o f  the solutions was also adjusted, to prevent swelling or shrinking o f cells 
during the whole-cell configuration as a result o f a difference in osmotic pressure. A 
vapour-pressure osmometer (Wescor) was used. The external solution was adjusted to 
320 mOsm and the internal solution was adjusted to 310 mOsm, by adding sucrose 
solution in both cases.
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tsA-201 cells do not express many channel types endogenously, hence their selection for 
use as an expression system. An exception to this is the expression o f K+ channels (Yu 
and Kerchner, 1998). These channels were blocked by including Cs+ ions in the internal 
solution and Ba2+ ions in the external solution.
2.7.4.1 Using Ba2+ ions as charge carrier
1 mM or 10 mM Ba2+ was used as the charge carrier in patch clamp experiments. The 
use o f Ba2+ ions rather than Ca2+ ions in calcium channel recordings has an impact on
94- 94-the data obtained. Cav2.1 and Cav2.2 channels are more selective for Ba ions than Ca 
ions. Therefore more ions pass through the channel per unit time that the channels are 
open, and hence larger currents were obtained for the equivalent test-pulse.
In addition, the use o f Ba2+ ions reduces the extent o f calcium-dependent inactivation o f 
currents, allowing voltage-dependent inactivation to be isolated. However, it has been 
suggested that some calcium-dependent inactivation still occurs even when using Ba2+ 
ions, and that monovalent ions should be used to completely prevent it (reviewed in 
Lacinova, 2005).
2.7.5 Data acquisition: whole-cell voltage-clamp
All experiments were carried out at room temperature (21-24°C). Green cells were 
selected by illumination with ultraviolet (UV) light. A typical tsA-201 cell had a 
capacitance o f  roughly 5 pF. Having found a suitable target cell, UV illumination was 
switched off and a pipette was back-filled with internal solution using a non-metallic 
syringe needle. Any bubbles were removed by gentle tapping o f the side o f the pipette. 
The pipette tip was dipped in Sigmacote solution (Sigma-Aldrich) in order to reduce the
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capacitive transient caused by w ater creeping up the shank o f  the pipette. The pipette 
was then fastened into the holder on the headstage.
R.
Output
*f+vref
Patch
pipette
r e fCell
Figure 2.5 Schem atic representation o f  the headstage circuit. The current response to the 
applied potential difference is fed into the headstage am plifier and subsequently to the 
output (A xopatch am plifier).
A pproaching the cell w ith the pipette proceeded as follows. The pipette was attached to 
the m icroelectrode holder, and the holder orientated tow ards the cell. Positive pressure 
was applied to the internal solution in the pipette using a syringe. The current was 
zeroed using the over-ride control on the am plifier. Then pipette was then m anoeuvred 
tow ards the cell, and into the bath solution using a m acro-m anipulator (Narishige).
Having placed the pipette over the cell ( -1 0  - 20 jam), control was switched to the 
m icro-m anipulator (N arishige). The electrode potential between the pipette and bath 
solution was adjusted to zero, and a 5 mV square-w ave test potential applied in the 
“Sealtest” function o f  C lam pex. This was used to provide an estim ate o f  pipette 
resistance. The positive pressure in the pipette was rem oved, and the cell approached 
slowly until the current response to the square-wave reduced. This w as due to increased 
resistance as a result o f  pipette contact with the cell (see Figure 2.6). A t this point, gentle 
negative pressure was applied to encourage gigaseal form ation. With gigaseal form ation
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obtained, negative pressure was removed, and a holding potential o f  -90 mV applied to 
the cell. Fast capacitative transients (relating to the pipette capacitance) were cancelled. 
Short, sharp bursts o f  suction were then applied to cause the m embrane seal to break, 
and for the cell to enter the whole-cell configuration. Series resistance and whole-cell 
capacitance were com pensated (up to 80-90%). An estim ate o f  cell surface area was 
provided by cancelling the capacitative transient resulting from the whole-cell 
capacitance. Run-up o f  currents was left to com plete (as observed by a application o f  a 
square wave, which plateaued in am plitude) before recording data com menced (see 
Section 2.7.4.1).
A. To l/V 
amplifier
Patch
pipette
Seal
External
solution
Bath electrode
0000
B.
External
Membrane
Internal
Rpip
Rpatch
P sea !
4 ~T
W  V ref
L
Rcell
\N amplifier
Earth
H '-----------
Figure 2.6. Schem atic representation o f  the circuit produced when forming a seal. (A), 
Diagram o f  the m icroelectrode tip making contact with the cell mem brane. (B), The cell 
(R ceii), patch (Rpatch), seal (R seai) and pipette walls ( R PjP) all have a resistance. The bath 
electrode com pletes the circuit through the external solution, and is earthed. The pipette
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electrode feeds to the I/V amplifier (via the headstage amplifier). Figure adapted from 
Ogden (1994).
2.7.6 Voltage-clamp protocols and analysis
A number o f protocols were produced in Clampex, these are listed below. All protocols 
included a P/4 leak subtraction protocol, before the test pulse. The P/4 protocol applies 
four waveforms (each XA the amplitude o f the test pulse) o f opposite polarity to measure 
the linear passive current that represents the leak current passing through the membrane 
resistance / capacitance. This is calculated and removed from the recorded current trace.
2.7.6.1 Voltage-ramp
 . -80 mV
A:
200 pA
SO ms
Figure 2.7. The voltage-ramp protocol. (A), Schematic representation o f the voltage- 
ramp protocol, from -90 mV to +80 mV, over 150 ms. (B), A representative current 
response to the voltage-ramp as recorded in a tsA-201 cell.
Having broken the membrane upon the addition o f suction from the syringe, a ramp 
protocol was applied to give an estimate as to the size o f the current, as shown in Figure 
2.7. In addition, it was then applied repeatedly at 10 second intervals for each cell, until
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“run-up” o f  current size had reached completion. This lasted from 30 to 90 seconds on 
average. Run-up is an ATP- and GTP-dependent process, and is less pronounced in the 
presence o f Ba2+ ions compared to Ca2+ ions (Wagner and Alger, 1994).
By convention, the inward flow o f divalent cations into cells is represented as a negative 
current, and a downward deflection on the current trace.
2.7.6.2 Current-Voltage relationship
The current-voltage (I-V) relationship is an important measure o f calcium channel 
activity. The shift in the curve (V50, act) to different potentials or an increase in current 
sizes obtained gives a measure o f factors such as the number o f active channels present 
in the membrane, or the biophysical properties they possess.
The I-V curve was obtained using a holding potential o f  -90 mV. Test potential steps 
were applied for 200 ms at potentials o f -30 mV to +80 mV, before returning to the 
holding potential. The period between each sweep was 10 s.
Analysis o f  the I-V data was carried out using the Clampflt program within the Clampex 
package. The mean current over a 2 ms period, 20 ms after the onset o f each test 
potential was used for analysis. The observed current at each point was then divided by 
the estimate o f  whole-cell capacitance (obtained when cancelling capacitive transients 
after obtaining the whole-cell configuration, as in Section 2.7.5). This value for 
current/capacitance was termed current density (in pA/pF), and plotted against the test 
potential in order to obtain an I-V curve (see Figure 2.8).
The section o f the I-V plot between -30 mV and +50 mV was used for analysis. The 
Origin 7.0 program (Microcal) was used. The use o f potentials up to +50 mV removed 
the rectifying component o f the I-V graph, so that the resulting line could be treated with
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the combination o f a Boltzmann single exponential function and a straight line 
component (termed IVFIT):
I = Gmax( V -  Vrev)/( 1 + exp( - (V -  V50,act) / k))
(Eq. 2)
Where:
I = current density (pA/pF)
Gmax = maximal whole-cell conductance, normalised to cell capacitance (nS/pF)
Vrev = an estimate o f apparent reversal potential (mV)
V 5 0 ,  a c t  = mid-point o f  maximal current density (mV)
k = maximal gradient o f the Boltzmann function fitted to activation
From Equation 2, it is possible to obtain estimates for the maximal conductance o f the 
cell ( G m a x ) ,  the mid-point o f current activation ( V 5 0 ,  a c t ) ,  the maximal downward slope 
(k), and from the intercept o f the straight line component with the x-axis- the apparent 
reversal potential (Vrev). The value obtained for Vrev was an underestimate in the 
majority o f cases, due to the inwardly rectifying nature o f  the I-V component near the 
true Vrev. Therefore the estimates o f Vrev obtained from applications o f IVFIT have been 
omitted. All data are presented as mean ± SEM.
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Figure 2.8. The current-voltage protocol, shown in atsA -201 cell expressing Cav2.1, p4, 
a 2§-2 . (A), Schematic representation o f the I-V protocol, depolarising voltage-steps are 
applied from the holding potential o f -90 mM to -30 mV to +80 mV (in 5 mV 
increments). (B), Representative current responses to the I-V protocol- example current 
responses at -30, 0, +15 and +50 mV are shown. (C), The mean current response 
(normalised to capacitance) over a 2  ms period 1 0  ms after the initiation o f the test-pulse 
is shown. (D), -30 mV to +50 mV section o f  the I-V relationship, fitted with the IVFIT 
function.
Complete I-V curves are presented in the results chapters. These include test potentials 
ranging from -30 mV to +80 mV. The mean (± SEM) values are plotted, and joined by a 
smooth line. Values for mean peak-current density are obtained by this method, rather 
than using the IVFIT function.
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2.7.6.3 Steady-state inactivation.
The steady-state inactivation curve is produced by applying varying conditioning 
potentials for a sustained period (five seconds), until the proportion o f channels in the 
cell that are in the inactivated state reaches equilibrium (or “steady-state”). A test- 
potential (usually one to give a maximal current response) is then applied in order to 
measure the proportion o f remaining non-inactivated current. The current response is 
that measured over a 2 ms period, 10 ms after the initiation o f the test-pulse. A plot o f 
normalised current (I/Imax) against the conditioning potential gives a curve that can be 
fitted with a Boltzmann equation o f the form:
I/Imax = ((A| - A2) / [1 + exp((V - ^ 50,inact) / ^)]) A2
(Eq. 3)
Where:
/max = maximal overall current
I = measured current o f the test potential
V 5 0 ,  in a c t  = the half-maximal voltage for current inactivation.
Ai = proportion o f inactivating current
A 2 = proportion non-inactivating current
An example o f a steady-state inactivation trace (and subsequent fit with Equation 3) is 
shown in Figure 2.9.
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Conditioning pulse (5 s) Test pulse (200 ms)
•120 mV
B: C: io -  . .  .  .
500 pA
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Conditioning Potential (mV)
Figure 2.9. The steady-state inactivation protocol, shown in a tsA-201 cell expressing 
Cav2.1, p4, (X25-2  subunits. (A), Schematic representation o f  the steady-state inactivation 
protocol. (B), Current response to the +10 mV test potential following conditioning 
potentials o f  -120 mV to +30 mV. The mean current response over a 2 ms period 10 ms 
after the initiation o f the test-pulse is shown, and fitted with the Boltzmann function 
(Equation 3).
2.7.6.4 Fit o f inactivation kinetics
Inactivation kinetics were measured as a response to a long depolarising pulse (see 
Figure 2.10), applied for 900 ms (usually to +10 mV). The decay component o f the 
current response was fitted with a single exponential curve. Inactivation data have 
previously been fitted with either a single exponential (Felix et al., 1997) or double 
exponential (Sokolov et al., 1999), however in this study a single exponential was 
sufficient for a satisfactory fit o f  the current decay:
y = A , e (x- y0)/T + C
-  1 0 2 -
Where:
x = Time (msec)
y = Current (pA)
y° = Initial current (pA)
x = Time-constant o f inactivation (termed ijnact; ms)
C = Non-inactivating current (pA)
A: B
900 ms
-90 mV
+10 mV
250 pA
200 ms
Figure 2.10. The long-pulse protocol. (A), Representation o f the long-pulse protocol 
(B), Sample current trace in response to a 900 ms voltage step to +10 mV, in a tsA-201 
cell expressing Cav2.1, p4, 0x26-2 . The current trace has been fitted with an exponential 
function (shown in red) to calculate X jn a ct-
2.7.6 Sources o f error
A number o f potential errors are present in the recordings made, which must be 
accounted for.
One such error is that introduced by the series resistance (Rs) o f the cell membrane and 
the pipette. Rs produces a discrepancy between the current flowing across the membrane 
and the true potential difference. The voltage-drop across Rs was compensated to 
between 80-90 % in order to avoid the injected current causing oscillations. Rs was o f
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the order o f 5 -  10 MQ for tsA-201 cells and 1 0 - 1 5  MQ for DRGs. Passing a 1 nA 
current across a cell with a Rs o f 5 MQ will produce an error o f 5 mV when 80% 
compensated. It is possible to minimize this error by reducing the concentration o f Ba2+ 
in the external solution (thus reducing the current flow). 10 mM Ba2+ was selected for 
use in external solutions for patching tsA-201 cells (1 mM Ba2+ for DRGs owing to their 
larger size) to allow large currents without introducing excessive error from 
uncompensated Rs.
The junction potential between the internal and external solutions is another source o f 
error. This is caused by the differing mobilities o f the different ions comprising each 
solution. The junction potential between the Ag/AgCl pellet and the external solution 
was nulled between entering the bath solution and making contact with the cell. The 
junction potential between the internal and external solutions was not compensated. It 
was calculated as ~ 6  mV.
2.8 Statistical analysis
Differences between mean values (e.g. peak-current density) were assessed for statistical 
significance using either a Student’s t-test or a one-way analysis o f variance (ANOVA) 
followed by a Dunnett’s test. The threshold for statistical significance was ^<0.05.
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Chapter 3: Results 
Investigation of the function of the a2S VWA domain
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3.1 Introduction
As discussed in the Introduction, 0128 subunits contain a VWA domain, which are also 
found in a number o f adhesion proteins such as integrins (Whittaker and Hynes, 2002). 
This chapter explores the functional contribution o f the VWA domain to functionality o f 
the 0126 subunit. As a potential binding domain, it was thought possible that the 
0128 subunit might be able to bind a small protein ligand through the VWA domain. As 
the 0128 subunit plays an intracellular role in enhancing expression o f the Cava l  subunit 
(Shistik et al., 1995; De Waard and Campbell, 1995), this interaction could be 
intracellular. However, as the VWA domain lies within the entirely extracellular 012 
portion o f the 0128 subunit when expressed at the cel 1-surface, an interaction through the 
VWA domain may also be extracellular. VWA domain-mediated protein interactions 
made by integrins are primarily extracellular, and often involve binding to extracellular 
matrix proteins.
Therefore experiments were carried out to look at the effect o f disrupting the VWA 
domain by mutating the MIDAS m otif (see Introduction), with the aim o f preventing the 
0128-mediated enhancement o f Cava i subunit expression. This would identify either an 
intracellular function o f the (X2S VWA domain (upon enhancement o f Cava i subunit cell- 
surface expression) or a cell-surface function (for instance upon the 0128-mediated 
changes in biophysical properties o f expressed VGCCs). Additionally, co-cultures o f 
tsA-201 cells (expressing VGCC subunits) and cerebellar granule cells (GCs) were used 
to look for evidence o f  an interaction between the two cell-types that might be mediated 
by protin binding at the VWA domain. GCs were used due to their synaptic contact with 
cerebellar Purkinje cells. The work involved whole-cell patch clamp performed on tsA- 
201 cells, expressing Cava l ,  p and clz8  subunits, y subunits were omitted from the 
transfection in all cases. 10 mM Ba2+ ions were used as charge carrier.
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3.2 Results
3.2.1 Characterisation o f the function o f aib-2
The (X25-2  jiMIDAS construct was used to assess the importance o f the (X28-2  VWA 
domain (Canti et al., 2005), as is described in Section 3.2.2. However before examining 
the effects o f a mutated VWA domain in the (X28 -2  subunit, an initial investigation into 
the function o f 0128-2 itself was carried out. (X28 subunits are known for their ability to 
increase the number o f  DHP binding-sites at the channel membrane, an effect thought to 
be mediated by a enhancing effect on Cava i subunit cell-surface expression (Shistik et 
al., 1995). An enhancement o f current density agrees with the view that more channels 
are present at the membrane. In addition, 0128 effects on the channel properties include a 
hyperpolarisation o f the voltage o f current activation, steady-state inactivation, as well 
as effects on macroscopic current activation and inactivation kinetics (see Introduction). 
This section examines some o f the effects o f 012S-2  co-expression with the Cav2.1, (34 
subunit combination.
The data in this section are not taken from an individual experiment, rather they are 
comprised o f the pooled results o f a number o f  experiments, always directly pairing 
control (no 012S-2 ) data with co-expressed (X2S-2  data. Where (X28-2  cDNA is omitted 
from the transfection mixture, the equivalent volume is made up with empty vector 
(pMT-2) cDNA (see Materials and Methods).
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A:
50-,
B:
C ontrol +  a 28 - 2
■ — C o n t r o l  (3 9 )  
— a 5-2 (40)
Test Potential (mV)
Control a25-2 Control a28-2
Figure 3.1. Co-expression o f  0 2 8 - 2  enhances Iea in channels composed o f Cav2.1 and (34 
subunits. (A), Current-voltage relationships for Iea in the Cav2.1, (34, (black squares, 
n=39) and Cav2.1, (34, 0 2 8 - 2  (red circles, n=40). Current amplitude was normalised to 
whole-cell capacitance and plotted against membrane potential. Holding potential was - 
90 mV. (B), Representative current traces for the two conditions in response to -30 to 
+ 15 mV voltage steps. A schematic o f the I-V protocol is shown. Mean values for Gmax 
(C) and V 5 0 ,  act (D) were obtained from fits o f individual I-V relationships using the 
IVFIT function. * denotes P<0.05, *** denotes P>0.001 (Student’s t test).
Figure 3.1 shows how the co-expression o f 0 ,2 8 - 2  affects current amplitude o f the 
heterologously expressed Cav2.1, (34 subunit combination. Control data was obtained 
using a Cav2.1, (34, pM T-2cDNA mix. Control data is shown in black, and the condition 
including heterologous expression o f 0 2 8 - 2  is shown in red. 0 2 8 - 2  co-expression results
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in a significant increase in current amplitude and peak current-density (Figures 3.1 A & 
B respectively). Mean peak current-density was enhanced significantly with the presence 
o f CX2 8 - 2  (-234.6 ± 12.6 pA/pF), in comparison to the control condition (-57.1 ± 4.4 
pA/pF, PO.OOl). Whole-cell conductance (Gmax) and the voltage-dependence o f 
activation o f currents ( V 5 0 ,  a c t )  were measured by fitting -30 mV to +50 mV portions o f 
the I-V relationship with the IVFIT function, as described in Materials and Methods. 
The maximal whole-cell conductance o f the expressed currents was increased with the 
co-expression o f  0 1 2 8 -2  with Cav2.1, (34. Gmax was increased from 1.6 ± 0.1 nS/pF in the 
control condition to 6.0 ± 0.3 nS/pF in the CC2 8  condition (PO.OOl), shown in Figure 3.1 
C. Co-expression o f 0 1 2 8 -2  has an effect on the voltage-dependence o f current activation, 
causing a slight hyperpolarisation in V50, act (from +7.0 ± 0.6 mV to +5.0 ± 0.5 mV, 
P O .05), shown in Figure 3.1 D.
A : B :
E 300
^  200
C o n tro l
a 25-2
C o n t r o l a„6-2 200 ms
Figure 3.2. Co-expression o f  (X2 8 - 2  causes an increase in inactivation kinetics o f 
channels composed o f Cav2.1 and (34 subunits. (A), Mean time-constant o f inactivation 
(Xinact) data is shown for the Cav2.1, (34, (black, n=8 ) and Cav2.1, (34, (X2 8 - 2  (red, n=17). 
The decay phase o f individual current traces at +10 mV was fitted with a single 
exponential function. Flolding potential was -90 mV. (B), Representative current traces
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in response to a long depolarising voltage step to +10 mV, traces are normalised to peak. 
** denotes P<0.01, (Student’s t test).
Inactivation kinetics were hastened by the co-expression o f 0 ,2 6 - 2  (Figure 3.2). A single 
exponential function was fitted to the decaying portion o f  currents through expressed 
channels in response to a voltage step to +10 mV for 800 ms. Tjnact was reduced from
402.7 ± 36.2 ms in the control condition to 283.8 ± 18.8 ms with the co-expression o f 
0 2 6 - 2  (P<0.01), as shown in Figure 3.2 A. Sample current traces are shown in Figure 3.2 
B.
A:
I
-110mV
0 8 -
X 0 .6 -(0E
0 .4 -
0 2 -
■ Control (18)
•  a 28-2 (14)0 .0 -
-80 -60 -40 0 20-20
B:
>
E
Conditioning Potential (mV) Control a.6-2
Figure 3.3. M easurement o f  steady-state Ca2+ channel inactivation and the effect o f  0 2 6 - 
2 co-expression. (A), Steady-state inactivation curves for Cav2.1, p4, (black squares, 
n=18) and Cav2.1, P4, 0 1 2 6 -2  (red circles, n=14) conditions. (B), Mean V50, mactdata were 
obtained by fitting a Boltzmann function to individual steady-state inactivation curves. 
** denotes P<0.01, (Student’s t test).
The presence o f  ct2 6 - 2  also causes a hyperpolarisation in the steady-state inactivation o f 
currents, obtained in response to a constant voltage step following a conditioning 
potential o f  varying voltage (Figure 3.3 A). V50, jnact in the a 26  condition (-35.6 ± 2.0
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mV) was significantly more negative than the control condition (-28.1 ± 1.2 mV, 
P O .O l), as shown in Figure 3.3 B.
Therefore the co-expression o f ot28-2  with Cava i and (34 subunits has significant effects 
on various channel properties, in agreement with previous studies (see Introduction).
3.2.2 a 28-2 pMIDAS
The identification o f a VWA domain in a 28 subunits hinted at an additional role for the 
subunit in terms o f extracellular ligand binding, or at least a site by which its 
intracellular interaction with the Cavcxi subunit might be mediated. The VWA domain o f 
mouse (X2 8-2  was mutated in the lab (by molecular biology technician Wendy Pratt) in 
order to probe its function (see Canti et al., 2005). Three point-mutations were 
introduced into the MIDAS, to convert the DVSGS m otif to AVAGA. This mutant was 
denoted 0128-2 pMIDAS. The effect o f a 2S-2 pMIDAS co-expression with Cav2.1, (34 
was compared to co-expression o f WT a 28-2, or empty vector (pMT-2) as a control 
condition.
Co-expression o f (X2S-2  pMIDAS with the Cav2.1, (34 subunit combination failed to 
enhance current amplitude over those o f the control condition (Figure 3.4 A). The 
current response to a range o f potentials (Figure 3.4 A), as well as the I-V curve (Figure
3.4 B) suggest that (X28-2  pMIDAS is non-functional as an 0128-2 subunit in terms o f  its 
ability to enhance current size. The peak current density o f the (X2S-2  pMIDAS condition 
was similar to that o f the control condition (-40.2 ± 5.1 pA/pF and -43.1 ± 5.3 pA/pF 
respectively), both o f which were significantly lower than the WT 0128-2 condition (-
222.7 ± 18.2 pA/pF, PO.OOl for both). There was no significant increase in the whole 
cell conductance measured for the (X28-2  pMIDAS condition (1.1 ± 0.1 nS/pF) over 
control (1.1 ± 0.1 nS/pF), both o f which were significantly smaller than the WT 0128-2 
condition (5.7 ± 0.5 nS/pF, PO.OOl for both), as shown in Figure 3.4 C. Similar values
- I l l  -
were obtained for V 5 0 , a c t  ( + 5 . 0  ±  0 . 7  m V  for control, + 4 . 1  ±  0 . 2  m V  for W T  0 1 2 8 - 2 ,  + 5 . 1  
±  0 . 1  m V  for 0 ^ 5 - 2  pM IDAS conditions, see Figure 3.4 D), which were not significantly 
different.
Insufficient data were obtained to establish mean values for either V50, inact or Tjnact, 
although similar work (using (X2 8 - 2  pM IDAS co-expressed with Cav2.2, p lb )  found a 
failure o f 0 1 2 8 -2  pM IDAS to hyperpolarise the V50, m a c t  in a similar manner to WT azS-2 
(Canti et al., 2005).
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Figure 3.4. Failure o f  a 25-2 pM IDAS co-expression to enhance IBa through Cav2.1, p4 
channels. (A), Representative current traces for the three conditions in response to -30 to 
+ 15 mV voltage steps. (B), Current-voltage relationships for Cav2.1, P4, (black, n=12), 
Cav2.1, p4, a 2 8 - 2  (blue, n=16) and Cav2.1, p4, a 2 5 - 2  pM IDAS (red, n=21) conditions. 
All currents are normalised to whole-cell capacitance and plotted against membrane 
potential. Holding potential was -90 mV. Gmax in the ot2 5 - 2  condition was significantly
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increased (P<0.001, ANOVA) over control, whereas there was no significant increase in 
the 0x26-2  pMIDAS condition. No significant difference was observed between V5o,actof 
the three conditions (P>0.05, ANOVA).
3.2.3 Mutations o f a putative VWA binding site on the Cavcxi subunit
Given the importance o f the VWA domain in the interaction between the (X28 and Cavcxi 
subunits, the next step was to determine whether the VWA domain was binding to a 
domain on the Cav<xi subunit, and if  so, to which amino acids it was binding.
Biochemical experiments performed in the lab (by Isabelle Foucault) using candidate 
peptides suggested the involvement o f an extracellular loop o f the rabbit Cav2.2 subunit. 
This residue would possess a negatively charged side-chain, be located outside the 
selectivity filter, and would be conserved in all HVA Cava i  subunits. An aspartic acid 
residue at position 325, was chosen. One mutation, D325N, converted the OH polar 
group o f the aspartic acid residue to an NH2 in order to remove the carboxylic group but 
maintain the hydrophilicity o f the residue. Another point mutation replaced the aspartic 
acid residue with a serine (D325S) to preserve an OH group but compromise 
hydrophilicity. Mutations in rabbit Cav2.2 were introduced by Isabelle Foucault.
The results obtained from whole-cell recordings o f cells co-expressing WT Cav2.2, 
Cav2.2 D325S or Cav2.2 D325N with (31b, ( X 2 8 - I  indicated that the D325S and D325N 
mutations did not prevent the association o f the Cavoci subunit with 0 1 2 8 -1. The mean 
peak-current densities were similar in the D325N (-337.3 ± 143.4 pA/pF) and D325S (- 
452.9 ± 101.7 pA/pF) conditions to that o f the control condition (413.0 ± 83.0 pA/pF), 
as shown in Figure 3.5 A. Whole-cell conductance was not significantly impaired by 
either the D325N or D325S mutations. Gmax values o f 9.9 ± 3.8 nS/pF for the D325N 
condition and 14.8 ± 3.1 nS/pF were similar to that o f the control condition (12.6 ± 2.6 
nS/pF), as shown in Figure 3.5 B. Similarly, no change in the voltage-dependence o f 
current activation was observed. V50, act values for the D325N and D325S conditions
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(+7.4 ± 2.4 mV and +12.3 ± 1.3 mV respectively) were similar to the V 5o , a c t observed for 
the control condition (+7.7 ± 2.3 mV), shown in Figure 3.5 C. No negative control 
condition in the absence o f the a^S-l subunit was included. However, the similar values 
for peak-current density and Gmax among the D325N, D325S and control suggest that an 
interaction between the Cav2.2 and 0126-1 subunits still occurs.
Control D325N
■ —Control (6)
•  -  D325N (4)
a -  D325S (4)
Test Potential (mV)
D325NControl
Figure 3.5. I-V relationships o f channels including Cav2.2 D325N or Cav2.2 D325S 
subunits are not significantly different from those including WT Cav2.2. (A), Current- 
voltage relationships for p lb , ct2 5 - l ,  co-expressed with: WT Cav2.2 (black squares); 
Cav2.2 D325N (blue circles) and Cav2.2 D325S (red triangles). All currents are 
normalised to whole-cell capacitance and plotted against membrane potential. Holding 
potential was -90 mV. Mean values for Gmax (B) and V50, act(C) were obtained from fits 
o f individual I-V relationships using the IVFIT function. In all cases, the D325N and 
D325S conditions were not significantly different from the control condition (ANOVA).
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3.2.5 The use o f GC cultures as a source of the putative binding partner o f the 
(X28-2 VWA domain
The 0128 VWA domain is important for enhancing trafficking o f the calcium channel 
complex to the membrane. However, the vast majority o f VWA domain interactions are 
extracellular, such as those involving integrins and extracellular matrix proteins 
(Whittaker and Hynes, 2002). Coupled with the fact the (X28 VWA domain is located in 
the 012 portion o f the subunit, which is entirely extracellular when expressed at the cell 
surface, it is reasonable to propose that some extracellular interaction might be mediated 
through the 0128 VWA domain.
If  0128 (0128-2 in the case o f the study) were to bind to an extracellular protein, a 
reasonable place to look for this binding partner protein would perhaps be synapses on 
nerve cells, given the functional importance o f the presence o f 0,28 and VGCCs at the 
plasma membrane. Therefore, a tissue was selected according to the synaptic 
connectivity between cells, in order to maximise the occurrence o f the putative binding 
partner.
The parallel fibres o f GCs make extensive synaptic contacts with ct28-2 -containing 
Purkinje cells in the molecular layer o f the cerebellum. The molecular layer o f the 
cerebellum contains the parallel fibres o f  the GCs and the dendrites o f Purkinje cells, 
and displays significant 3H-PGB binding (Bian et al., 2006). Therefore, cerebellar GC 
cultures were selected as a potential source o f binding partner for the (X28 VWA domain.
3.2.5.1 Assessment of culture media
When cultured separately, tsA-201 cells and GCs are grown in different media (D-MEM 
and BME respectively). Therefore an initial assay was set up to determine which 
medium to select for co-cultures. This was attempted with 2 separate cultures for GCs 
(cultured in D-MEM), and 2 separate flasks o f tsA-201 cells (cultured in BME). Whilst
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no striking differences were observed in either the appearance or number o f tsA-201 
cells cultured in BME compared to D-MEM, a large proportion o f the GCs failed to 
adhere / survive in D-MEM. Therefore, co-cultures proceeded to use BME as a culture 
medium. Cells o f the control condition (tsA-201 cells “alone”) were also cultured in 
BME, despite the absence o f GCs. Images o f tsA-201 / GC co-cultures are shown in 
Figure 2.1).
3.2.S.2 Testing a mid HA-tagged a 28-2 stable-cell line
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Figure 3.6. Functionality o f the stable a 28-2 mid-HA construct. (A), Representative 
current traces for Cav2.1, p4, (control, black), Cav2 .l, p4, a 28-2 (blue) and Cav2.1, p4, 
a 28-2 stable mid-HA (red) conditions in response to -30 to +15 mV voltage steps. (B), 
Current-voltage relationships for the three conditions. All currents are normalised to 
whole-cell capacitance and plotted against membrane potential. Holding potential was - 
90 mV. (C) Mean Gmax values o f Cav2.1, P4, a 28-2 Cav2.1, p4, a 28-2 stable mid-HA
- 1 0 0 -
Control (12)
— a 2S-2 (16)
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were significantly different from control (ANOVA). (D) Mean values for V 5 0 ,  a c t  were 
different among the three conditions. Values for (C) and (D) were obtained from fits o f 
individual I-V relationships using the IVFIT function.
One route o f investigation that was followed up was the possibility that the 0128 VWA 
domain bound an extracellular protein ligand. This would involve co- 
immunoprecipitation experiments, and therefore a stable tsA-201 cell-line expressing an 
HA-tagged (X28-2  was produced in the lab (by Jack Wratten). Before use in experiments, 
it was necessary to demonstrate the construct was expressed as a functional tagged 0 ,28-2  
protein (0 2 8 -2  mid-HA).
Cell culture and electrophysiological recording using the 0 2 8 -2  mid-HA stable cell-line 
were carried out in the same way as previous electrophysiological experiments (see 
Materials and Methods for more detail). However, the volume o f cDNA in the 
transfection mix that was normally made up by 0 2 8 -2  was instead made up by empty 
vector (pMT-2) in the case o f this experiment.
The stably expressed 0 2 8 -2  mid-HA construct enhanced IBa through co-expressed 
Cav2.1, p4 channels to the same extent as transiently transfected WT 0 2 8 -2 , as shown in 
Figure 3.6. Representative current traces show an increase in current amplitude in both 
the 0 2 8 -2  and stable 0 2 8 -2  mid-HA conditions over that o f the control condition (Figure
3.6 A). The mean peak-current density was significantly larger (3.8-fold) in both the WT 
0 2 8 -2  (-236.4 ± 23.7 pA/pF) and stable 0 2 8 -2  mid-HA (-234.0 ±31 .6  pA/pF) conditions 
compared to the control condition (63.5 ± 6 .8  pA/pF, P<0.001 for both, ANOVA), 
shown in Figure 3.6 B. Maximal whole-cell conductance was also increased to the same 
extent by the stable 0 2 8 -2  mid-HA condition (6.0 ± 0.7 nS/pF) as by WT a 28-2 
condition (6.1 ± 0.6 nS/pF) over the control condition (1.7 ± 0.2 nS/pF, P<0.05 for both, 
ANOVA), as shown in Figure 3.6 C. In contrast to data shown in Figure 3.1 D, mean 
values o f V50, act o f transient WT 0 2 8 -2  (and stable 0 2 8 -2  mid-HA) conditions were not 
significantly different to that o f the control condition (Figure 3.6 D). The ability o f a 28
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to hyperpolarise V50, act is not certain, with some studies not finding 0 2 8  (0128- 1 ) 
expression to alter V50, act (Shirokov et al., 1998), whilst another study found it to 
hyperpolarise V50 , act (Felix et al., 1997).
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Figure 3.7. Stably transfected 0 ,2 8 - 2  mid-HA affects inactivation kinetics of Cav2.1, p4 
channels. (A), Mean time-constant o f inactivation (imact) data is shown for the control 
Cav2.1, p4, (black, n=4) and Cav2.1, p4, stable 0 2 8 - 2  mid-HA (red, n=6 ) conditions. 
Holding potential was -90 mV. The decay phase o f individual current traces at +10 mV 
was fitted with a single exponential function. (B) Representative current traces in 
response to a long depolarising voltage step to +10 mV, traces are normalised to peak. * 
denotes P<0.05, (Student’s t test).
In addition, the time-constant o f inactivation o f currents was significantly reduced by co­
expression o f the stable 0 .2 8 - 2  mid-HA construct (291.0 ± 40.7 ms) compared to the 
control condition (467.0 ± 28.0 ms, P<0.05), as shown in Figures 3.7 A & B. 
Unfortunately, insufficient data were obtained for the transiently-transfected WT a 28-2 
condition. However, equivalent data are presented in Figure 3.2 for transiently- 
transfected WT a 28-2. The stable a 28-2 mid-HA construct also had the same effect on 
steady-state inactivation o f the currents as the WT 0 2 8 - 2  (Figure 3.8 A). The V5 0 , mact 
values for stable 0 2 8 - 2  mid-HA (-29.5 ± 1.9 mV) was hyperpolarised compared to that
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of the control condition (-23.9 ± 1.3 mV, P<0.05, Student’s t test), as shown in Figure 
3.8 B. Unfortunately, insufficient WT a 25-2 data were obtained for analysis.
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Figure 3.8. Effect o f stable a 28-2 mid-HA expression on the steady-state inactivation of 
Cav2.1, p4 currents. (A), Steady-state inactivation curves for control Cav2 .l, |34 (black 
squares, n=7) and Cav2 .l, |34, stable a 25-2 mid-HA (red circles, n=8 ) conditions. (B), 
Mean V50, inact data were obtained by fitting a Boltzmann function to individual steady- 
state inactivation curves. Individual values for V5o, inact in the a 28-2 condition are shown. 
* denotes P<0.05, (Student’s t test).
3.2.5.3 P rotein  from  the GC cultures binds to a 28-2  mid-HA
Initially, it was important to ascertain whether of not any proteins from the GC cultures 
bound to a 28-2. In order to do this, co-immunoprecipitation experiments were carried 
out using co-cultures o f tsA-201 cells (stably expressing a 25-2 mid-HA) and GC 
cultures.
Two co-immunoprecipitation experiments were carried out (Figure 3.9). These involved 
lysis and solubilisation of cells in tsA-201 / GC co-cultures, and binding o f a 28-2 mid- 
HA protein to protein G / sepharose beads. This was followed by SDS-PAGE separation
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and silver-staining o f the gel in order to detect protein (see Materials and Methods). The 
first experiment (Figure 3.9 A) compared tsA-201 transfected with Cav2.1, (34, stable 
0128-2 mid-HA cultured either alone, or with GCs to see if any extra protein would be 
bound to the 0028-2 mid-HA. Extra protein was observed at ~70 kDa. Whether this 
represents another band, or extra material (of the same band seen in the tsA-201 cells 
cultured alone) is not clear (see Figure 3.9 B for more detail).
The experiment was repeated with extra conditions (Figure 3.9 C), in order to further 
clarify the extra protein observed from the first experiment. Column 5 shows non­
specific binding o f material to 0128-2 mid-HA. The 0028 protein itself (-170 kDa) is 
present in all 0028-2 mid-HA-transfected lanes (3, 4, 6  and 7). Once again, when tsA-201 
cells expressing stable 0028-2 mid-HA were co-cultured with GCs, an extra band / 
additional protein was observed at ~70 kDa (black arrow in Figures 3.9 C & D). This 
material was not observed in co-cultures which did not express stable 0028-2 mid-HA 
(lane 5). In addition to the extra material observed at ~70 kDa, two further bands o f  -75  
kDa (red arrow) and -65  kDa (green arrow) were observed (Figures 3.9 C & D).
This result suggested that protein from the GC cultures bound to the mid-HA 0028-2 
expressed on tsA-201 cells. At this point, there was no way o f distinguishing any 
difference as being an effect o f ligand binding to the VWA domain rather than some 
other effect elicited by the GCs. For a VWA domain ligand to be detected by co- 
immunoprecipitation, it had to remain bound to the VWA domain for the entirety o f the 
immunoprecipitation process. The switching o f the VWA to the inactive state in the 
absence o f divalent cations also had to be considered. However, although the likelihood 
o f one o f the identified extra proteins being a VWA domain ligand was negligible, it was 
still investigated by electrophysiology. This involved examining the currents formed by 
Cav2.1, p4, stable mid-HA a 28-2 expressed in tsA-201 cells, according to their 
proximity to GC projections.
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F igure 3.9. Co-immunoprecipitation o f  tsA-201 / GC co-cultures. (A), Silver-stained 3- 
8 % tris-acetate gel o f protein pulldown using Protein G / sepharose beads and anti-HA 
antibody. Lane 1- Protein G; lane 2- tsA-201 expressing Cav2.1, (34 stable 0 0 2 8 -2  mid- 
HA; lane 3- tsA-201 expressing Cav2.1, (34 stable 0 1 2 8 -2  mid-HA + GC. Green arrow 
refers to an additional protein band at -7 0  kDa in co-cultures. (B), Enlarged section o f 
lanes 2 and 3 in the region o f 75 kDa. (C), Silver-stained 3-8% tris-acetate gel o f  protein 
pulldown using Protein G / sepharose beads and anti-HA antibody. Lane 1- GC; lane 2- 
untransfected tsA-201 + GC; lane 3- tsA-201 expressing stable a 28-2 mid-HA; lane 4- 
tsA-201 expressing Cav2.1, (34 stable 0 1 2 8 -2  mid-HA; lane 5- untransfected tsA-201 + 
GC; lane 6 - tsA-201 expressing stable a 28-2 + GC; lane 7- tsA-201 expressing Cav2.1, 
(34 stable 0 0 2 8 -2  mid-HA +GC. Additional protein bands in co-cultures were observed at 
-7 5  kDa (red arrow), -7 0  kDa (black arrow) and -65  kDa (green arrow). The blue arrow 
refers to 0 0 2 8 - 2  mid-Ha protein. (D), Enlarged section o f lanes 5-7 in the region o f  75 
kDa. Arrows refer to additional protein in co-cultures.
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3.2.5.4 Whole-cell electrophysiology using tsA-201 / GC co-cultures
Having established the possibility of protein binding to the 0 ,2 8 - 2  subunit when co­
cultured with GCs, cells were patched in an attempt to see the effect that binding o f a 
putative ligand to the VWA domain might have on the currents obtained through co­
expressed calcium channel subunits. As with the co-immunoprecipitation assay, the 
Cav2.1, p4, stable mid-HA 0 2 8 - 2  subunit combination was selected. It was hypothesised 
that the ligand likely to be an extracellular or secreted protein. Therefore, the effect of 
proximity to, and contact with GCs was investigated.
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Figure 3.10. GC contact inhibits IBa in cells expressing Cav2.1, p4, stable (X2 8 - 2  mid- 
HA. (A), Representative current traces for the three conditions in response to -30 to +15 
mV voltage steps. (B), Current-voltage relationships for Cav2.1, p4, stable a 28-2 mid- 
HA cultured alone (control condition; black, n=6 ), near to GC projections (blue, n=12) 
and in contact with GC projections (red, n=l 2) conditions (P<0.05, ANOVA). All 
currents are normalised to whole-cell capacitance and plotted against membrane
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potential. Holding potential was -90 mV. Mean values for Gmax (C) and V5o, act(D ) were 
obtained from fits o f individual I-V relationships using the IVFIT function. Mean Gmax 
of the control condition was significantly higher than the contact condition (P<0.05, 
ANOVA), this was not the case for the near condition. No significant difference in V5o, 
act o f the three conditions was observed (P>0.05, ANOVA)
The conditions were defined as follows. tsA-201 cells seen touching or laying on top of 
a GC projection were defined as “in contact” . tsA-201 cells which appeared in the same 
field o f view as a GC was defined as “near”. This distance could feasibly have been up 
to -5 0  pm. Mitotic inhibitors (such as cytosine arabinoside) were not included in the 
culture media. In an experiment assessing the possibility o f secreted ligands for the ot2§- 
2 VWA domain, it was not felt that preventing growth o f non-neuronal cells would be 
advantageous.
Close proximity o f VGCC-expressing tsA-201 cells to GC projections resulted in an 
inhibition o f the current amplitude, as seen from representative current traces (Figure 
3.10 A, the red trace corresponds to cells in contact with GC projections and the blue 
trace corresponds to cells near to GC processes), as well as the resultant I-V plots 
(Figure 3.10 B). Mean peak current-density was reduced in the contact condition (-91.3 
± 22.8 pA/pF) when compared to either the near condition (-228.1 ± 39.2 pA/pF, 
P>0.05) or the control condition (-255.5 ± 86.3 pA/pF, P>0.05, ANOVA), as shown in 
Figure 3.10 B. Regarding whole-cell conductance, both the control and near conditions 
were similar (7.9 ± 2.4 nS/pF and 6.5 ± 1.0 nS/pF respectively). The control condition 
was significantly larger than that o f the contact condition (2.9 ± 0.8 nS/pF, P>0.05 
ANOVA), shown in Figure 3.10 C. Despite the reduction in mean peak-current density 
seen in the contact condition, no change was observed in the voltage-dependence o f 
current activation, with the V50, act similar in all three conditions (+7.4 ± 2.1 mV in the 
control condition, +6.4 ± 1.5 mV in the near condition, +6 .6  ± 1.8 mV in the contact 
condition), shown in Figure 3.10 D.
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Steady-state inactivation was also affected by proximity to GC projections (Figure 3.11). 
Shown in Figure 3.11 A are the three experimental conditions (along with a green dotted 
line corresponding to previous data obtained for the Cav2.1, p4 subunit combination, in 
order to illustrate the steady-state inactivation in the absence o f 0(2 8 -2 ). Whilst no 
significant change was observed in V50, jnact of the near condition compared to control 
condition ( V 5 0 ,  in a c t  values o f -32.7 ± 1.4 mV and -30.7 ±1.1 mV respectively, ANOVA), 
a significant hyperpolarisation in V50, inact was observed in the contact condition (-37.9 ±
1.6 mV) compared to mean V50, act for the control condition (P<0.05, ANOVA). This is 
shown in Figure 3.11 B.
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F igure 3.11. Effect o f GC projection contact on the steady-state inactivation o f Cav2.1, 
p4 stable 0(2 8 - 2  mid-FIA currents. (A), Steady-state inactivation curves for control 
(black, n= 11), near to (blue, n=6 ) and in contact with GC projection (red, n=5) 
conditions (P<0.05), also displayed is a representative mean curve for Cav2.1, p4 
currents from unpaired data (green, n=7). (B), Mean V50, mact data were obtained by 
fitting a Boltzmann function to individual steady-state inactivation curves. * denotes 
P<0.05 between mean V50, inactof the contact condition and control condition (ANOVA).
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3.3 Discussion
The co-expression o f aib-2  as a VGCC auxiliary subunit
The discovery o f  a VWA domain (Whittaker and Hynes, 2002) within the 0 ^ 5  subunit 
(see Introduction) suggested that 0126 might make functional adhesion interactions via 
this domain in a divalent cation dependent process, much in the same way as integrins 
and other VWA domain-containing proteins. Experiments using an 0128-2 subunit 
containing a mutated MIDAS m otif (Canti et al., 2005) also suggested that the 0128-2 
VWA domain was important in the intracellular interaction the 0128 makes with the 
Cava i subunit to enhance its cell-surface expression.
Before using the 0128-2 pMIDAS construct, the effects o f  (X28-2  co-expression were 
examined, when transiently expressed in the tsA-201 cell-line as part o f the heterologous 
Cav2.1, (34, 012S-2  subunit combination.
0,28 subunits affect expressed VGCCs in a number o f  ways (see Introduction). From 
what is known from their characterisation so far, the modulatory effects are fairly well 
conserved amongst the 4 isoforms o f CC28 . Co-expression o f 0,28 subunits causes an 
increase in observed current amplitude through VGCCs (Qin et al., 2002; Klugbauer et 
al., 1999; Singer et al., 1991). However, the importance o f  a (3 subunit (and more 
specifically the exact isoform o f |3 subunit) must also be taken into account (Walker and 
De Waard, 1998). The most well characterised 0128 subunit, 0128-1, is known to increase 
activation and inactivation kinetics, as well as hyperpolarising both the steady-state 
inactivation and I-V curves (Singer et al., 1991; Welling et al., 1993; Bangalore et al.,
1996). The results o f the 0128-2 co-expression experiment (Figures 3.1 -  3.3) agree with 
previous studies which have reported these effects.
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Non-functionality o f the (X28-2 pMIDAS construct
The use o f the aib-2 pMIDAS construct illustrates the importance o f the (X28-2  VWA 
domain. In this study, the lack o f  a functional VWA domain resulted in an inability o f 
0128-2 to enhance current density when co-expressed with Cav2.1, (34 subunits. These 
data are in agreement with data (obtained in the lab at the same time as this study was 
carried out), which demonstrates this lack o f function as resulting from the failure o f 
0128-2 juMIDAS to enhance Cav2.2 trafficking and subsequent cell-surface expression 
(Canti et al., 2005).
The (X2 8-2  pM IDAS mutation was further characterised by Canti et al., (2005). 0128-2 
pMIDAS was expressed to the same extent as WT 0128-2 when expressed alone (i.e. in 
the absence o f  Cav2.2). It also bound GBP with the same affinity (Canti et al., 2005), 
suggesting that the 0 ,28-2  pMIDAS is functionally expressed and properly folded when 
expressed alone, but retained intracellularly when co-expressed with Cav2.2 (and p lb), 
hence the lack o f enhanced current amplitude and failure to hyperpolarize V 5 0 ,  in a c t  of 
expressed currents.
The binding o f  divalent cations to the 0 2 8  MIDAS m otif is also important, given that it 
is an auxiliary subunit o f  a calcium channel. Replacing Ba2+ ions with Na+ ions as the 
charge carrier (calcium channels also permit Na+ ion permeation, but only in the 
complete absence o f  divalent cations) still did not cause an a 28-mediated enhancement 
o f current amplitude in the (X28-2  pMIDAS condition (Canti et al., 2005), suggesting the 
pMIDAS did not affect the ability o f ions to permeate through the channels.
Membrane protein processing (after the assembly o f  an amino acid chain at the 
ribosome) involves the ribosome / nascent peptide / translocon complex. The nascent 
peptide is fed from the ribosome, through the translocon- and is arranged across the ER 
membrane (Deutsch, 2003). When ot28-2  pMIDAS is co-expressed with Cav2.2, it 
appears that both subunits are “trapped” in an intracellular compartment- most likely the
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ER (Canti et al., 2005). Therefore the interaction between a 2S and Cavoti subunits is 
likely to be during their time in the ER, although the exact mechanism is not clear.
It is not known whether the VWA-mediated interaction between the a 28  and Cavoii 
subunits involves an immature a 28  protein, or a fully processed one. However, the a 28  
subunit undergoes glycosylation and cleavage steps before its functional expression 
(Douglas et al., 2006). a 28  subunits that are not fully glycosylated fail to enhance 
current amplitude to the same extent as fully glycosylated a 28  (Sandoval et al., 2004). It 
has been shown that the vast majority o f  a 28  remains un-cleaved following heterologous 
expression (Douglas et al., 2006). The a 28  subunits in these cells still produce an 
enhancement o f current amplitude, although it is not clear whether this effect is 
mediated by un-cleaved a 28 , or by the small proportion o f  cleaved a 28 . Therefore, it is 
feasible that the a 28  VWA domain-mediated enhancement o f  trafficking occurs in the 
ER after glycosylation, and could occur before or after cleavage into a 2 and 8 .
The function o f a 28  as an auxiliary subunit aiding the trafficking o f  the pore-forming 
subunit is not unique. The calcium channel (3 subunit binds to the I-II loop o f the Cava i 
subunit in the ER and blocks an ER retention signal located on the Cav(Xi subunit (Bichet 
et al., 2000). This Cavoti retention signal acts as both a quality control mechanism and an 
expression “brake”, with the result that control over Cav(3 subunit expression leads to 
control over the functional expression o f Cava i subunits. Facilitating ER transport is a 
major activity o f many ion channel subunits, preventing ER retention and helping 
subunit proteins enter the ER exit pathway.
Ligands of the a 28-2 VWA domain
The importance o f the a 28  VWA domain in the role o f trafficking the Cava i subunit to 
the membrane is detailed above, and this intracellular action may well be the only role o f 
the VWA domain. An effort to identify the VWA domain binding site on Cav2.2 (using
- 127-
the D325N and D325S mutations) proved unsuccessful (Figure 3.5). The experiment 
was carried out in the absence o f a negative control for the 0128 subunit, however the 
peak-current density and whole-cell conductance o f currents obtained from both mutants 
was similar to that o f the control condition. Therefore, the putative site on the Cava i 
subunit where the (X28 VWA domain binds remains unidentified.
The importance o f VGCCs at the presynaptic membrane is well established (Dunlap et 
al., 1995). In addition, it has been shown that association o f neuronal VGCCs with 
laminin is important in the formation and maintenance o f active zones in the synaptic 
cleft (Nishimune et al., 2004). This interaction is just one o f many adhesion interactions 
in the synaptic cleft required to maintain the synapse. The possibility o f the VGCC 
0128 subunit being involved in a trans-synaptic interaction with a post-synaptic protein is 
plausible, perhaps to maintain positioning o f VGCCs within the active zone.
Some o f the most widespread proteins to carry the VWA domain are those o f the 
integrin family. These are proteins comprised o f an a  and a (3 subunit, both o f which 
span the cell membrane, with the majority o f the protein in the extracellular space 
(Amaout et al., 2005). 18 a  subunits and 8 p subunits have been identified in mammals, 
which assemble to form 24 different integrins (Hynes, 2002). The VWA domain is 
found in roughly half o f the known integrin a-subunits (Amaout et al., 2005), where it 
forms the functional binding site. The presence o f the VWA domain in integrins is 
integral for their role in binding extracellular molecules, for example fibronectin and 
laminin via an RGD amino acid m otif (Amaout et al., 2005), and linking them across the 
cell membrane to the cytoskeleton.
Much like integrins, VGCC (X28 subunits contain a VWA domain in the extracellular 
portion o f the protein. Whether this confers a physical adhesion or signalling function to 
the Cava i subunit is not yet known, neither is the mechanism by which the VWA 
domain o f (X28 enhances the cell-surface expression o f VGCCs. It is believed that the 8 
subunit makes an interaction with the C av(Xi subunit at the cell-surface, through which
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the biophysical effects on ct2S-channel properties are elicited (Felix et al., 1997). Should 
the VWA domain-containing 012 subunit make an additional extracellular interaction 
with the Cavoci subunit, this is not apparent from changes in channel permeation 
properties (Canti et al., 2005).
The (X26 VW A domain may have an additional role in EC activity
There are other means o f investigating the inhibitory effect o f GC proximity. These 
would include using co-expression o f the (X28-2  pM IDAS construct in an attempt to 
establish whether the inhibitory effects on IBa occurred as a result o f ligand binding the 
VWA domain.
The study failed to identify a binding partner for the 0 ,28 -2  VWA domain. A small 
number o f  candidate ligand proteins were identified in the co-immunoprecipitation 
experiment (for example one at ~70 kDa, Section 3.2.5.3). However the amount of 
cerebellar material required in order to produce sufficient protein for identification o f 
these bands proved prohibitive. In addition, the lack o f  a tagged a 28-2 pMIDAS meant 
that the extra protein bands observed in co-cultures could not necessarily be attributed to 
material binding to the VWA domain. Other means o f  purifying a putative ligand (such 
as the use o f antibody columns) would encounter the same problems, and therefore this 
work remains within the scope for future experimentation.
Contact with GC projections resulted in an inhibition o f current amplitude in Cav2.1, (34, 
stable (X28-2  mid-HA (expressed in tsA-201 cells). Once again, it was not possible to 
determine if this inhibitory effect was absent from an 0 2 8 -2  pMIDAS condition as a 
stable mid-HA tagged cell-line was not produced. Therefore the inhibitory effect cannot 
be attributed to an adhesion interaction at the VWA domain, rather it may be a non­
specific effect. In addition to the use o f a stable a 28-2 pMIDAS cell-line, a control
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condition measuring currents through expressed potassium or sodium channels would be 
able to determine whether this is the case.
Conclusion
The 0 2 8  VWA domain has been shown to be important in the intracellular interaction 
between the CavOi and 0 2 8  subunits which allows enhancement o f Cava i  cell-surface 
expression. Mutation o f  amino acids in the MIDAS m otif o f  the 0 2 8 -2  subunit prevents 
enhancement o f cell-surface expression o f the VGCC complex (Canti et al., 2005). This 
may be the result o f inability o f the VWA to function (in terms o f ligand binding) This 
study provides evidence that the ot25-2  subunit binds (an as-tey unidentified) protein 
when stably expressed in tsA-201 cells and co-cultured with GCs, and demonstrates an 
inhibitory effect o f  GC contact upon Cav2.1, p4 stable 0 2 8 - 2  mid-HA currents. The 
study does not however attribute these observed effects directly to involvement o f the 
0 2 8 - 2  VWA domain.
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Chapter 4: Results
Effects of mutation of an RRR motif on the a28 subunit 
necessary for gabapentin binding.
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4.1 Introduction
The mutation o f an RRR m otif in the 0128 subunit (RRA) results in an 0128 protein that 
displays negligible GBP binding (Wang et al., 1999). This mutation has been previously 
engineered into CI28-I (R217A) and (X28-2  (R282A) subunits (Wang et al., 1999; Davies 
et al., 2006). This chapter details some experiments carried out to examine the effect o f 
the RRA mutation on the function o f (X28 at the cellular level.
Once the VGCC (X28 subunit was established as the binding protein for GBP, it was 
proposed that the anti-epileptic effects o f  GBP might be mediated through the (X28 
subunit, resulting in an inhibitory effect on the VGCCs with which they associate (Gee 
et al., 1996). A subsequent study (Wang et al., 1999) located a number o f regions within 
the 012 portion o f the subunit that were important for GBP binding. These included 
residues 206-222, 516-537 and 583-603 (in porcine 0028-1). In addition, a single-point 
arginine to alanine mutation at residue 217 resulted in an 0128-1 protein that displayed 
negligible GBP binding.
0 1 2 S - I  null mutant mice die during embryonic development, making it difficult to 
examine the importance o f 0 1 2 8 -1 in terms o f physiological function and drug-binding 
(Joshi and Taylor, 2006). However, a transgenic knock-in mouse-line containing the 
0 1 2 8 -1 R217A mutation was produced, in order to determine the location and importance 
o f GBP binding to the CC2S-I subunit (Bian et al., 2006). Autoradiographic binding 
studies using this transgenic mouse strain found a loss o f  binding o f both 3H-GBP and 
H-PGB in areas o f the brain and spinal cord which express ( X 2 8 - I ,  compared to 
significant binding in the wildtype mice. Binding o f  these ligands was still present in 
areas such as Purkinje cells in the Purkinje cell layer and the molecular layer o f the 
cerebellum, due to the presence o f  0028-2 .
However, the protein expression o f  0128-I R217A (in neocortex brain samples taken for 
western blot analysis) was similar to that o f  WT 0028-!, as was the level o f expressed
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ot2§-l R217A mRNA (Field et al., 2006). 0128-1 R217A mice displayed no grossly 
abnormal phenotype (Field et al., 2006; Bian et al., 2006), and exhibited much the same 
normal behaviour as WT mice such as the nocifensive response to formalin injection. 
Whole-cell recording o f  DRG neurons cultured from (X28- 1 R217A mice found a similar 
current amplitude to those o f WT mice (Field et al., 2006), suggesting the 0128-1 R217A 
mutation did not impair the current amplitude in native neurons. However, (X28-I R217A 
mice were non-responsive to PGB or GBP in a chronic constriction injury model o f 
neuropathic pain, but responsive to opiates and to the tricyclic antidepressant 
amitriptyline (Field et al., 2006). An additional study showed (100 pM) PGB to reduce 
the strength o f  muscle contractions, through presynaptic action at the neuromuscular 
junction (rather than an effect on excitation-contraction coupling). This effect was seen 
in WT , but not 0128-1 R217A mice (Joshi and Taylor, 2006).
Given the importance o f the RRR m otif on 0128-1 and 0128-2 subunits for binding GBP, it 
was o f interest to know the implications o f disrupting this motif. Therefore, effects o f 
RRR m otif disruption were investigated in this study. The 0128-1 R217A and (X28-2  
R282A mutant subunits were co-expressed in tsA-201 cells along with Cavoti and p 
subunits to determine what the implications would be on the observed effects o f 0,28 co­
expression (see Chapter 3). The function o f the RRR m otif had already been established 
(Wang et al., 1999), however the normal functionality o f RRA mutant 0128 subunits (i.e. 
in the absence o f  GBP) had not been tested. This was therefore the aim o f the study.
A previous study has shown that dilaysis o f membrane preparations (expressing ( X 2 8 - I )  
results in the removal o f a bound ligand (< 12 kDa in size) from the ( X 2 8 - I  protein, and 
that removal o f this ligand results in an increase in affinity in 0128-1 3H-GBP binding 
(Dissanayake et al., 1997). This raises the possibility that GBP binding to CX28 subunits 
may interfere with the binding o f a ligand normally bound to 0 1 2 S  subunits. As non GBP- 
binding proteins, the RRA mutant 0128 proteins might also not bind this ligand. The 
inability o f RRA mutant a 2S subunits to bind this ligand might potentially explain any 
differences seen when compared to WT 0128 subunits.
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Two 0 ,28-1 R217A subunits were used in this the study: porcine and rat 0 2 8 -1  R217A 
(see Section 2.1.2). The porcine 0 2 8 -1  R217A has been described previously (Wang et 
al., 1999). The rat 0 2 8 -1  R217A (as well as the rat 0 2 8 - 2  R282A) was produced in the 
lab (by Wendy Pratt).
4.2 Results
4.2.1 Radioligand binding
GBP binding to the 0 2 8  subunit has been previously demonstrated for both 0 2 8 -1  and 
0 2 8 -2 , but not 0 2 8 -3  or 0 2 8 -4  (Marais et al., 2001; Qin et al., 2002; Gong et al., 2001). 
These subunits do not possess the RRR m otif necessary for GBP binding (Wang et al., 
1999). Previous studies have demonstrated a lack o f PGB binding to the 0 2 8-1  R217A 
protein in comparison to WT 0 2 8 - 1 , both in autoradiographic studies on brain and spinal 
cord (Bian et al., 2006) as well as in GBP binding assays using porcine 0 2 8 -1  R217A 
transiently expressed in HEK293 cells (Field et al., 2006).
In this study, radioligand binding assays were carried out to determine the amount o f 
GBP-binding to (the previously untested) rat 0 2 8 -1  R217A relative to rat WT 0 2 8 - 1 . 3H- 
GBP was used as the radioligand (see Materials and Methods, Section 2.6). 0 2 8  was 
transfected alone (i.e. in the absence o f other VGCC subunits). Co-expression o f other 
VGCC subunits was not expected to cause a significant increase in cell-surface 0 2 8  
subunit expression (altering binding) to warrant their presence.
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Figure 4.1. The a 2S-l R217A mutation results in impaired 3H-GBP binding. (A), 
Specific binding o f JH-GBP to membranes from cells expressing WT a 28-l (black 
squares, n=5) or a 28-l R217A (red circles, n=5). The curves are hyperbolae fitted to the 
mean data. (B), a 28-l is present in lipid raft peak-fractions. An anti a 28-l 
immunoreactive band at ~170 kDa is present in a number o f lipid-raft fractions (top 
panel), but mainly in the peak-fractions (4 & 5), corresponding to the presence o f an 
anti-flotillin-1 immunoreactive band at 50 kDa (lower panel). (C), a 28-l R217A was 
present in lipid-raft fractions. A nti-a28-l immunoreactivity was detected in the peak- 
fractions (5 & 6), which corresponded to immunoreactivity for anti-flotillin-1. (D), 
Specific binding o f ’H-GBP to lipid rafts from cells expressing WT a 28-l (black
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squares, n=4) or (X28-I R217A (red circles, n=3). The curves are hyperbolae fitted to the 
mean data. Mean values for Bmax (E) and KD (F) were calculated from fitting individual 
experiments with a hyperbola function. *** denotes P<0.001 (Student’s t-test).
4.2.1.1 3H-GBP binding to GI28-I R217A: membrane preparations
Membrane samples (from tsA-201 cells) were prepared as described in Materials and 
Methods. Vastly reduced binding o f  H-GBP was observed in the resultant binding 
assays (Figure 4.1 A). The observed binding for the 0128-1 R217A condition was 
negligible compared to that o f the control (X28-I condition. Individual binding 
experiments o f the control condition were fitted with a hyperbola function, which gave 
mean values for Kd and Bmax o f 231.5 ± 33.8 nM and 1.7 ± 0.4 pmol/mg protein, 
respectively. Equivalent values for the 0128-1 R217A experiments were not obtained as 
negligible binding observed rendered curve-fitting to the majority o f individual 
experiments impossible.
4.2.1.2 3H-GBP binding to (X28-I R217A: lipid-raft preparations
Detergent-insoluble membrane fractions were prepared from WT CX2S-I and (X28-I 
R217A-transfected cells, as these proteins localise in lipid-rafts, as discussed in the 
Introduction (Section 1.8.4). This allowed further characterisation o f  3H-GBP binding to 
(X28-I, as shown in Figure 4.1.
As shown in Figures 4.1 B and 4.1 C, both WT 0128-1 and 0128-1 R217A were found to 
be present in the Triton X-100-insoluble membrane fractions when separated across a 
sucrose gradient (see Materials and Methods). This indicated they localised to lipid rafts.
3 • • • •H-GBP binding to (X28-I R217A in lipid raft fractions displayed the same significant 
reduction in binding (~ 100-fold decrease in Bmax) when compared to WT a 28 - l ,  as
- 136-
shown in Figure 4.1 D. Despite the low amount o f binding, it was possible to fit 
individual binding curves to 0128-1 R217A binding data, suggesting that binding still 
occurred. The observed Bmax was reduced from 51.8 ± 4.8 pmol/mg protein in the 
control condition to 4.5 ± 1.8 pmol/mg protein in the ( X 2 8 - I  R217A condition (P<0.001), 
as shown in Figure 4.1 E. The mean KD (137.9 ± 14.8 nM) was significantly higher than 
the control condition (37.9 ± 4.1 nM, PO.OOl), as shown in Figure 4.1 F. Additionally, 
3H-GBP binding to WT 0 1 2 8 - 1 resulted in a significantly increased (6.1-fold) affinity (a 
Kd o f 37.9 ± 4.1 nM in lipid-raft preparations, compared to 231.5 ± 33 nM in membrane 
samples, P<0.01).
4.2.2 W hole-cell electrophysiology
4.2.2.1 (X28-I R217A does not enhance Iea to the same extent as WT (X28-I
when co-expressed with Cav2.2, (31b
Flaving confirmed that 0128-1 R217A is expressed in tsA-201 cells, but does not bind 
GBP, it was necessary to examine how it would compare to WT 0 1 2 8 - 1 in terms o f its 
ability to alter characteristics such as V50, inacb V5o,act, and Gmax. Therefore, tsA-201 cells 
co-expressing Cav2.2, (3lb  and either WT 0 1 2 8 - 1 or C X 2 8 - 1 R217A were subjected to 
whole-cell patch-clamp electrophysiology, as shown in Figure 4.2.
The immediate difference observed between currents obtained with Cav2.2, (31b co­
expressed with either C C 2 8 - I  R217A or WT ( X 2 8 - I  was a smaller enhancement o f the 
current size (see sample traces in Figure 4.2 A), as well the mean current density across 
a range o f test-potentials (Figure 4.2 B). The mean peak-current density recorded for the 
0 1 2 8 - I  R217A condition was -94.1 ± 23.2 pA/pF, a value significantly lower than that 
recorded for the WT 0 1 2 8 - I  condition (-284.1 ± 85.5 pA/pF, P<0.05, ANOVA), but 
significantly increased over control (-39.8 ± 8.7 pA/pF, P<0.05, ANOVA). As shown in 
Figure 4.2 C, the ( X 2 8 - I  R217A condition had an intermediate Gmax as well, with a mean
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value o f (2.7 ± 1.0 nS/pF) compared to values o f 7.5 ± 5.2 nS/pF for the WT condition 
(which was not significantly different at P<0.05, ANOVA) and 1.2 ± 1.0 nS/pF in the 
control condition (P<0.05, ANOVA). No significant differences in V50,act were observed 
between the 0 ,26-1 R217A, WT 0(25-1 and control conditions (Figure 4.2 D).
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Figure 4.2. Submaximal enhancement o f IBa with co-expression o f (X2 6 -I R217A co­
expressed with Cav2.2, p ib  subunits. (A), Representative current traces for the three 
conditions in response to -30 to +15 mV voltage steps. A schematic o f  the I-V protocol 
is shown. (B), I-V relationships for IBa in the Cav2.2, p ib  control (black squares, n= 11), 
a 25-l (blue circles, n=9) and a 25-l R217A (red triangles, n = l l )  conditions (P<0.05, 
ANOVA). Current amplitude was normalised to whole-cell capacitance and plotted 
against membrane potential. Holding potential was -90 mV. Mean values for Gmax (C) 
and V50, act (D) were obtained from fits o f individual I-V relationships using the IVFIT 
function. A significant increase (P<0.05, ANOVA) in Gmax was observed in the Cav2.2, 
pib,  WT a 2 5 -l condition and 0(2 8 -1 R217A conditions compared to control (P<0.05 for 
both, ANOVA). No significant diference among means values for V50, act was observed 
(P>0.05, ANOVA).
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Unfortunately, due to the fragility o f the cells when in the whole-cell configuration (as 
well as an increase in series resistance and Iieak), insufficient steady-state inactivation 
and long-pulse data were obtained to allow adequate analysis.
4.2.2.2 (X28-2 R282A does not enhance Iea to the same extent as WT 028-2
when co-expressed with Cav2.1, p4
The equivalent single-point mutation was introduced into 0 2 8 -2  in the lab (by Wendy 
Pratt), and termed 0 2 8 -2  R282A (see Materials and Methods). This subunit was co­
expressed with Cav2.1, p4 in order to assess its functionality, compared to WT 0128-2 and 
an empty-vector control condition (see Figures 4.3 -  4.5).
As with the 0 1 2 8 - 1 R217A subunit, the ( X 2 8 - 2  R282A caused a reduced enhancement o f 
current size compared to WT 0 ,28-2 . Figure 4.3 A shows the intermediate current size o f 
a representative 0 2 8 -2  R282A current trace, compared to control and WT 0 2 8 -2  
representative traces. The mean I-V curve o f the 0 2 8 -2  R282A (Figure 4.3 B) was also 
intermediate between control and WT 0 2 8 -2  conditions, with a mean peak-current 
density o f  162.8 ± 23.0 pA/pF, significantly larger than that o f  the control condition (-
65.1 ± 9.3 pA/pF, P<0.05, ANOVA), and significantly lower than that o f the WT 0 2 8 -2  
(-241 ± 21.0 pA/pF P<0.05, ANOVA). The mean Gmax o f both the 0 2 8 -2  R282A 
condition (4.4 ± 0.6 nS/pF) and WT 0 2 8 -2  (6 .1 ± 0.5 nS/pF,) conditions were increased 
over the value for control (1 .8  ± 0.2 nS/pF, P<0.05, ANOVA), as shown in Figure 4.3 C. 
No significant differences were observed in V50, act, with only a small non-significant 
hyperpolarisation seen in the WT 0 2 8 -2  condition (+3.9 ± 1.0 mV) compared to control 
(+7.2 ± 1.4 mV, P>0.05, ANOVA), and an intermediate value for the 0 2 8 -2  R282A 
condition (+6.2 ± 0.9 mV, P>0.05, ANOVA), shown in Figure 4.3 D.
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Figure 4.3. Current amplitude in the ai^-2 R282A condition is intermediate between the 
control and WT 0 1 2 8 -2  conditions. (A), Representative current traces for the three 
conditions in response to -30 to +15 mV voltage steps. A schematic o f the I-V protocol 
is shown. (B), I-V relationships for IBa in the control (black squares, n=14), 0 1 2 8 -2  (blue 
circles, n=14) and 0 1 2 8 -2  R282A (red triangles, n=18) conditions. Current amplitude was 
normalised to whole-cell capacitance and plotted against membrane potential. Holding 
potential was -90 mV. Mean values for Gmax (C) and V50, act (D) were obtained from fits 
o f individual I-V relationships using the IVFIT function. Gmax o f both 0 1 2 8 -2  and a 28-2 
R282A were significantly increased over the control condition (P<0.05, ANOVA). No 
significant difference was observed among values for V50,act(P>0.05, ANOVA).
No significant change was observed in the inactivation kinetics o f the currents. Tjnact was 
similar between the oc28-2 and a 28-2 R282A conditions (279.9 ± 20.5 ms and 335.5 ±
41.6 ms respectively), although neither o f these values were significantly different from 
control (338.4 ± 5 1 . 0  ms), as shown in Figure 4.4 A. Respresentative current traces are 
shown in Figure 4.5 B.
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Figure 4.4. Inactivation kinetics of channels containing 0 1 2 8 -2  R282A (co-expressed 
with Cav2.1, p4 subunits) remain similar to those containing WT 0 1 2 8-2 . (A), Mean time- 
constant o f inactivation (tinact) data is shown for control (black, n=4), WT (X2 8 - 2  (blue, 
n=l 1) and OC2S- 2  R282A (red, n=l 1) conditions. The decay phase o f individual current 
traces at +10 mV was fitted with a single exponential function. Holding potential was - 
90 mV. (B) Representative current traces o f control (black, n=4), WT 0 1 2 8 -2  (blue, n=l 1) 
and ct2 8 - 2  R282A (red, n=l 1) conditions in response to a long depolarising voltage step 
to +10 mV. Traces are normalised to peak. No significant difference among mean values 
for Tinact was observed (ANOVA).
In addition to a sub-maximal enhancement o f current size, the CX2S- 2  R282A condition 
had a similar mean effect on steady-state inactivation curve to WT 0 1 2 8 -2  (Figure 4.5 A). 
The mean V50, inact in the a 28-2 R282A condition (-37.3 ± 2 mV) was similar to the WT 
(X2S- 2  condition (-37.0 ± 2 mV), both o f which were significantly more negative than the 
mean V50, inact observed in the control condition (-30.8 ± 1 mV, P<0.05 for both, 
ANOVA), as shown in Figure 4.5 B. This suggested a 28-2 R282A maintained its ability 
to hyperpolarise the steady-state inactivation curve.
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Figure 4.5. Hyperpolarisaton o f the steady-state inactivation curve with (X2 8 - 2  R282A 
(co-expressed with Cav2.1, p4 subunits). (A), Steady-state inactivation curves for control 
(black squares, n=l l ) ,  0 1 2 6 -2  (blue diamonds, n-11) and (X2 6 - 2  R282A (red triangles, 
n=9) conditions. Holding potential was -100 mV. Curves are Boltzmann fits to the mean 
data. (B), Mean V50, inact data were obtained by fitting a Boltzmann function to individual 
steady-state inactivation curves. * denotes P<0.05 (ANOVA).
4.2.2.3 Increasing the proportion of 0 ,26-! R217A cDNA present in the
transfection m ixture did not cause a recovery of cu rren t am plitude
Both the ( X 2 8 - I  R217A and (X2 8 - 2  R282A mutant constructs displayed an ability to 
enhance IBa when co-expressed with Cavoti and p subunits, but not to the same extent as 
WT 012 8-1 or WT 0C2 8 -2 . However, co-expression o f the OC2 8 - 2  R282A subunit still 
caused the characteristic hyperpolarisation o f V 5 0 ,  in a c t-  One possible interpretation o f this 
result was that the 0 , 2 8 - 1 R217A and (X2 8 - 2  R282A did not facilitate the trafficking o f as 
many Cava i subunits to the cell-surface (see Discussion). This raised questions as to the 
mechanism o f ot2 8 -mediated enhancement o f Cavcti expression, and also the efficiency 
and mechanism o f heterologous expression o f VGCC subunits.
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An experim ent was carried out to determ ine w hether a higher proportion o f  (X2 8 -I 
R217A in the transfection m ixture could result in a recovery o f  the 0128-m ediated 
enhancem ent o f  current size. This experim ent assum ed that cells transfected with a 
cDNA m ixture containing double the proportion o f  01 2 8-1 R217A cDNA would be 
individually transfected with double the proportion o f  0 1 2 8-1 R217A (see Discussion).
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Figure 4.6. D oubling 012 8 -1  R217A cDNA did not cause a recovery o f  current 
am plitude. (A), I-V relationships for IBa in the control condition containing Cav2.1, p ib , 
a 28 -l R217A (black squares, n= 6 ) and the sam e cDNA com position but with double the 
volum e o f  R217A cDN A (“2x R217A ”, red circles, n= 8 ) conditions. Current am plitude 
was norm alised to whole-cell capacitance and plotted against m em brane potential. 
Holding potential w as -90 mV. M ean values for G max (B) and V50? act (C) were obtained 
from fits o f  individual I-V relationships using the IVFIT function. No significant 
difference in either G max or V5o,actw as observed (S tudent’s t-test).
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As shown in Figure 4.6, an increase in the proportion o f ct25-l R217A cDNA used in the 
transfection mixture failed to increase the current amplitude. Mean peak-current 
densities were similar in both conditions (-162.6 ± 56.7 pA/pF in the control condition, 
and -161.7 ± 46.1 pA/pF in the 2x R217A condition), as shown in Figure 4.6 A. There 
was no significant difference observed in the Gmax (3.9 ± 1.3  nS/pF in control and 4.6 ±
1.1 nS/pF in the 2x R217A condition) or V5o, act (+10.1 ± 1.9 mV in control and +5.2 ± 
2.5 mV in the 2x R217A condition) o f either condition, as shown in Figures 4.6 B and C 
respectively.
4.2.3 Whole-cell lysate protein expression o f (X28-I R217A remained
similar to WT a25-l
The electrophysiological studies identified the 0128-1 R217A and 0128-2 R282A as sub- 
maximal in terms o f their ability to enhance current size to the same extent as WT GI28-I 
or WT 0128-2 . Experiments examining the relative protein expression o f WT CI28-I and 
0128-1 R217A, as well as their effect on whole-cell expression o f the Cav2.2 were carried 
out, in order to examine whether the effects seen in the electrophysiological studies were 
due to a possible reduction in protein expression. The pig WT ( X 2 8 - I  and C C 2 8 - I  R217A 
proteins were used for this experiment (see Materials and Methods).
Figure 4.7 shows the whole-cell protein expression from three separate experiments, 
comparing expression o f 0128-1 R217A to WT 0128-1. As shown in Figure 4.7 A, the 
immunoreactivity detected using the 0128-1 antibody demonstrates the similar expression 
between the two conditions. Further analysis using ImageQuant software shows the 
mean normalised immunoreactivity is similar between both 0128-1 R217A and WT CI28-I 
conditions (Figure 4.7 B).
Further experiments were performed to examine how the presence o f  CC28-I R217A 
would affect Cav2.2 expression, compared to the presence o f  WT CI28-I. Unfortunately
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only one experiment was successful (see Figure 4.7 C), although it suggested a possible 
reduction in whole-cell expression o f Cav2.2 in the presence o f 0 ,2 8 -1 R217A when 
compared to WT ( X 2 8 - I .  However, more work is required to demonstrate this 
conclusively.
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Figure 4.7. Whole-cell lysate protein expression is similar in the 0 ,2 8 -1 R217A 
condition, compared to WT 0C2 8 -I. (A), Immunoreactive bands at -170  kDa were 
detected using the anti-0 1 2 8 -2  Ab for WT 01 2 8-1 and 0C2S-I R217A conditions (n = 3 for 
each). (B), No significant difference in mean normalised immunoreactivity o f the bands 
shown in (A), following analysis using ImageQuant software. (C), Immunoreactive 
bands at -190  kDa were detected using an anti-Cav2.2 Ab. Lanes: 7, no transfection; 2, 
Cav2.2; 3, Cav2.2, p ib , WT a 2S-l; 4, Cav2.2, p ib , a 28 -l R217A.
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4.2.4 Lipid-raft localisation o f (X28
The binding-experiments carried out (see Section 4.2.1) involved using 0128-1 and 0128-1 
R217A purified as lipid-raft preparations. This work confirmed the localisation o f 0128-1 
to lipid-rafts, in agreement with previous observations made for the 0128-2 subunit 
(Davies et al., 2006). In addition to their WT counterparts, both 0128-1 R217A and (X28-2  
R282A are also present in lipid-rafts (see Figure 4.1 D), as is WT 0 ,28*2 (Davies et al., 
2006). Despite lipid-raft localisation targeting o f 0 2 8  subunits not being affected for 
02 8 -1  R217A or 0 2 8 -2  R282A (as they also localise to lipid-rafts), a small separate study 
was carried out to look into the functional importance o f  this localisation.
An experiment was performed to investigate the effect o f  manipulating lipid-rafts, either 
by cholesterol depletion or cholesterol enrichment, in order to examine the impact this 
disruption would have upon o^S-mediated effects on co-expressed VGCC currents. The 
Cav2.1, (34 subunit combination transfected into a stably-expressing (X28-2  mid-HA cell- 
line was used for the experiments. This cell-line has previously been shown to be fully 
functional, in terms o f the (X28 present within it (see Section 3.2.5.2).
4.2.4.1 Cholesterol depletion
Cholesterol was depleted from the cells as described in Materials and Methods. Whilst 
no assessment o f  cholesterol depletion was carried out, the protocol used has been 
previously demonstrated to cause a reduction in membrane cholesterol (Christian et al.,
1997). The results are shown in Figures 4.8 & 4.9.
Application o f 5 mM methyl-(3-cyclodextrin (MBCD) for 1 h (immediately before 
experimentation) caused a significant increase in size o f  currents observed (Figure 4.8 
A), as well as the observed mean peak-current density (-387.5 ± 44.9 pA/pF) compared 
to the control condition (-266.7 ± 34.7 pA/pF, P<0.05), as shown in Figure 4.8 B. This
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increase in peak current density did not translate to a significant increase (at P<0.05) in 
whole-cell conductance o f the MBCD condition (9.5 ± 4 . 2  nS/pF) over the control 
condition ( 6 . 8  ±  1 . 6  nS/pF), as shown in Figure 4 . 8  C. Similarly, no differences in V 5 o , a c t  
of the two conditions were seen, as shown in Figure 4 . 8  D.
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Figure 4.8. Disruption o f lipid rafts causes an increase in current amplitude through co­
expressed Cav2.1, (34 stable a 2 5 - 2  mid-FIA channels. (A), Representative current traces 
show the increase in current amplitude in response to a range o f test-potentials (-30 mV 
to +15 mV). (B), I-V relationships o f control (black squares, n=17) and 5 mM MBCD 
(red circles, n=17) conditions. Holding potential was -90 mV. Mean values for whole­
cell conductance (C) and V50, act (D) were obtained from fits o f individual I-V 
relationships using the IVFIT function. No significant difference in either Gmax or V50, 
was observed.
a c t
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The mean steady-state inactivation curves were similar (Figure 4.9 A), and the resultant 
mean V50, inact for the 5 mM MBCD condition (-36.3 ± 2.0 mV) was not significantly 
different from the control condition (-42.4 ± 1.3 mV), as shown in Figure 4.9 B.
A: B:
0 .8 -
0 .4 -
0 .2 -
■ Conrtol (14)
0 . 0 -
-1 4 0  -1 2 0  -1 0 0  -8 0  -60  -40  -20  0  2 0  4 0 Control MBCD
Conditioning potential (mV)
Figure 4.9. Treatment o f cells with 5 mM MBCD does not affect steady-state 
inactivation o f co-expressed Cav2.1, [34 stable 0 1 2 8 -2  currents. (A), Steady-state 
inactivation curves for control (black squares, n=14) and MBCD (red diamonds, n=5) 
conditions. Holding potential was -100 mV. Curves are Boltzmann fits to the mean data. 
(B), Mean V 5 0 ,  in a c t  data were obtained by fitting a Boltzmann function to individual 
steady-state inactivation curves, no significant difference was observed (P>0.05, 
Student’s t test).
4.2.4.2 Cholesterol addition
Since the depletion o f cholesterol from tsA-201 cells co-expressing Cav2.1, p4, stable 
0 1 2 8 -2  mid-HA caused an unexpected increase in the size o f current amplitude, the 
opposite treatment was applied to see the effect this would have on macroscopic 
currents. The same subunit combination (Cav2.1, p4, stable 0(2 8 - 2  mid-HA) was used, 
and cells were treated with combined 5 mM MBCD / 1 mM cholesterol in order to load 
the cells with cholesterol.
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Figure 4.10. Cholesterol enrichment inhibits Iea through co-expressed Cav2.1, p4, stable 
ct2 5 - 2  mid-HA channels. (A), I-V relationships o f  control (black squares, n=13) and 5 
mM MBCD / 1 mM cholesterol (red circles, n=13) conditions. Mean values for whole­
cell conductance (B) and V5o,act(C ; no significant difference) were obtained from fits o f 
individual I-V relationships using the IVFIT function. (*** denotes P 0 .0 0 1 , Student’s 
t-test).
Treatment with 5 mM MBCD / 1 mM cholesterol resulted in an inhibition o f Iea through 
the co-expressed Cav2.1, p4, stable ct2 8 - 2  combination, as shown in Figure 4.10. The 
mean peak-current density was reduced from -271.7 ± 45.3 pA/pF in the control 
condition to -67.4 ± 12.3 pA/pF in the MBCD / cholesterol condition (P 0 .0 0 1 ) , as 
shown in Figure 4.8A. A similar reduction in whole-cell conductance (6.4 ±1.1 nS/pF in 
the control condition, 1.6 ± 0.3 nS/pF in the MBCD / cholesterol condition, P 0 .0 0 1 )  
was also observed (Figure 4.10 B). No significant changes were observed between 
conditions for V50,act (Figure 4.10 C).
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A hyperpolarisation was observed in the mean steady-state inactivation curve (Figure
4.11 A), which equated to a significant hyperpolarisation in V50, inact in the MBCD / 
cholesterol condition (-46.3 ± 2.5 mV) compared to that o f the control condition (-39.9 ±
1.4 mV, PO .O l), as shown in Figure 4.11 B.
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Figure 4.11. Treatment o f cells with 5 mM MBCD / 1 mM cholesterol does not affect 
steady-state inactivation o f co-expressed Cav2.1, (34 stable 0 2 8 - 2  currents. (A), Steady- 
state inactivation curves for control (black squares, n=5) and MBCD / cholesterol (red 
circles, n=5) conditions. Holding potential was -100 mV. Curves are Boltzmann fits to 
the mean data. (B), Mean V50, inact data were obtained by fitting a Boltzmann function to 
individual steady-state inactivation curves. ** denotes P<0.01, (Student’s t-test).
4.2.4.3 Co-expression of stom atin w ith C av2.1, 04, stable 0 ,26-2  mid-HA
Stomatin is known to co-localise as a constituent protein o f lipid-rafts as a member of 
the SPFH (stomatin/prohibitin/flotillin/HflK) family (Davies et al., 2006). a26-2 was 
found to precipitate with both stomatin-like protein-2 and prohibitin (Davies et al., 
2006), suggesting the potential for a physical interaction.
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A similar structural protein, caveolin-1, is also concentrated in detergent-resistant 
membranes. Stable transfection o f caveolin-1 into an NG-108 cell-line resulted in an 
inhibition o f  N-type current (Toselli et al., 2005). In an effort to examine the effect that 
proximity to an SPFH-family protein would have on ot2§, stomatin was over-expressed 
along with the co-expressed Cav2.1, (34, stable 0 ,2 5 - 2  mid-HA subunit combination.
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F igure  4.12. Co-expression o f stomatin inhibits Iea through co-expressed Cav2.1, (34, 
stable a 25-2 mid-HA channels. (A), I-V relationships o f control (black squares, n=4) and 
stomatin (red circles, n=6 ) conditions. The mean peak current-density is smaller in the 
stomatin condition, but not significantly smaller (P>0.05, Student’s t-test). Mean values 
for whole-cell conductance (B) and V50, act(C ) were obtained from fits o f individual I-V 
relationships using the IVFIT function, no significant difference was observed 
(Student’s t test).
The results are shown in Figure 4.12. A reduction in mean peak-current density (Figure
4.12 A) was observed in the stomatin condition (-195.5 ± 46.3 pA/pF) compared to the
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control condition (-303.3 ± 37.6 pA/pF), although this was not statistically significant. A 
similar non-significant reduction in Gmax was observed (7.6 ± 0.7 nS/pF in the control 
condition, and 4.9 ± 0.9 nS/pF in the stomatin condition), as shown in Figure 4.12 B. No 
significant change in V5o,actwas observed (Figure 4.12 C).
4.3 Discussion
The data presented in this demonstrate the importance o f the RRR m otif in normal 
physiological function o f  the (X28-I and 1x28-2  subunits on which they are found. The 
functional binding and activity o f the anti-epileptic and anti-nociceptive drug GBP is 
reliant on the RRR m otif (Field et al., 2006; Wang et al., 1999). The work presented here 
potentially provides a link between the presence o f the RRR m otif important for GBP 
binding, and the ability o f 0128 subunits to enhance cell-surface expression o f the VGCC 
complexes with which they associate.
(X28-I R217A and (X28-2 R282A display negligible binding to 3H-GBP
The binding data confirm that the RRR m otif at position 215-217 on 0128-1 is essential 
for GBP binding. The OC28-I R217A mutation resuslts in negligible 3H-GBP binding, as 
observed in both membrane and lipid raft preparations. An absence o f binding has been 
shown previously in membrane preparations o f (X28-I R 217A-transfected COS-7 cells 
(Wang et al., 1999).
Binding o f 3H-GBP to OC28 has been demonstrated previously in lipid rafts for the 0128-2 
subunit (Davies et al., 2006). A 4.8-fold increase in affinity was observed in lipid raft 
preparations over membrane preparations (both made from mouse cerebellum). This 
corresponds to a 6.1-fold increase in affinity seen for 0128-I in this study. Dialysis o f 
(X28-I has been shown to result in a two-fold increase in affinity (Dissanayake et al., 
1997; Brown et al., 1998), attributed to removal o f a 12 kDa endogenous ligand.
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Whole cell electrophysiology suggests the functionality o f the (X28-I R217A and CX28- 
2 R282A subunits is impaired
When co-expressed with Cava i and p subunits, both the 0128-1 R217A and 0128-2 R282A 
subunits fail to enhance current size to the same extent as their WT 0128 counterparts. 
However, a significant enhancement o f  current size over control conditions was 
observed in both experiments. This result has also been observed in Xenopus oocytes 
expressing the Cav2.2, p lb , 0128-I subunit combination (Field et al., 2006).
This intermediate enhancement o f current size was observed in conjunction with 
changes in V5o, inact as normally elicited by (X28 co-expression. The hyperpolarisation of 
V 5 0 ,  in a c t ,  measured from the steady-state inactivation curves obtained in the 0128-2 
R282A experiment (see Figure 4.5) was similar between the WT 0128-2 and 1x28-2 
R282A conditions. Both o f  these values were significantly hyperpolarised compared to 
the control condition.
A number o f changes normally elicited by 0128 co-expression were seen when co­
expressing both (X28-I and 1x28-2 , but were not considered statistically significant. Co­
expression o f both WT (X28-I and WT CX2S-2  caused a hyperpolarisation o f V 5 0 ,  a c t  
compared to their respective control conditions, although these changes were not 
significant. It is worth noting that both the a 28 -l R217A and 1x28-2  R282A elicited the 
same trend as their WT 1x28 counterparts (see Figures 4.2 and 4.3 respectively). In 
addition neither the WT (X2S-2  or 1x2 8 -2  R282A Tjnact values were significantly different 
from control (at P<0.05), despite being the case for previous experiments. These results 
differ from those shown in Chapter 3, despite the conditions for the experiments (i.e. 
[Ba ], transfection procedure etc.) being the same. Such differences may perhaps 
highlight a flaw in the reproducibility o f the transfection procedure. The ability o f  1x28 to 
hyperpolarise V5o,act is not certain, with some studies not finding 1x28 (CX2S-I) expression 
to alter V 5 0 ,  a c t  (Shirokov et al., 1998), whilst another study found it to hyperpolarise V 5 0 ,  
act (Felix et al., 1997).
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The only overall difference between the WT 0 ,28-1 Vs (X28-I R217A and the WT 0128-2 
Vs (X28-2  R282A in the experiments was the increase in amplitude o f currents observed: 
the R282A subunit produced a 3.8-fold increase over control current density, compared 
to a 2.3-fold increase over control current density in the case o f ( X 2 8 - I  R217A. One 
interpretation o f these results is that the lack o f a GBP binding-site on 0 1 2 8 - 1 and 0 1 2 8 - 2  
impairs the ability o f CC28 subunits to increase the cell-surface expression o f the pore- 
forming Cavcii subunit, resulting in smaller recorded macroscopic currents.
Whole-cell lysate expression o f (X28-I R217A
The observed electrophysiological differences observed when co-expressing ( X 2 8 - I  
R217A or WT 0 1 2 8 - 1 are not a result o f impaired expression o f the C X 2 8  protein. No 
significant difference was observed in the amount o f 0 1 2 8 - 1 protein present in either WT 
or R217A conditions. This data corresponds to the finding that ( X 2 8 - I  R217A protein 
expresses in the cortex (of R217A mice) to the same extent as WT ( X 2 S - I  protein in WT 
mice (Field et al., 2006). However, the pMIDAS (X2S-2  protein (see Chapter 3) 
expressed to the same extent as WT (X28-2  when expressed alone, but intracellular 
retention occurred when it was co-expressed with Cav2.2 (Canti et al., 2005). Initial but 
incomplete evidence (n= l) for a reduction in Cav2.2 expression is seen when co­
expressed with C C 2 8 - I  R217A compared to WT ( X 2 8 - I  (Figure 4.7 C), although it cannot 
be concluded that this is due to intracellular retention o f 0 1 2 8 - 1 R217A / Cav2.2.
Increasing the proportion o f (X28-I R217A cDNA in the transfection mix
One effect o f co-expression o f either the 0 1 2 8 - 1 R217A or 0 1 2 8 - 2  R282A mutations was to 
impair, but not abolish the ability o f the a 28  subunits to enhance cell-surface expression 
o f Cava i  subunits, compared to WT ( X 2 8 - I  or WT ( X 2 8 - 2 .  These mutant a 28  subunits still
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retain a partial functionality in the enhancement cell-surface expression o f the Cavoti 
subunits, due to the significant increases in current density over control when co­
expressing both the 0126-I R217A and 0126-2 R282A subunits.
This raised questions as to the production and processing o f 0126 subunits, their 
intracellular interaction with the Cava i subunit, and the role o f the RRR motif. Work 
carried out using DRGs from an ct25-l R217A knock-in mouse line suggested that these 
currents were similar in terms o f size to those from WT mice (Field et al., 2006). If it 
was possible that some compensatory mechanism was active in order to produce ( X 2 8 - I  
R217A currents the same size as WT 0 ,28-1 currents, perhaps this could be reproduced in 
a cell-line. One possible method o f doing this was to increase the proportion o f 028-1  
R217A cDNA in the transfection mixture, and to look for a “recovery” o f current size.
The validity o f this experiment rested upon the notion that all VGCC subunits are 
successfully transfected into each cell. From personal experience, it has been found that 
cells that are labelled by GFP, but have no detectable macroscopic current are relatively 
rare, suggesting the co-expression o f VGCC subunits is successful the majority o f the 
time.
The failure o f increasing the proportion o f (X28- 1 R217A (into the transfection mixture) 
to increase peak current density suggests that its intermediate enhancement o f currents 
represents a qualitative impairment o f an intracellular function o f the 0 1 2 8  protein, rather 
than a quantitative factor such as a reduction o f CX28-I R217A expression. A previous 
study (Sandoval et al., 2004) has found similar a similar intermediate enhancement o f 
current size, using co-expression o f (two different) ( X 2 8 - I  subunits with single-point 
mutations. Each single-point a 28 -l mutant failed to fully enhance current size to the 
same extent as WT a 28 - l ,  and an 0 1 2 8 - 1 subunit with both mutations introduced into it 
displayed current amplitudes similar to those without co-expressed ( X 2 8 - I .  These 
reductions in current amplitude came in the absence o f any observed changes in V50, in a c t  
in the 0128-2 R282A experiment (see Figure 4.5).
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The observation that the a 28 -l R217A protein has the same level o f whole-cell 
expression as WT ot28 - l ,  coupled with the absence o f any changes in observed V5o, inact 
or V50, act seen when co-expressing a 28 -l R217A or a 28-2 R282A instead o f WT a 28 , 
suggests that the a 28 -l R217A and a 28-2 R282A proteins are produced and expressed to 
the same extent at their WT a 28  counterparts, and when co-expressed with Cava i 
subunit will still make a functional interaction at the cell surface.
Further work is required to demonstrate that the impaired current amplitude caused 
when co-expressing an a 28 -l R217A or a 28-2 R282A subunit arises as a result o f 
impaired expression or stability o f  the respective Cavoti subunit. Cell-surface 
biotinylation of, or radioligand binding to expressed Cav(Xi subunits would be a good 
way to demonstrate this.
Conclusion: a 28 -l R217A and a 28-2 R282A
In addition to a cell-surface interaction with the pore-forming Cava i subunit that 
changes biophysical properties o f the expressed channels (Gumett et al., 1997; Felix et 
al., 1997) a 28  subunits are implicated in facilitating the trafficking o f the Cava i subunit 
(Canti et al., 2005). This study demonstrates the importance o f RRR motif on a 28 -l and 
a 2S-2 in facilitating a full increase in current amplitude o f co-expressed Cav(Xi (and p) 
subunits, potentially by an effect on cell-surface expression o f  the channels.
4.4 Manipulation of cell-membrane cholesterol
Preparation o f fractions o f cells transfected with either a 28 -l R217A or WT a 28 -l 
across a sucrose gradient (for the binding experiment detailed in Section 4.2.1.2) 
confirmed that both these proteins are targeted to lipid rafts. This is in agreement with
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similar data showing that the mature, cleaved forms o f both WT 0128-2 and 0128-2 R282A 
are located entirely in lipid-rafts (Davies et al., 2006).
Lipid-rafts are heterogenous sterol- and shphingolipid-enriched structures within 
membranes that are about 10-200 nm in size (reviewed in Jacobson et al., 2007). Lipid 
raft targeting may be o f importance for neuronal calcium channel subtypes. Cholesterol 
addition has been previously shown to inhibit calcium currents in NG108-15 and smooth 
muscle cells (Jennings et al., 1999; Toselli et al., 2005). Cav2.1 is targeted to lipid-rafts, 
where it makes functional interactions with SNARE proteins (Tavema et al., 2004). 
Disruption o f these structures (using saponin) led to a reduction in both basal and 
depolarisation-induced Ca2+ influx into synaptosomes through neuronal VGCCs. This 
suggests the lipid raft localisation o f Cav2.1 and SNARE-complex proteins may be o f 
importance in pre-synaptic neurotransmitter release. Similarly, the presence o f caveolin- 
1, a protein implicated in the delivery o f cholesterol from the ER to the plasmalemma, 
caused an inhibition in N-type current amplitude. This reduction in amplitude occurred 
in the absence o f any changes in V5o,actor Tinact (Toselli et al., 2005). The inhibition o fN - 
type current was paralleled by the addition o f  cholesterol to cells. Both these studies hint 
at the importance o f neuronal VGCC localisation and modulation in lipid rafts.
The findings o f cholesterol manipulation experiments in this study suggest an important 
modulatory effect o f membrane cholesterol upon Cav2.1 currents. Depletion o f 
membrane cholesterol (and therefore disruption o f the lipid rafts) led to a small but 
significant increase in the peak-current density o f Cav2.1 currents. Addition of 
cholesterol to cells resulted in an inhibition o f the Cav2.1, as well as a hyperpolarisation 
o f V5o, inact- Previous work suggests that the exogenous addition o f membrane cholesterol
affects neuronal calcium channels in a specific manner, as no inhibitory effect was seen
2 +  ^  
on non-neuronal L-type Ca or delayed-rectifier K current (Toselli et al., 2005). This
inhibition was attributed to a shift in single-channel kinetics to favour the null P0 mode,
rather than being attributed to an increase in VGCC turnover.
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The cholesterol manipulation experiments leave plenty o f scope for future work. It 
would be interesting to examine whether or not the modulation o f Cav2.1 currents seen 
with cholesterol manipulation is reversible, either by the opposite treatment with MBCD 
/ cholesterol, or by a recovery o f the original membrane cholesterol levels by the cell 
itself. Additionally, if the inhibition o f Cav2 .1 currents seen in this study arises from a 
shift to the null PG mode, it remains to be determined whether or not the increase in 
current amplitude seen upon depletion o f membrane cholesterol is due to a shift in the 
channel population to favour the normal P0 mode. Although the data collected in the 
stomatin experiment were not sufficient in order to claim an inhibitory effect o f co­
expressed stomatin, such an inhibition may arise from the same cholesterol-addition 
mechanism seen previously (Toselli et al., 2005) and the cholesterol addition experiment 
shown here.
Conclusion: Lipid-raft localisation and modulation o f Cav2.1
The Cav2.1 and 0126-2 subunits used in the experiments both partition into lipid-rafts. 
The ability o f MBCD and MBCD / cholesterol to alter the membrane cholesterol level, 
results in a modulatory effect on the current amplitude through the expressed channels. 
This raises questions as to the localisation o f VGCCs at the cell-surface, and the 
subsequent implications for their functionality.
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Chapter 5: Results 
Chronic inhibition of VGCCs by gabapentin
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5.1 Introduction
The results from the study examining the single-point mutations made in (X28-I (R217A 
and 0128-2 (R282A) (see Chapter 4) showed an inability o f the mutant 0128 to fully 
enhance current size o f co-expressed VGCC subunits. However, the mutant (X28 
subunuts still elicit changes in biophysical characteristics (such as V50, a c t ,  V 5 0  i n a c t )  seen 
with WT 0128. A possible explanataion for this is that the RRR site is required for the 
o^S-mediated enhancement o f cell-surface expression o f Cava i subunits (see Chapter 4).
The importance o f  the RRR site for enhancing currents through co-expressed VGCC 
complexes (potentially by enhancing cell surface expression), coupled with the 
importance o f the site in binding GBP led to the idea that GBP might act chronically 
rather than acutely. Evidence for a long-term action o f GBP rather than acute has been 
put forward before (Alden and Garcia, 2001).
Therefore, the mechanism o f GBP action could be tested with the hypothesis that it acts 
chronically, perhaps to interfere with VGCC cell-surface expression. It is feasible that 
GBP is able to bind 0128 either at the cell surface (the GBP-binding 0,2 subunit being 
extracellular (reviewed in Davies et al., 2007)) or intracellularly (GBP is taken into cells 
via the System-L amino acid transport system (Su et al., 1995)). It was therefore 
hypothesised that GBP acts intracellularly (via uptake into cells) in binding (X28 subunits 
and prevents the ct28-mediated enhancement o f VGCC cell-surface expression.
A number o f  ligands for (X28 exist (see Introduction), some o f which are amino acids 
such as leucine and isoleucine (Lynch, III et al., 2006). An endogenous ligand was 
proposed to be removed from the 012S protein during lipid-raft preparations, as a large 
decrease in KD o f 3H-GBP binding was observed (Dissanayake et al., 1997). If  GBP acts 
to displace this ligand, this interaction may also occur inside the cell. GBP-treated cells
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(expressing 0128) might be expected to have similar impairments in current density as 
seen in the RRA 0126 mutants (see Chapter 4).
5.2 Results
As mentioned above, GBP is not the only ligand o f  (X28 subunits. Several amino acids 
also bind (X28 and compete with GBP for binding (Thurlow et al., 1993), some o f which 
were present in the culture medium (leucine and isoleucine (both at 800 pM) and valine 
(400 pM)). Coupled with the idea that GBP is to be taken up into cells, and the lack o f 
clear electrophysiological evidence for an action o f  GBP at lower doses, two 
concentrations o f GBP were selected for initial experiments- these were 100 pM and 1 
mM. Drug was present from 1 h after the point o f  transfection to avoid any interference 
in the transfection procedure (see Materials and Methods), up to the point o f re-plating 
cell cultures for recording. As the hypothesis supports an inhibitory effect on the 
trafficking function o f 0128 rather than channel-block, GBP was omitted from the 
cultures after re-plating.
5.2.1 Inhibition o f VGCCs by chronic exposure to GBP
5.2.1.1 Calcium channel currents resulting from the Cav2.1, 04, (X28-2
subunit combination are affected by chronic 100 pM GBP 
application
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Figure 5.1. C hronic application o f  100 pM  G B P inhibits Ib3 through co-expressed 
C av2.1, (34, a 2 8 - 2  channels. (A), Representative current traces for the two conditions in 
response to  -30 to +15 m V voltage steps. A schem atic o f  the I-V protocol is shown. (B), 
I-V relationships for Iea in the control (black squares, n=14) and 100 pM  GBP (red 
circles, n=10) conditions. Current am plitude was norm alised to whole-cell capacitance 
and plotted against m em brane potential. Holding potential was -90 mV. M ean values for 
G max (C) and V 50, act (D; no significant difference) were obtained from fits o f  individual 
I-V relationships using the IVFIT function. * denotes P<0.05 (S tudent’s t test).
The results o f  chronic application o f 100 pM  GBP are shown in Figures 5.1 to 5.3. 
Chronic application o f  100 pM  GBP produced a significant inhibition o f  current 
am plitude, as shown in representative current traces (Figure 5.1 A), which corresponded 
to a decrease in peak current density o f  45.0 % ± 9.9 %  (a decrease from -228.5 ± 32.5 
pA /pF to -125.7 ± 22.6 pA/pF, P<0.05) when applied chronically (Figure 5.1 B). This
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inhibition coupled with a decrease in whole-cell conductance (from 5.8 ± 0.9 nS/pF in 
the absence o f GBP to 3.3 ± 0.6 nS/pF in the presence o f GBP, P<0.05), as shown in 
Figure 5.1C. However, chronic application o f 100 pM  GBP did not elicit a shift in V 5 o , 
aCt (Figure 5.1 D).
C ontrol
Figure 5.2. Effect o f chronic 100 pM GBP application upon inactivation kinetics o f Iea 
through co-expressed Cav2.1, (34, (X2 8 - 2  channels. (A), Mean time-constant o f 
inactivation (Tinact) data is shown for control (black, n=5) and 100 pM  GBP (red, n=6 ) 
conditions. The decay phase o f individual current traces at +10 mV was fitted with a 
single exponential function. Holding potential was -90 mV. (B) Representative current 
traces o f control (black) and 100 pM GBP (red) conditions in response to a long 
depolarising voltage step to +10 mV. Traces are normalised to peak. * denotes P<0.05, 
(Student’s t-test).
Inactivation kinetics o f Cav2.1, (34, cc2 5 - 2  channels were slowed by chronic application 
o f 100 pM GBP (Figure 5.2 A). Tinact was 450.3 ± 56.7 ms in the 100 pM GBP 
condition, compared to 296.6 ± 31.3 ms in control (Figure 5.2 B). However, chronic 100 
pM GBP application had no impact on steady-state inactivation curves o f currents
C ontrol
- 163-
through these channels (Figure 5.3 A). V50, inact was not altered significantly (-33.9 ± 2.5 
mV in the absence and -32.2 ± 3.2 mV in the presence o f GBP, shown in Figure 5.3 B).
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Figure 5.3. Steady-state inactivation in cells expressing Cav2.1, (34, 0 ,2 6 - 2  channels is 
not affected by 100 pM GBP. (A), Steady-state inactivation curves for control (black 
squares, n=7) and 100 pM GBP (red circles, n=7) conditions. Holding potential was - 
100 mV. Curves are Boltzmann fits to the mean data. (B), Mean V50, inact data were 
obtained by fitting a Boltzmann function to individual steady-state inactivation curves, 
and showed no significant difference between control and 100 pM GBP conditions.
Chronic application o f 1 mM GBP affected currents obtained (from Cav2.1, p4, ct2 5 - 2  
channels) in such a way as to suggest either a partial or total reduction in functionality o f 
OC2 5 -2 . Sample current traces are shown in Figure 5.4 A, and show the reduction in 
current size in response to chronic application o f GBP. The mean peak current density (-
247.8 ± 43.8 pA/pF in the control condition) was inhibited by 72.2 ± 4.2 % (to -6 8 . 8  ±
10.5 pA/pF, P O .0 1 ) in the 1 mM GBP condition (Figure 5.4 B). This inhibition was 
greater than that seen with 100 pM GBP, and corresponded to a greater reduction in the 
whole-cell conductance (from 5.7 ± 0.9 nS/pF in the control condition to 1.7 ± 0.3 nS/pF 
in the chronic presence o f  1 mM GBP, PO .01), as shown in Figure 5.4 C. A significant 
depolarisation in V50, act was observed with chronic GBP application (+5.4 ± 1.2 mV in
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the absence and +10.5 ± 0.9 mV in the presence o f 1 mM GBP, P<0.05), as shown in 
Figure 5.4 D. In addition, the steady-state inactivation curve was depolarised by the 
chronic presence o f 1 mM GBP (shown in Figure 5.5 A). V5o, inact was depolarised from - 
37.6 ± 2.1 mV to -28.3 ± 2.7 mV (P<0.05) as shown in Figure 5.5 B. This depolarisation 
o f V5o, inact was not seen when applying 100 pM GBP. The depolarised steady-state 
inactivation curve obtained in the presence o f chronic 1 mM GBP was similar to the one 
obtained in the absence o f (X2 8 - 2  (a V5o,jnactof -28.1 ± 1.2 mV), as shown in Figure 3.3A.
Chronic application o f GBP therefore affected calcium channel IBa in a concentration- 
dependent manner. The inhibition seen when using 1 mM GBP was larger than that 
seen when using 100 pM, as summarised in Figure 5.4 E.
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Figure 5.4. Chronic application o f 1 mM GBP inhibits IBa through co-expressed Cav2.1, 
p4, a 28-2 channels. (A), Representative current traces for the two conditions in response 
to -30 to +15 mV voltage steps. A schematic o f the I-V protocol is shown. (B), I-V
- 165 -
relationships for Iea in the control (black squares, n = 13) and 1 mM GBP (red circles, n 
= 11) conditions, mean peak current density was significantly different (P<0.01, 
Student’s t-test). Current amplitude was normalised to whole-cell capacitance and 
plotted against membrane potential. Holding potential was -90 mV. Mean values for 
Gmax (C) and V5o,act(D) were obtained from fits o f  individual I-V relationships using the 
IVFIT function. (E), The mean peak-current density o f the 1 mM GBP condition (n=l 1) 
is significantly smaller than that o f the 100 pM GBP (n=10) and control (n=14) 
conditions (both from Figure 5.1). * denotes P<0.05, ** denotes P<0.01 (Student’s t test 
for B, C, D; ANOVA for E).
In summary, the results showed a concentration-dependent inhibition o f calcium channel 
currents (peak-current reductions o f 45.0 ± 9.9 % in the presence o f 100 pM GBP and
72.2 ± 4.2 % in the presence o f 1 mM GBP). Biophysical characteristics o f the channel 
appeared largely unchanged by the application o f 100 pM  GBP, but significantly altered 
by 1 mM GBP application. Overall this suggests an impairment o f functionality o f ot26 - 
2 , in terms o f its ability to enhance current size and also to elicit biophysical changes on 
macroscopic currents arising from expressed channels.
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Figure 5.5. Steady-state inactivation o f co-expressed Cav2.1, p4, a 25-2 channels is 
depolarised by 1 mM GBP. (A), Steady-state inactivation curves for control (black
■ °6'
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squares, n=13) and 1 mM GBP (red circles, n=l 1) conditions. Curves are Boltzmann fits 
to the mean data. (B), Mean V50, inactdata were obtained by fitting a Boltzmann function 
to individual steady-state inactivation curves. * denotes P<0.05, (Student’s t test).
5.2.1.2 The C av2.2, (31 b, 0 ,28-1 subun it com bination is also inhibited by
chronic GBP application
The experiments detailed in Section 5.2.1 imply that 1 mM GBP is a more appropriate 
concentration to use in order to see significant changes in the electrophysiological 
properties o f expressed calcium channels. Having established inhibitory effects o f GBP 
using the Cav2.1, (34, 0 2 8 - 2  subunit combination, it was necessary to correlate these with 
the other GBP-binding 0 2 8  subunit, 0 2 8 -!.
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Figure 5.6. Chronic application o f 1 mM GBP inhibits Ib3 through co-expressed Cav2.2, 
(31b, (X28-I channels. (A), Representative current traces for the two conditions in 
response to -30 to +15 mV voltage steps. A schematic o f the I-V protocol is shown. (B), 
I-V relationships for Ib3 in the control (black squares, n = 8) and 1 mM GBP (red circles, 
n = 10) conditions. Current amplitude was normalised to whole-cell capacitance and 
plotted against membrane potential. Holding potential was -90 mV. Mean values for 
Gmax (C) and V5o,act(D) were obtained from fits o f  individual I-V relationships using the 
IVFIT function. * denotes P<0.05 (Student’s t test).
The same experiment (i.e. using 1 mM GBP) was carried out, this time using the Cav2.2, 
(31b, C X 2 8 - I  subunit configuration (Figures 5.6 to 5.8). The ( X 2 8 - I  subunit has been more 
extensively studied as a pharmaceutical target for GBP treatment o f neuropathic pain 
(Bian et al., 2006; Field et al., 2006). The same result was obtained, namely an inhibition 
o f currents when cells were chronically exposed to 1 mM GBP. Sample current traces 
for the control and 1 mM GBP conditions are shown in Figure 5.6 A. The mean peak- 
current density in the control condition was -340.9 ± 95.0 pA/pF, and was reduced to -
94.5 ± 27.7 pA/pF in the presence o f chronically applied 1 mM GBP (P<0.01), as shown 
in Figure 5.6 B. This corresponded to a significant reduction in the whole-cell 
conductance (from 9.6 ± 2.7 nS/pF in the control condition, to 2.8 ± 0.7 nS/pF in the 
presence o f 1 mM GBP, P<0.05) as shown in Figure 5.6 C. A slight depolarisation in 
V50, act was seen, from +7.8 ± 1.6 mV to +12.1 ± 1.0 mV in the presence o f 1 mM GBP 
(P<0.05), as shown in Figure 5.6 D.
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Figure 5.7. Effect o f chronic 1 mM GBP application upon inactivation kinetics o f Ib3 
through co-expressed Cav2.2, (31b, 012 8-1 channels. (A), Mean time-constant o f 
inactivation (Tjnact) data is shown for control (black, n=2) and 1 mM GBP (red, n=4) 
conditions. The decay phase o f individual current traces (at +10 mV) was fitted with a 
single exponential function. Holding potential was -90 mV. (B), Representative current 
traces o f control (black) and 1 mM GBP (red) conditions in response to a long 
depolarising voltage step to +10 mV. Traces are normalised to peak. * denotes P<0.05, 
(Student’s t test).
As with the previous experiment, a significant (P<0.05) reduction in the rate o f current 
inactivation was observed with chronic application o f 1 mM GBP (as shown in Figure
5.7 A). The mean Tinact in the control condition (129.4 ± 0.3 ms) was slowed in the 1 mM 
GBP condition (209.2 ± 12.6 ms), as shown in Figure 5.7 B. Finally, a depolarising shift 
in the steady-state inactivation curve was also observed using (X28-I  (shown in Figure
5.8 A). V50, inact was shifted from -55.5 ± 3.4 mV in the control condition, to -39.7 ± 2.6 
mV in the presence o f  1 mM GBP (P<0.05), as shown in Figure 5.8 B.
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Figure 5.8. Steady-state inactivation o f co-expressed Cav2.2, (31b, ( X 2 8 - I  channels is 
depolarised by 1 mM GBP. (A), Steady-state inactivation curves for control (black 
squares, n=4) and 1 mM GBP (red circles, n=4) conditions. Holding potential was -100 
mV. Curves are Boltzmann fits to the mean data. (B), Mean V50, inact data were obtained 
by fitting a Boltzmann function to individual steady-state inactivation curves. * denotes 
P<0.05, (Student’s t test).
Therefore, the same inhibition o f calcium channel currents observed using the Cav2.1, 
[34, (X2 5 - 2  subunit combination was observed using the Cav2.2, (31b, OC2 8 -I subunit 
combination.
5.2.1.3 I b3 in cu ltured  neurons is inhibited by chronic exposure to Im M  GBP
It was important to demonstrate that the effects seen thus far could be replicated in a 
neuronal system. DRGs have been identified as a site where 0128-1 is up-regulated after 
nerve injury (Luo et al., 2001). If GBP were to act in these circumstances to have 
therapeutic effect, it is important to demonstrate that GBP could elicit an inhibitory 
effect on calcium channels in DRGs. DRGs were taken from Sprague-Dawley rats (see 
Materials and Methods). Culture o f DRGs was performed by a Fay Hebich, and the
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following results from DRGs were obtained jointly with her (roughly haf-half). The 
internal and external solutions used for whole-cell patch clamp were the same as for 
patching tsA-201 cells, however the external solution contained 1 mM BaCl as opposed 
to 10 mM BaCl (see Materials and Methods) due to the larger size o f DRGs compared to 
tsA-201 cells. GBp was applied chronically (for 40 h as in tsA-201 cells), application 
effectively ceased when DRGs were replated.
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Figure 5.9. Chronic exposure to 1 mM GBP inhibits IBa in cultured DRGs. (A), 
Representative current traces for control and 1 mM GBP conditions, in response to test 
potentials from -40 mV to +10 mV. Holding potential was -40 mV. (B). 1-V 
relationships for the control (black squares, n=22) and 1 mM GBP (red circles, n=19) 
conditions. The mean data are fitted with the IVFIT function. Mean data for Gmax (C) 
and V50 , act (D; no significant difference) were obtained by fitting individual I-V traces 
with the IVFIT function. * denotes P<0.05 (Student’s t test).
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DRGs express a number o f VGCC types, including N-type, P/Q type and T-type (Varadi 
et al., 1999). T-type current was inactivated by holding cells at -40 mV, and sodium 
currents blocked using 500 nM TTX (see Materials and Methods).
As shown in Figure 5.9, the inhibition observed in DRGs was in line with that seen 
using tsA-201 cells. These included a significant inhibition o f current amplitude (Figure
5.9 A), as well as the corresponding peak-current density (Figure 5.9 B). Mean peak- 
current density was reduced by chronic exposure to 1 mM GBP from -39.6 ± 7.4 pA/pF 
in its absence, to -23.6 ± 3.2 pA/pF in its presence (P<0.05). A significant reduction in 
the whole-cell conductance was seen (from 1.3 ± 0.2 nS/pF in the absence o f GBP, to 
0.8 ± 0.1 nS/pF in the presence o f GBP, P<0.05), as shown in Figure 5.9 C. However, no 
change in V50, act was observed (Figure 5.9 D). Insufficient data were obtained to 
determine whether there was a depolarisation o f the steady-state inactivation curve.
Taken together, these data suggest an inhibitory effect o f 1 mM GBP upon calcium 
channel currents in DRGs. However, the inhibition was less extensive than that seen in 
tsA-201 cells.
5.2.1.4 IBa through co-expressed Cav2 .1, P4, 028-2 channels was not affected
by acute application o f GBP
It is generally accepted that GBP does not inhibit VGCCs via a physical binding and 
immediate block o f the channels. Currents in tsA-201 cells (expressing the same Cav2.1, 
P4, 0 2 8 -2  as used in previous experiments) were recorded as usual, and run-up o f 
currents allowed to proceed to completion. A test potential o f  + 10 mV was then applied 
every 30 seconds (Figure 4.10 A). Acute application o f GBP for 10 min (via a gravity 
feed) did not cause a significant inhibition o f current amplitude, as shown in 
representative current traces comparing zero (black) and 10  min (blue) after application 
o f GBP (or external solution in the control condition), as shown in Figure 5.10 B. The
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mean data showed no significant inhibition o f 1 mM GBP applied for 10 min both over 
the 10 minute period (Figure 5.10 C), or afterwards (Figure 5.10 D).
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Figure 5.10. Acutely applied 1 mM GBP does not inhibit calcium channels. (A), A test 
potential o f +10 mV was applied to cells (holding potential was -90 mV). (B), 
Representative current traces before (black) and after (blue) a 10 minute application o f 
external solution (control) or external solution containing 1 mM GBP. (C), Time-course 
o f drug-application. Currents are normalised to the mean value o f three time-points 
immediately preceding the initiation o f drug application. (D), Bar-chart showing the 
mean normalised IBa after 1 0  min o f drug application. No significant difference was 
observed between the means.
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The findings o f these initial experiments describe the inhibitory effects o f chronic 
application o f GBP. The inhibition is concentration-dependent, and the results are 
consistent with an impairment o f CC28 functionality. The same results were obtained for 
subunit combinations containing both the 0 ,28-1 and 0 2 8 -2  subunits with the chronic 
application o f 1 mM GBP, as well as being replicated in DRGs. The reduction in current 
density was not observed using 1 mM GBP when it was applied acutely.
5.2.2 Control experiments
Having observed a significant inhibition o f calcium currents using GBP, it was 
necessary to demonstrate this as a function o f 0 2 8  binding and subsequent interference 
o f 0 2 8  function.
The protocol used for transfection o f the cells, and subsequent application o f GBP 1 h 
later, meant it was feasible that GBP application could interfere with the incorporation 
o f plasmids into the tsA-201 cells. It was necessary to determine whether or not this was 
the case.
The hypothesis proposed that GBP acts via binding to OC28 proteins. Therefore several 
experiments were carried out, all using co-expressed (X28 proteins that have been shown 
not to bind GBP: (X28-I R217A (Bian et al., 2006); ot2S-2 R282A (Davies et al., 2006); 
and 0128-3 (Marais et al., 2001), in order to show that GBP binding is necessary for the 
inhibitory effects observed.
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5.2.2.1 a 25-l R217A
Chronic application o f 1 mM GBP was found not to inhibit currents produced by co­
expressed Cav2.2, p lb  and ot2 5 -l R217A (Figure 5.11 A). The mean peak current density 
observed in the presence o f 1 mM GBP (-100.3 ± 18.4 pA/pF) was similar to that 
observed in control (-91.7 ± 25.7 pA/pF), as shown in Figure 5.11 B. Furthermore, no 
significant change (at P<0.05) in whole-cell conductance (3.8 ± 1.1 nS/pF in the 
absence, 3.5 ± 0.9 nS/pF, in the presence o f 1 mM GBP) was detected (Figure 5.11 C), 
as was the case for V5o>act (Figure 5.11 D).
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Figure 5.11. Co-expressed Cav2.2, pib,  a 25-l R217A currents were unaffected by 
chronic exposure to 1 mM GBP. (A), Representative current traces for the two 
conditions in response to -30 to +15 mV voltage steps. A schematic o f the I-V protocol 
is shown. (B), I-V relationships for IBa in the control (black squares, n=5) and 1 mM 
GBP (red circles, n=4) conditions. Current amplitude was normalised to whole-cell 
capacitance and plotted against membrane potential. Holding potential was -90 mV.
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Mean values for Gmax (C) and V50, a c t  (D) were obtained from fits o f individual I-V 
relationships using the IVFIT function. No significant difference in mean values for 
Gmax or V50, act were observed.
S.2.2.2 a 25-2 R282A
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Figure 5.12. Co-expressed Cav2.1, p4, (X2 8 - 2  R282A currents are unaffected by chronic 
exposure to 1 mM GBP. (A), Representative current traces for the two conditions in 
response to -30 to +15 mV voltage steps. A schematic o f the I-V protocol is shown. (B), 
I-V relationships for IBa in the control (black squares, n=12) and 1 mM GBP (red circles, 
n=12) conditions. Current amplitude was normalised to whole-cell capacitance and 
plotted against membrane potential. Holding potential was -90 mV. Mean values for 
Gmax (C) and V50>act(D ) were obtained from fits o f individual I-V relationships using the 
IVFIT function. No significant difference in mean values for Gmax were observed.
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1 mM GBP was applied chronically to cells co-expressing the C av2 .1, (34 and (X2 8 - 2  
R282A subunit combination. The currents obtained were unaffected by chronic exposure 
to 1 mM GBP (Figure 5.12 A). M ean peak-current densities obtained in the presence (-
156.3 ±  29.5 pA/pF) and absence (-163.0 ± 40.3 pA/pF) o f  1 mM GBP were sim ilar 
(Figure 5.12 B). G max (4.1 ±  1.0 nS/pF in the control condition and 4.0 ± 0.8 nS/pF in the 
1 mM GBP condition) rem ained unaffected by chronic application o f  1 mM GBP 
(Figure 5.12 C). Flowever, a significant hyperpolarisation o f  V 5 0 , act (+10.5 ± 0.9 mV in 
the control condition and +7.2 ± 1.1 in the 1 mM  GBP condition, P<0.05) was observed.
W hilst a depolarising shift was observed using the WT 0126-2 , this shift was not 
observed when using Im M  GBP on currents formed with (X2 6 - 2  R282A, as shown in 
Figure 5.13 A. V 5 0 ,m a c t was not significantly altered by chronic exposure to Im M  GBP (-
30.1 ± 3.2 mV in the control condition, com pared to -33.1 ± 2.9 mV in the presence o f  1 
mM GBP), as shown in Figure 5.13 B.
Control
Conditioning Potential (mV)
Figure 5.13. Steady-state inactivation o f  co-expressed Cav2.1, (34, 0 1 2 6 -2  R282A 
channels rem ains unaffected by chronic exposure to 1 mM GBP. (A), Steady-state 
inactivation curves for control (black squares, n=7) and 1 mM GBP (red circles, n=5) 
conditions. Curves are Boltzm ann fits to the mean data. (B), M ean V50. jnact data were 
obtained by fitting a Boltzm ann function to individual steady-state inactivation curves, 
and were not statistically different.
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5.2.2.3 a 28-3
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F igure 5.14. Chronic 1 mM GBP application does not inhibit Isa through co-expressed 
C av2 .1, p4, a 25-3 channels. (A), Representative current traces for the two conditions in 
response to -30 to +15 m V voltage steps. A schem atic o f  the I-V protocol is shown. (B), 
I-V relationships for Iea in the control (black squares, n=8) and 1 mM GBP (red circles, 
n=9) conditions. Current am plitude was norm alised to whole-cell capacitance and 
plotted against m em brane potential. Holding potential was -90 mV. M ean values for 
G max (C) and V50, act(D ) were obtained from fits o f  individual I-V relationships using the 
IVFIT function. N o significant difference in m ean values for G max or V50, act w ere 
observed.
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The (X2 8  RRA proteins have impaired function, as discussed in Chapter 4. Therefore, 
(X2 8 - 3  was selected for use as a “fully-functional” (X2 8  protein that would not bind GBP. 
As was the case for the two RRA mutant 0128 subunits, the expression o f (X2 8 - 3  (in this 
case co-expressed with Cav2.1, (34) resulted in Ba2+ currents that were unchanged by 
chronic GBP application. Current amplitude remained unaffected by chronic 1 mM GBP 
application (Figure 5.14 A), as did the corresponding mean peak-current density (-302.9 
± 35.4 pA/pF in the control condition, -258.7 ± 46.8 pA/pF in the 1 mM GBP condition, 
Figure 5.14 B). No significant change was seen in the whole-cell conductance (7.6 ± 0.9 
nS/pF n the absence, and 7.0 ± 1.3 nS/pF in the presence o f 1 mM GBP, Figure 5.14 C) 
or V50, act (Figure 5.14 D). Steady-state inactivation was also similar in both conditions 
(Figure 5.15 A). V 5 0 ,  in a c t  was similar in both the control (-40.6 ±4.3 mV) and 1 mM 
GBP (-39.0 ±3.2 mV) conditions (Figure 5.15 B).
Contro1 1 mM G B P
■ Control (4)
•  1mM GBP (7)
-140 -120 -100 -80 -60 -40 -20 0 20 40
C onditioning  P o ten tia l (mV)
Figure 5.15. Steady state inactivation o f co-expressed Cav2.1, (34, a 28-3 channels is 
unaffected by 1 mM GBP. (A), Steady-state inactivation curves for control (black 
squares, n=4) and 1 mM GBP (red circles, n=7) conditions. Curves are Boltzmann fits to 
the mean data. Holding potential was -100 mV. (B), Mean V 50, inact data were obtained by 
fitting a Boltzmann function to individual steady-state inactivation curves, and were not 
statistically different (Student’s t-test).
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These control experiments therefore demonstrate that the a .28 proteins known to display 
negligible binding o f GBP are not affected by the chronic application o f GBP, thereby 
indicating that the inhibition o f currents by GBP shown initially is mediated by ot28 
subunits, and their binding to GBP.
5.2.3 Block o f GBP-mediated inhibition using 2-Aminobicyclo(2,2,l)-
heptane-2-carboxylic acid
If GBP were to interfere with the trafficking o f calcium channels, it would need to be 
present in the cytoplasm, in order to bind (X2S protein before or during trafficking. 
Therefore GBP would elicit the inhibitory effects seen in previous experiments inside 
the cell, rather than at channels already expressed at the cell surface.
GBP has been shown to be taken up into cells by the System-L amino-acid transporter 
(Su et al., 1995). Therefore, the System-L transport mechanism was blocked with 10 
mM 2-Aminobicyclo(2,2,l)heptane-2-carboxylic acid (BCH), in an effort to prevent 
GBP entry into the cell, and determine whether this affected the inhibitory effects o f 
chronic 1 mM GBP application. BCH is a competitive blocking agent for System-L that 
prevents uptake both o f neutral aromatic amino acids and also GBP (Su et al., 1995). 
BCH has also been shown to be a ligand for a 28 , albeit with a lower affinity than GBP 
or other amino acids such as leucine / isoleucine (Gong et al., 2001).
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5.2.3.1 Chronic application of  BCH alone
It was important to determine whether chronic application o f BCH had a noticeable 
effect on calcium channel currents when applied at a concentration o f 10 mM. BCH was 
applied in the same way as GBP, after transfection o f VGCC subunits and for a period o f 
-40 h. No effect on the current amplitude (Figure 5.16 A) or mean peak-current density 
(Figure 5.16 B) was observed. The mean peak current density obtained in the presence 
o f chronic BCH application was similar (-333.0 ± 73.2 pA/pF) to that obtained in its 
absence (-330.2 ± 84.7 pA/pF). Values for Gmax (8.0 ± 2.1 nS/pF in the absence, and 8.4 
± 1.8 nS/pF in the presence o f 10 mM BCH, as shown in Figure 5.16 C) and V50,act(+3.4 
± 1.5 mV in the absence, and +5.4 ± 0.9 mV in the presence o f 10 mM BCH, as shown 
in Figure 5.16 D) were also similar.
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Figure 5.16. Application o f 10 mM BCH has no effect on IBa through co-expressed 
Cav2.1, (34, ct2 8 - 2  channels. (A), Representative current traces for the two conditions in
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response to -30 to +15 mV voltage steps. A schematic o f the I-V protocol is shown. (B), 
I-V relationships for IBa in the control (black squares, n=7) and 1 mM GBP (red circles, 
n=8 ) conditions. Current amplitude was normalised to whole-cell capacitance and 
plotted against membrane potential. Holding potential was -90 mV. Mean values for 
Gmax (C) and V50, act(D) were obtained from fits o f individual I-V relationships using the 
IVFIT function. No significant difference in mean values for Gmax or V5o, act were 
observed (Student’s t-test).
However, the steady-state inactivation curve obtained in the presence o f 10 mM BCH 
was depolarised from the control curve (Figure 5.17 A). V50, inact was shifted significantly 
(-39.9 ± 2.0 mV in the control condition, and -32.0 ± 2.0 mV in the 10 mM BCH 
condition, P<0.05), as shown in Figure 5.17 B.
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Figure 5.17. Effect o f  chronic application of 10 mM BCH upon steady state inactivation 
o f co-expressed Cav2.1, (34, (X2 8 - 2  channels. (A), Steady-state inactivation curves for 
control (black squares, n=5) and 1 mM GBP (red circles, n=6 ) conditions. Curves are 
Boltzmann fits to the mean data. (B), Mean V50, inact data were obtained by fitting a 
Boltzmann function to individual steady-state inactivation curves. * denotes P<0.05 
(Student’s t-test).
- 182-
Together, these results allude to a possible inhibition o f ct26  biophysical effect at the 
channel surface, but that the ability o f (X28 to enhance expression o f the Cavcti subunit 
remains intact.
5.2.3.2 Chronic BCH application in conjunction with ImM GBP
10 mM BCH was applied to cells for 1 h before chronic 1 mM GBP application, and for 
the entire period o f GBP application (see Materials and Methods). This prevented the 
inhibitory effect o f 1 mM GBP on the currents (Figure 5.18 A). As shown in previous 
experiments, chronic 1 mM GBP application acted to inhibit Iea (from -251.1 ± 39.3 
pA/pF to 118.6 ± 30.12 pA/pF, P<0.05) and reduce the Gmax o f cells (from 6.0 ± 0.8 
nS/pF to 3.1 ± 0.8 nS/pF, P<0.05), as shown in Figures 5.18 B and C respectively. Co­
application o f  10 mM BCH with 1 mM GBP (BCH 1 h beforehand) prevented any 
observed inhibitory effect, the mean peak current density o f BCH / GBP currents (-226.6 
± 43.4 pA/pF) was similar to that o f untreated cells (-251.1 ± 39.3 pA/pF), and 
significantly larger than the GBP condition (P<0.05), as shown in Figure 5.18 B. BCH 
also prevented the GBP-mediated reduction in Gmax (5.8 ± 1.0 nS/pF was similar to the 
control value), as shown in Figure 5.18 C. Neither GBP o f GBP + BCH had an effect on 
V 5 0 , act (shown in Figure 5.18 D).
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Figure 5.18. 10 mM BCH prevents the inhibitory effects of 1 mM GBP upon IBa 
through VGCCs composed o f Cav2.1, (34, 0 ,2 6 -2 . (A), Representative current traces for 
the three conditions in response to -30 to +15 mV voltage steps. A schematic o f the I-V 
protocol is shown. (B), 1-V relationships for IBa in the control (black squares, n=10), 
GBP (red circles, n = l l )  and GBP + BCH (green triangles, n=10) conditions (P<0.05, 
ANOVA). Current amplitude was normalised to whole-cell capacitance and plotted 
against membrane potential. Holding potential was -90 mV. Mean values for Gmax (C) 
and V50, act (D) were obtained from fits o f individual I-V relationships using the IVFIT 
function. No significant difference in mean values o f V50, act was observed. * denotes 
P<0.05 (ANOVA).
1 mM GBP also failed to cause depolarising shift in the steady-state inactivation whilst 
in the presence o f 10 mM BCH (Figure 5.19 A). The significant depolarising shift in V50, 
inact (-31.7 ± 3.1 mV) from the control condition (-42.0 ± 3.6 mV, P<0.05) was not
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replicated with 1 mM GBP co-applied with 10 mM BCH, which was similar (-39.2 ± 1.7 
mV) to that obtained in the control condition, although not significantly different from 
the V5o, mact values obtained for either the control condition o f the GBP condition (as 
shown in Figure 5.19 B).
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F igure 5.19. 10 mM BCH prevents the GBP-mediated depolarisation o f steady-state 
inactivation in cells expressing Cav2.1, (34, aih-2. (A), Steady-state inactivation curves 
for control (black squares, n=7), GBP (red circles, n=7) and GBP + BCH (green 
triangles, n=5) conditions (P<0.05, ANOVA). Curves are Boltzmann fits to the mean 
data. (B), Mean V50, inact data were obtained by fitting a Boltzmann function to individual 
steady-state inactivation curves. * denotes P<0.05 (ANOVA). No significant difference 
was observed between the means o f the GBP and GBP + BCH conditions.
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5.2.4 Effect of chronic 1 mM GBP application on calcium  channel cu rren ts
resulting from  C av2.1, p4, in a stable ct25-2  cell-line
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F igure  5.20. Chronic ImM GBP inhibits currents formed by channels including stably- 
expressed a 26-2 co-expressed with Cav2.1 and p4. (A), Representative current traces for 
the two conditions in response to -30 to +15 mV voltage steps. A schematic o f the I-V 
protocol is shown. (B), I-V relationships for control (black squares, n = l l )  and 1 mM 
GBP (red circles, n=12) conditions. Current amplitude was normalised to whole-cell 
capacitance and plotted against membrane potential. Holding potential was -90 mV. 
Mean values for Gmax (C) and V50, act (D) were obtained from fits o f individual I-V 
relationships using the IVFIT function. * denotes P<0.05 (Student’s t-test).
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The application o f GBP to cells transiently transfected with calcium channel subunits 
was engineered in such a way that GBP would enter the cells and bind 0126 protein 
before it is functionally expressed at the cell surface. However, it was also important to 
determine how GBP would affect a system where functional 0128 already expressed at 
the cell surface as well as being present inside the cell. A stably-transfected 0 1 2 8 -2  mid- 
HA cell-line was used for this experiment. This 0 ,2 8 - 2  mid-HA cell-line was known to 
be fully functional, both in terms o f ability to enhance trafficking o f the Cavoti subunit, 
and also ability to change the biophysical properties o f the expressed channels, as 
demonstrated in Chapter 3.
Control 
1 mM GBP
C ontrol
Figure 5.21. Effect o f chronic exposure to 1 mM GBP upon IBa inactivation kinetics o f 
co-expressed Cav2.1 and p4 in a stable a 28-2 mid-HA-expressing cell-line. (A), Mean 
time-constant o f inactivation (Tmact) data is shown for control (black, n=4) and 1 mM 
GBP (red, n= 8 ) conditions (in response to a test-potential o f +20 mV for 800 ms). 
Holding potential was -90 mV. The decay phase o f individual current traces at +10 mV 
was fitted with a single exponential function. (B), Representative current traces o f 
control and 1 mM GBP conditions in response to a long depolarising voltage step to +20 
mV, traces are normalised to peak. * denotes P<0.05, (Student’s t-test).
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Application o f chronic 1 mM GBP had the same inhibitory effect on stably-transfected 
ao8-2 subunits as was seen with transiently transfected (X2 8 - 2  subunits. Representative 
current traces show the reduction in current amplitude observed in the 1 mM GBP 
condition (Figure 5.20 A). Similar reductions in current density (-283.6 ± 56.4 pA/pF 
reduced to -132.2 ± 39.8 pA/pF, P<0.05), as shown in Figure 5.20 B. A corresponding 
reduction in whole-cell conductance (6.54 ± 1.0 nS/pF reduced to 3.16 nS/pF ± 0.8, 
P<0.05) was observed, as well as a shift in V50, act (shifted from +2.0 ± 1.6 mV to +7.3 ±
1.2 mV, P<0.05), as shown in Figures 5.20 C and D respectively.
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F igure 5.22. Effect o f chronic exposure to 1 mM GBP upon steady-state inactivation o f 
Cav2.1, p4, stable ot2 5 -2 -expressing cells. (A), Steady-state inactivation curves for 
control (black squares, n=7) and 1 mM GBP (red circles, n=9) conditions. Curves are 
Boltzmann fits to the mean data. (B), Mean V50, jnact data were obtained by fitting a 
Boltzmann function to individual steady-state inactivation curves, and were not 
statistically different. * denotes P<0.05 (Student’s t-test).
A reduction in the rate o f channel inactivation was also observed, from 226.2 ± 9.5 ms in 
the control condition, to 316.4 ± 25.5 ms in the presence o f chronic 1 mM GBP 
(P<0.05), as shown in Figure 5.21 A. Representative current traces are shown in Figure
- 188-
5.21 B. The steady-state inactivation curve was depolarised by chronic exposure to 1 
mM GBP (Figure 5.22 A), to the same extent as observed when using transiently 
transfected 0128-2 . V50, inact was shifted from -40.4 ± 3.7 mV, to -30.1 ± 2.2 mV (P<0.05), 
as shown in Figure 5.22 B.
The similar inhibition o f stably transfected (X2S-2  to transiently transfected 0128-2 by 
GBP, coupled with its lack o f inhibition on OC28-2  when applied acutely, provides 
evidence that GBP can interfere with 0128 function through penetrating the cell and 
interfering with forward trafficking o f calcium channel subunits within the cell.
5.2.5 Lack o f effect of PGB on VGCC currents
5.2.5.1 Calcium channel currents resulting from the Cav2.1, 04, (X28-2
subunit combination are not affected by chronic applications of 200
pM PGB
Given the slightly higher affinity o f PGB for (X28 subunits over GBP, coupled with the 
significant inhibition seen with chronic exposure to 100 pM GBP, an initial 
concentration o f 200 pM PGB was selected for use (see Figure 5.23 A). However, no 
significant inhibition o f currents (through co-expressed Cav2.1, 04, (X28-2  channels) was 
observed. The mean peak current density for currents recorded in the presence o f 200 
pM PGB was reduced (-199.7 ± 38.6 pA/pF), although not significantly compared to 
those recorded in the absence o f PGB (-241.0 ± 29.8 pA/pF).
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Figure 5.23. Chronic exposure to 1 mM PGB does not inhibit Iea through co-expressed 
Cav2.1, P4, 0 .2 6 - 2  channels. (A), I-V relationships for control (black squares, n=12) and 
200 pM PGB (red circles, n=22) conditions. (B) I-V relationships for control (black 
circles, n=10) and 1 mM PGB (red triangles, n= 8 ) conditions, as well as a control 
condition excluding co-expressed 0 2 5 - 2  (green squares, n=6 ) are shown. Holding 
potential was -90 mV. (C), Corresponding mean values for Gmax were calculated by 
fitting the IVFIT function to -30 to + 50 mV portions o f individual I-V curves (* denotes 
P<0.05, ANOVA). (D), Steady-state inactivation curves for control (black squares, n=7) 
and 1 mM PGB (red circles, n=9) conditions. Curves are Boltzmann fits the the mean 
data. (E), No difference was observed in the mean values for V50. mact of the two 
conditions.
5.2.5.2 C alcium  channel cu rren ts  resulting from  the C av2.1, p4, ot2 5 -2
su b u n it com bination are  affected by chronic applications of 1 m M  
PG B
Therefore, chronic application o f a larger concentration (1 mM) o f  PGB was used. The 
reduction in mean peak current density from the control (from -219.3 ± 56.0 pA/pF to -
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154.6 ± 3 1 .4  pA/pF) was larger, but still statistically non-significant, suggesting a lack 
o f perceivable effect o f chronic application o f 1 mM PGB (Figure 5.23 B). This was also 
seen in the similar Gmax values obtained for the two conditions, both o f which were 
significantly larger (P<0.05) than that seen in the condition excluding 0128-2 co­
expression (Figure 5.23 C).
Steady-state inactivation was not affected by chronic exposure to 1 mM PGB (Figure 
5.23 D). V50, inact was also unaltered (Figure 5.23 E), with similar values obtained in the 
absence (-33.9 ± 3.5 mV) and presence (-31.3 ± 2.5 mV) o f 1 mM PGB.
5.3 Discussion
Since the discovery that GBP binds the calcium channel 0128 subunit (Gee et al., 1996), 
many studies have examined whether GBP has an inhibitory effect on calcium channel 
currents. The concept o f GBP acting to reduce calcium channel function, and by 
extension, reduce neurotransmitter release, has long been a proposed mechanism o f 
action (Taylor et al., 1998). A number o f studies have demonstrated small or state- 
dependent reductions in neurotransmitter release when GBP has been applied (see 
Introduction).
The inhibitory effect of GBP is mediated through the (X28 subunit
GBP remains a ligand known to bind only to the 0128-1 and (X28-2  subunits, and this has 
been shown to be important for its action (Field et al., 2006). Therefore the link between 
GBP and a reduction in neurotransmitter release most probably lies in its binding to the 
0128 subunit (Taylor et al., 1998). Non-GBP-binding 0128 protein was used in this study 
as a means o f  implicating CC28 as the site o f action o f GBP. GBP binding to (X28 has been 
shown to be mediated through an RRR m otif in the ot2 subunit (Wang et al., 1999). This 
study used the RRA mutant a 28  proteins that do not bind GBP (Field et al., 2006; Davies
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et al., 2006). Use o f either RRA mutant 0128, co-expressed with Cavoii and p subunits 
resulted in a lack o f inhibition when applying GBP. In addition, use o f the non GBP- 
binding 0128-3 subunit (Marais et al., 2001) also resulted in a lack o f inhibition o f current 
amplitude by chronic ImM GBP.
As no inhibitory effects o f 1 mM GBP were observed when using 0128 subunits that do 
not bind GBP, it can be concluded that the inhibitory effects o f GBP seen in this study 
are mediated through binding to the 0128 subunit.
GBP affects calcium channel currents chronically rather than acutely
Despite reducing the neurotransmitter release associated with P/Q type calcium channel 
function (Fink et al., 2000; Fink et al., 2002; van Hooft et al., 2002), a direct acute 
inhibition o f  calcium channel currents has not been conclusively demonstrated. This 
study has confirmed a lack o f acute inhibition when using 1 mM GBP (applied for 10 
min). However, the effects o f chronic GBP application suggest the time-course o f action 
is more long-term.
The ability o f GBP to inhibit currents on a longer-term time-scale suggests that GBP 
does not bind to 012S subunits in such a way as to result in channel block. GBP uptake 
studies (Su et al., 1995) suggest GBP is taken up into cells by amino-acid transporter 
mechanisms. This intracellular location then becomes a likely site o f action for GBP to 
have a chronic effect. The uptake of GBP would imply that it acts either on immature 
0C2S protein in the processing and trafficking process on the way to being expressed at 
the membrane, or 0128 that has entered the degradation / recycling pathway, having been 
expressed at the membrane.
The co-application o f BCH and GBP results in a prevention o f the otherwise inhibitory 
effects o f GBP (see Section 5.2.3). BCH application alone, however, does not cause an 
inhibition o f the currents, suggesting it acts by blocking 1-type amino acid transporters.
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BCH binds (X28 subunits (Gong et al., 2001), and presumably will bind a 28  at the cell 
surface. However this does not result in an inhibition o f current density, whole-cell 
conductance or voltage-dependence o f current activation.
When applied alone, BCH does appear to shift the steady-state inactivation curve, as 
seen in Figure 5.17. When co-applied with GBP, BCH prevents full depolarisation o f the 
steady-state curve (Figure 5.19), resulting in a V5o, inact intermediate to those o f the 
control and GBP conditions (and not statistically different to either). It could be argued 
that both BCH and GBP act as ligands for a 28, but that BCH binding has a relatively 
neutral, or less inhibitory effect.
There are several ligands for a 28 , many which have a similar action to GBP (tested in 
neuropathic pain models), but also those that have no effect (Lynch, III et al., 2006). 
There are also proposed positive modulators o f a 28 , amino acids such as leucine and 
isoleucine (Cunningham et al., 2004) that may be important in the production and 
function o f a 28  (Davies et al., 2006), and whose ability to bind and positively modulate 
a 28  might be prevent by ligands such as GBP.
Dose-dependence of GBP and the need for high concentrations to see inhibitory 
effects
100 pM  GBP has only marginal (if any) effects on the channel biophysics, whereas 1 
mM GBP results in Ba2+ currents that appear to imply the absence o f a 28 . Given the 
hypothesis that individual GBP molecules bind individual a 28  proteins to impair their 
function, it is feasible the biophysical change from full a 28  functionality to no 
functionality may be graded with GBP concentration. These might be difficult to 
determine by electrophysiology, hence the apparent lack o f effects o f 100 pM GBP on 
channel biophysics, yet the slowing o f inactivation kinetics.
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A previous study has demonstrated that GBP inhibits Iea o f calcium channels in DRGs in 
a transgenic mouse line which up-regulates production o f 0126-1 (Li et al., 2006). There 
was no inhibition o f the Iea reported in the normal mice. The electrophysiological 
characteristics o f DRGs with up-regulated 0 1 2 8 - 1 included significant increases in the 
currents and conductance o f the cells, as well as a hyperpolarised voltage-dependence o f 
current activation. This correlates with the data shown in this study if  the over­
expression o f ( X 2 8  in a cell-line can be said to compare with up-regulated ( X 2 8 - I  in a 
transgenic mouse. GBP application affected currents in the opposite way, currents and 
whole-cell conductances were smaller, and the voltage-dependence o f current activation 
was depolarised. In addition, many of these effects were not observed when applying 
100 pM GBP.
Therefore, it is plausible that the application o f fairly high concentrations o f GBP is 
necessary, in order to enable individual molecules o f GBP to bind individual (X28 
proteins intracellularly and prevent them from carrying out their normal regulatory 
function on the Cava i  subunit. Coupled with the need to be taken up into cells, and to 
compete with other ligands of the (X28 subunit, such as (L)-leucine (Thurlow et al., 
1993), this may explain the need for high concentrations o f GBP. Relatively large 
(compared to other drugs) dose of GBP are given, with maximal daily doses o f 1500 mg 
not uncommon (see Section 1.8.5). A dose o f  1424 mg/day equated to a plasma 
concentration o f 8.31 pg/ml (Bialer et al., 2007). This is roughly a 50 pM concentration. 
Significant differences in current amplitude were found in this study using concentration 
from 100 pM  (lower concentrations were not used). Therefore it is feasible that the 
effect seen when using 100 pM in an over-expression system may equate to the 
therapeutic dose seen in patients, although there are many factors ((X28 expression levels, 
cell uptake and subsequent intracellular GBP concentration) that need to be taken into 
account.
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The effect of GBP in different Cava i subunits
Inhibitory effects o f GBP have been demonstrated in DRGs (Li et al., 2006; Sutton et al., 
2002). These results are useful in linking binding o f GBP to 0128-1 subunits to 
therapeutic use, especially in neuropathic pain conditions- many o f which are due to an 
underlying over-activity o f primary afferent neurons. Both Cav2.1 and Cav2.2 channels 
are expressed in DRGs (Varadi et al., 1999), and implicated (although in different 
phases) o f the formalin response in which these neurons are responsible (Diaz and 
Dickenson, 1997).
Mutations in the CACNA1A gene can underlie conditions such as SCA -6  (See 
Introduction). Both GBP and PGB show efficacy in cortical cerebellar atrophy (a 
condition sharing neuropathological similarities to SCA-6 . This effect is hypothesised to 
be due to reducing inactivation rate in Cav2.1 channels (increased in SCA-6 , Gazulla 
and Tintore, 2007).
The importance of (X28 over-expression in the action o f GBP
One deciding factor in the inhibitory effects o f GBP may be its action in the sensitised or 
“0126-1 up-regulated” state. In the experiment comparing the transgenic mouse DRGs 
which over-produce 0128-1 to those of normal mice (Li et al., 2006), control DRGs were 
subjected to electrophysiology no later than 8 h after culturing. The DRGs used in the 
present study were cultured 2-4 days before patching. There is evidence to suggest that 
cell culture may be responsible for an up-regulation o f (X28 (and other proteins) in these 
cells, as the cutting o f axons and dendrites during the culture procedure effectively 
constitutes nerve injury.
This study found an inhibition o f peak current density o f around 45% when using 1 mM 
GBP chronically applied to DRGs for 48 h. This compares to an EC50 o f 2 pM GBP 
when applied acutely to transgenic mouse DRGs which over-produce a 28 - l (Li et al.,
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2006). Whilst it is not possible to compare the two experiments directly due to the 
different culture conditions and the inability to quantify 0128 up-regulation in either case, 
it shows the importance that up-regulation o f 0128 might have when it comes to the 
action o f GBP.
Comparison of observed effects with those described in the literature
The literature surrounding GBP action at calcium channels is expansive and often 
contradictory. The main consensus o f its mechanism o f action is that having bound to 
(X28  protein, GBP elicits a reduction in neurotransmitter release, most probably by an 
inhibitory effect upon calcium channel function (Taylor et al., 1998; Gee et al., 1996). 
However, the exact site, time-course and mechanism o f this inhibition are not yet fully 
understood.
The hypothesis o f this study was that GBP binds to either ( X 2 8 - I  or ( X 2 8 - 2  subunits o f 
calcium channels intracellularly and interferes with either their functional ability to 
enhance forward trafficking o f co-expressed calcium channel complexes to the 
membrane, or their ability to maintain functional channels at the cell-surface. This 
contrasts with other studies that find no direct inhibition o f calcium currents, but instead 
describe a reduction in ESPC amplitude or neurotransmitter release, often at much lower 
doses o f GBP and on a more short-term timescale (Cunningham et al., 2004; Dooley et 
al., 2000a; Dooley et al., 2000b). Therefore it is feasible that GBP acts upon 0,28 in more 
than one way.
Activation o f calcium channels results in an influx o f calcium ions, however this 
calcium does not diffuse far into the cell before it has bound sequestering proteins which 
maintain the low intracellular free calcium concentration. Therefore pre-synaptic 
calcium channels are closely localised with the vesicle-release machinery (Spafford and 
Zamponi, 2003). It may be the case that the 012S subunit facilitates some interaction with 
the vesicle release machinery to bring about an increase in neurotransmitter release,
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rather than just increasing the number o f  calcium channels in a pre-synaptic zone. The 
importance o f (X28 in enhancing trafficking and expression at the cell surface (and 
therefore pre-synaptic membrane) is well established (Canti et al., 2005). 0128 also elicits 
biophysical effects on expressed channels, such as the hyperpolarising shift in voltage- 
dependence inactivation (Singer et al., 1991), mediated through the delta subunit (Felix 
et al., 1997). An interaction between 0128 and structures involved in vesicle release may 
explain the increase in sensitivity in pain-states arising from 0128 up-regulation (Li et al., 
2006), and may also be blocked by the action o f drugs such as GBP. It is worth noting 
that the function o f VGCCs extends beyond allowing calcium into cells, as a study 
points to the importance o f  an interaction between Cav2 cti subunits and laminin P2 
subunits as a means o f maintaining active zones in the synaptic cleft (Nishimune et al., 
2004).
The calcium channel 012S subunit is fairly unique (Hess, 1990a), with perhaps the only 
molecular homologue being the sodium channel beta subunit. Whist its intracellular role 
in enhancement o f trafficking is known, its role at the cell surface as a component o f the 
calcium channel complex is less well-defined. As a component o f all Cav2.x channels, it 
is likely to have additional functions not yet discovered, which may shed more light on 
the link between 0C2S and neurotransmitter release, and also the inhibitory actions o f 
select (X2S ligands.
Conclusion
This study presents evidence for the inhibition of GBP upon calcium channel currents. 
This inhibition is likely to be mediated by GBP acting intracellularly to bind and 
obstruct the normal function o f calcium channel a 28  subunits, namely the enhancement 
o f calcium channel trafficking. This results in an expression o f calcium channels with 
similar characteristics to those expressed without (X28 subunits. This inhibitory action o f
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GBP may be different to the acute effects on EPSC and neurotransmitter release shown 
in other studies.
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Chapter 6: Concluding Discussion
Summary o f results
The three results chapters detail studies carried out to explore additional roles o f the 0128 
subunit, other than those biophysical effects on channel properties and trafficking effects 
already described in previous work.
The role o f the VGCC 0128-2 VWA domain so far appears limited to being intracellular, 
as a mechanism by which 0128-2 subunits cause the enhanced expression o f Cava i 
subunits when co-expressed (Canti et al., 2005). Chapter 3 explored the possibility that 
0,28 might be involved in physical interactions linking it (and possibly associated 
calcium channels) to extracellular proteins. The pMIDAS mutant 0128-2 protein failed to 
elicit any o f the changes normally associated with (X28-2  co-expression. These included 
an increase in current amplitude, as well as depolarising shifts in V5o( act and V5o, inact- 
Therefore the VWA domain in the ct2 8 -2  subunit plays an intracellular role. The same 
was found for the 0628-1 subunit (Canti et ah, 2005). Co-cultures o f tsA-201 cells 
expressing VGCC complexes and GC cells were employed to examine a possible 
extracellular role o f  the 0128-2 VWA domain. For this, a stable-HA-tagged 0128-2 cell- 
line was produced, which was found to be fully functional when expressed with Cav2.1 
and p lb  subunits (and compared to transiently-transfected 0128-2 ). The presence o f GCs 
was hypothesised to lead to binding o f extracellular protein (from GCs) to the 0128-2 
VWA domain. The study failed to identify a direct interaction between 0128-2 and a 
protein ligand, However, at least one protein from GC cultures was found to bind 0128 in 
the 0128-2 stable-HA cell-line (in co-cultured tsA-201 cells). Unfortunately, this could 
not be attributed to VWA domain-binding, as a stable pM IDAS 0128-2 construct was not 
produced.
Chapter 4 examined the importance o f  a 3 amino acid (RRR) m otif essential for GBP 
binding to both 012S-I (R217A) and 0128-2 (R282A) subunits. Co-expression o f these 
subunits with Cavoti and p subunits resulted in a submaximal enhancement o f current 
size, compared to co-expression o f  WT 0128-I or WT ct2 8 -2  (Field et ah, 2006; Davies et
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al., 2007). Where tested, no differences in V5o,actor Vsojnact between mutant and WT a 28 
subunits were observed, suggesting the a 28 subunits lacking a functional GBP binding- 
site maintained their ability to elicit certain biophysical effects on co-expressed 
channels. Binding studies were carried out, to confirm that the a 28-l R217A subunit did 
not bind GBP. This had been established for a 25-l R217A membrane preparations 
(Wang et al., 1999) and a 28-2 R282A membrane / lipid raft preparations (Davies et al., 
2006) already. As with a 28-2 R282A, an increase in affinity for GBP was seen in a 28-l 
R217A lipid raft preparations compared to membrane preparations. This has been 
observed previously in WT a 28 -l, and attributed to the removal o f an endogenous 
ligand bound to a 2S-l in membranes, but removed upon further purification to a 2S-l in 
lipid rafts (Dissanayake et al., 1997).
The implication o f  lipid raft localisation o f a 28-2 upon its function was tested, by 
disrupting lipid rafts. Using the cholesterol acceptor MBCD, lipid rafts were disrupted in 
cells expressing Cav2.1, (34 and stable a 28-2-mid HA. This caused a small but significant 
increase in current density compared to non-treated cells. The reverse experiment 
involved introducing extra cholesterol into the cell membrane. This caused a 
corresponding significant reduction in current density. Taken together, the results 
indicated that cell membrane cholesterol plays an important role in regulating the 
activity o f  VGCCs. The mechanism o f this action has not as yet been determined.
The direct effects o f GBP application upon VGCCs were examined in Chapter 5. Acute 
application o f 1 mM GBP (up to 10 min) was found not to inhibit current density (tsA- 
201 cells expressing Cav2.1, p4, a 28-2 subunits. Chronic application (40 h) o f 100 pM 
and 1 mM GBP however was found to cause a significant inhibition o f current density, 
as well as preventing shifts in V 5 0 ,  a c t  and V 5 0 ,  in a c t  normally seen with a 28-2 co­
expression. Similar observations were made when Cav2.2, p lb , a 28-l subunits were co­
expressed into tsA-201 cells. These results implied that the action o f  a 28 were prevented 
by GBP when applied chronically. No such effects were seen when non-GBP binding 
a 28 subunits were used ( a 28-l R217A, a 28-2 R282A and a 28-3), implicating GBP
-201 -
binidng to 01,28 subunits as a mechanism o f  action. The system-L amino acid trasport 
system has previously been shown to be responsible for GBP uptake into cells (Su et al., 
1995). Blocking this transport system (using 10 mM BCH preincubated before GBP 
application) prevented the inhibitory effects o f  chronic 1 mM GBP application, implying 
GBP acted upon uptake into cells.
RRR motif 
1
a -
Cache domains 
1 i
5
N - - C
t
VWA
domain
F ig u re  6.1. Schem atic representation o f  0 ,2 8 - 1 / (X2 8 - 2  structure, with binding domains 
marked. Shown are the approxim ate relative positions of: the RRR m otif necessary for 
GBP binding (green); the (M IDAS m otif-containing) VW A dom ain (red) and the two 
cache domains (blue).
0126 as a ligand-b ind ing  su b u n it
It is therefore clear that (X2 8  contains a number o f potential interaction domains, and that 
their respective physiological functions are not yet fully clear.
The cache dom ains are predicted to be involved in binding small extracellular molecules 
(such as amino acids) as they are also found in prokaryotic chem otaxis receptors 
(Anantharam an and Aravind, 2000). Deletion m utations introduced into regions within 
the first cache domain (o f porcine a 2 8 - l )  also prevent GBP binding (W ang et al., 1999).
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It is possible GBP could bind as a ligand o f the cache domains, although the importance 
o f the RRR m otif in GBP binding suggests other sites are more important.
By virtue o f its structural similarity to integrin VWA domains, the (X28 VWA domain 
may well bind extracellular protein ligands, such as extracellular matrix proteins. 
Whether this would fulfil a signalling role or merely an adhesion role is not clear. A 
recent study (Garcia et al., 2007) explored the possible role o f 0128-1 in adhesion, in the 
context o f EC coupling in skeletal myotubes. Using siRNA to deplete ( X 2 8 - I  in 
myotubes, these cells were found to be less adherent to collagen-coated coverslips, 
suggesting an interaction between 0128-1 and collagen. Additionally, the loss o f ( X 2 8 - I  
did not inhibit current amplitude through L-type channels. The VWA domain constitutes 
the most likely candidate for a collagen binding-site on ( X 2 8 - I ,  although this was not 
confirmed by the study.
The same study (Garcia et al., 2007) also investigated the localization o f 0128-1 and 
Cavl.l  subunits over time. After two days in culture, little co-localisation between 0 1 2 8 - I  
and Cavl.l  subunits was observed, with the 0 1 2 S - I  expressed strongly at the extremities 
o f the myotubes. The lack o f initial association between ( X 2 8 - I  and Cavl . l ,  in addition to 
the observation that ( X 2 8 - I  is expressed before Cavl . l  in skeletal myotubes, suggests that 
C C 2 8 - I  functions in an additional role rather than merely associating with the Cavcti 
subunit (and enhancing cel 1-surface expression).
Many o f the experiments performed have focused on the Cav2 .1 subunit, and the results 
therefore have implications for Cav2.1 subunit-containing VGCCs in their primary 
physiological role o f neurotransmitter release.
First o f all, the importance o f the VWA domain in Cava i  subunit trafficking has been 
demonstrated, both from work detailed in Chapter 3 as well as work carried out in the 
lab (Canti et al., 2005). The (X28 VWA domain is responsible for the increase in cell- 
surface expression (and subsequent increase in current amplitude) o f  the VGCC
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complex. Therefore, the VWA plays a vital role in providing an intitial control over the 
number o f  Cav2.1 channels at the presynaptic membrane, for their role in 
neurotransmission. It would be interesting to compare the phenotype o f a knock-in 
mouse containing the 0128-2 pMIDAS mutation with those o f other 0128-2 mutants (such 
as ducky and du2J) to examine whether this process would lead to impaired 
neurotransmission in vivo.
The proposed mechanism o f action o f GBP (Chapter 5) has implications for Cav2.1 and 
Cav2.2 synaptic pharmacology. The ability o f GBP to be taken into neurons and prevent 
the oi28-mediated enhancement o f VGCC channel trafficking would have an impact on 
neurotransmitter release. The mechanism demonstrated in this study would agree with 
other studies detailing an inhibition in neurotransmitter release (Dooley et al., 2002; 
Bayer et al., 2004; Cunningham et al., 2004) as a result o f action at Cav2.1 channels. The 
implications o f a drug affecting neurotransmission at central synapses are far-reaching. 
Reductions in neurotransmitter release by GBP (and PGB) have been demonstrated in a 
variety o f  tissues, and for a range o f neurotransmitters (see Section 1.8.5). This would be 
liable to cause an array o f unwanted side-effects. However, in many animal models, 
GBP has an effect on neurotransmitter release in hypersensitive neurons, rather than in 
normal neurons (Li et al., 2006; Patel et al., 2000), as well as having a subtle, sub- 
maximal influence on neurotransmission (reviewed in Dooley et al., 2007). It is perhaps 
these distinctions that allow the side-effect profile o f GBP/PGB to be fairly limited.
Additional roles o f the 0128 subunit
The (X2S subunit subtypes (1-4) all have similar effects when co-expressed with Cava i 
subunits (and p subunits), such as enhancing cell-surface expression o f Cava i subunits, 
as well as having minor influences upon electrophysiological properties o f the expressed 
channels (see Introduction). However, the differences between the VWA domains o f the 
a 28  subunit subtypes suggest they may perhaps have evolved to carry out different
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functions. All ot26  subunits contain VWA domains, however these are only completed 
by intact MIDAS motifs in CX28- 1 and ot28-2  (Whittaker and Hynes, 2002). It is not 
known whether the VWA domains in ct2§-3  and ot28-4  are functional, as they have not 
been tested (by disrupting sites within the VWA domain to see if  this is necessary for an 
interaction with Cava i subunits. However, as they do not contain intact MIDAS motifs, 
it could be suggested they cannot transition into the active state and bind the putative 
ligand. This may suggest that functional VWA domains were once present in these 
structures, but have become redundant or unnecessary. In addition, localisation o f the 
0128-2 subunit in the tumour suppression region o f chromosome 3 may again suggest an 
additional function.
Therefore, the conclusion o f this body o f work is that the 0126 subunit is involved in 
multiple interactions via adhesion domains. These interactions are important for the 
physiological function o f 0028 as a VGCC auxiliary subunit, although additional 
functions not involving the VGCC complex are also possible.
-205 -
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Appendix I: Buffers for lipid raft preparation
Solution Compound
Buffer 1 
50 ml w/ water
25 mM MES
150 mM NaCl
2x Protease inhibitor tablets
Buffer 2 
50 ml w/ water
25 mM MES
150 mM NaCl
2x Protease inhibitor tablets
2% Triton (v/v)
Appendix II: Base biochemical reagent compositions
Solution Compound Quantity
(4X) Loading sample 
buffer (LSB), 10 ml
Glycerol 4.00 g
Tris Base 0.682 g
Tris HC1 0 .6 6 6  g
Lithium dodecyl-sulfate 0.800 g
EDTA 0.006 g
Serva Blue G250 0.75 ml o f 1% solution
Phenol Red 0.25 ml o f 1% solution
DTT 200 pM
(20X) NuPage Tris-acetate | Tricine 89.5 g ( lM )
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running buffer, 500 ml
Tris Base 60.6 g ( lM )
SDS 10 g (69.3 mM)
(20X) NuPage MOPS 
running buffer, 500 ml
MOPS 104.6 g ( lM )
Tris Base 60.6 g ( lM )
SDS 10 g (69.3 mM)
EDTA 3 g (20.5 mM)
(20X) Nupage transfer 
buffer, 125 ml
Bicine 10.2 g (500 mM)
Bis-Tris 13.08 g (500 mM)
EDTA 0.75 g (20.5 mM)
Appendix III: Composition o f antibody diluent (pH 7.4)
Goat serum 10% (v/v)
Bovine serum albumin 3 % (w/v)
Ovalbumin 0.5% (w/v)
NaCl 500 mM
Tris-HCl 50 mM
Igepal 0 .1% (v/v)
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